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STELLINGEN 
behorend bij het proefschrift 
'Seroepidemiology of diphtheria, tetanus, poliomyelitis and pertussis. 
Evaluation of the national immunisation programme in the Netherlands' 
van Hester de Melker 
1. Het is niet (meer) gerechtvaardigd de ziekten uit het Rijksvaccinatieprogramma als 
kinderziekten aan te duiden. (Dit proefschrift) 
2. In seroepidemiologisch onderzoek naar de effecten van vaccinatie heeft (gedocumenteerde) 
vaccinatiestatus grote waarde. (Dit proefschrift) 
3. Onderzoekers moeten zieh er van bewust zijn dat het overhalen van mensen om mee te 
werken aan onderzoek niet hoeft te leiden tot betere representativiteit. (Dit proefschrift) 
4. Het is onjuist om de cumulatieve incidentie van Bordetella pertussis infecties direct te 
schatten uit de leeftijdspecifieke prevalentie van IgG antistoffen tegen pertussis toxine. 
(Dit proefschrift) 
5. Vaccinatie kan het slachtoffer worden van haar eigen succès. 
6. 'Meten is weten' is geen universele waarheid. 
7. Het op de markt brengen van schoonmaakmiddelen die 99,9% van de bactérien doden, 
verhoogt de kans op smetvrees voor de 0,1% niet-gedode bactérien. 
8. Alhoewel immuniteit tegen intolerant gedrag goed van pas kan komen, is het verbeteren van 
de algemene tolerantie een veel beter uitgangspunt. 
9. De kracht van een (hockey)team moet niet alleen worden vastgesteld aan de hand van de 
positie op de ranglijst. 
10. Terwijl sommige gaven van 'zwakbegaafden' verwonderlijk mooi zijn, is het gemis van 
sommige gaven van '(hoog)begaafden' verwonderlijk vervelend. 
11. Het künnen maken van keuzes in het leven, zou veel meer als een voorrecht beschouwd 
moeten worden. 
12. Geografische afstand kan ook positief zijn geassocieerd met kwaliteit van communicatie. 
13. Distance makes the heart grow fonder! 
Wageningen, lOdecember 1999 
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ABSTRACT 
Seroepidemiology of diphtheria, tetanus, poliomyelitis and pertussis. 
Evaluation of the National Immunisation Programme in the Netherlands 
PhD Thesis. Wageningen University and the National Institute of Public Health and the Environment, 
Bilthoven, the Netherlands 
Hester de Melker 
In view of the evaluation of the National Immunisation Programme in the Netherlands the main 
objectives were to obtain insight into the immunity to diphtheria, tetanus and poliomyelitis, into the occurrence 
of pertussis and to improve serodiagnosis of pertussis. 
In a population-based nationwide sampling, 8359 sera (response 55%) were collected, and to gain 
assess to orthodox reformed individuals refusing vaccination, in a sample from municipalities with low vaccine 
coverage 1589 sera (response 52.5%). In the nationwide sample, the prevalence of diphtheria and tetanus 
antibodies (> 0.01 IU/ml in toxin inhibition assay) was 58% and 72.5%, resp. In at least 90% antibodies (titre 
>1:8 in neutralisation assay) against poliovirus types 1, 2 and 3 were measured. For those bom after mass 
vaccination was introduced (<45 years) the prevalence of antibodies to diphtheria, tetanus, poliovirus types 1 
and 2 was at least 92.5% and for poliovirus type 3 at least 80%. Diphtheria and tetanus antibodies decreased 
with age for those bom before vaccination was introduced (>45 years). Only 40% of orthodox reformed 
individuals had diphtheria and/or tetanus antibodies and less than 70% had poliovirus type 1, 2 and/or 3 
antibodies. We concluded that the Dutch immunisation programme induced long-term diphtheria, tetanus and 
poliomyelitis immunity. While adults are very well protected against poliomyelitis, a great number of adults 
lack diphtheria or tetanus antitoxin antibodies. These adults might benefit from diphtheria (re)vaccination; 
however, offering a primary tetanus vaccination to cohorts bom before the introduction of vaccination would 
probably be more effective than routine revaccination. Introduction of C. diphtheriae or poliovirus in socio-
geographically clustered orthodox reformed groups might constitute a danger of spread of these pathogens. 
Pertussis surveillance data from notifications, positive serology and hospital admissions (1976-98) 
showed a sudden increase in the number of pertussis cases in 1996-97. According to notifications and serology 
data, the increase among, mostly unvaccinated, children less than 1 year was similar to the increase in hospital 
admissions. For older, mostly vaccinated, individuals the increase in hospital admissions was relatively small. 
The increase of reported vaccinated patients of all ages was higher than for unvaccinated patients. We 
postulated that the proportion of pertussis infections resulting in recognizable symptoms has increased among 
vaccinated individuals due to a mismatch of the vaccine strain and circulating B. pertussis strains. 
To investigate at which level IgG antibodies against pertussis toxin (IgG-PT) in a single serum sample 
are indicative for recent pertussis, IgG-PT was analysed in 7756 population-based sera, in sera of 3491 
patients with at least a fourfold IgG-PT increase, in paired sera of 89 patients with positive cultures or 
polymerase chain reactions and in sera of 57 pertussis patients with a median follow-up of 1.4 years. IgG-PT 
levels of at least 100 U/ml were present in less than 1% of the population, are reached by most pertussis 
patients within 4 weeks after disease onset and persist only temporarily. We concluded that such levels are 
diagnostic for recent or actual infection with B. pertussis. 
Our results not only show that childhood vaccination should be sustained, but that adult vaccination 
could be considered. We have to anticipate long-term effects of mass vaccination, such as gaps in immunity as 
a result of decreased circulation of the pathogens and waning immunity. Epidemiological studies directed 
towards evaluation of vaccination should continue to provide a scientific basis for vaccination strategy. 
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Control of vaccine-preventable diseases 
The first part of the twentieth century is regarded as a golden age in public health mainly because 
of the advances in control of infectious diseases (1,2). With the exception of safe water, no other 
intervention, not even antibiotics, is as powerful and cost effective in disease prevention as 
immunisation. As a result of immunisation, smallpox has been eradicated and poliomyelitis 
eradication is well on the way (2-4). 
In the absence of immunisation, an estimated number of 5 million deaths from smallpox, 2.7 
million from measles, 2.0 million from neonatal tetanus, 1.0 million from pertussis, 600,000 deaths 
or paralytic cases of polio and 300,000 deaths from diphtheria would occur worldwide each year 
(2). Death due to smallpox is prevented and the Children's Vaccine Initiative1 estimates that at 
least 60% of otherwise expected deaths from other diseases are prevented (2). 
However, the bad news is that infectious diseases are still the leading cause of death worldwide 
and that diseases are (re)emerging (1,5,6). Even among the vaccine-preventable diseases of 
childhood included in the Global Program for Vaccines and Immunisation (previously the 
Expanded Programme on Immunisation), many deaths are not prevented. Nearly 40% of 
potentially preventable deaths due to pertussis, measles and neonatal tetanus still occur (2). 
The disease occurrence is not spread evenly over the world. The control of vaccine-preventable 
diseases is better in developed countries than in developing countries. However, even in an 
industrialised country such as the Netherlands, which has high vaccination coverage, epidemics of 
some vaccine-preventable diseases still occur, and the re-emergence of other vaccine-preventable 
diseases is possible (7-13). 
Factors similar to those thought to be involved in the (re)emergence of infectious diseases in 
general might play a role in the occurrence of vaccine-preventable diseases (5). For example, the 
adaptation of the pathogen might have contributed to a pertussis outbreak in the Netherlands and 
a poliomyelitis outbreak in Finland (5,8,12). The breakdown of public health measures was a 
major factor involved in the re-emergence of diphtheria in the former Soviet Union (5). As a 
result of international travel, import and spread of the bacterium was feared in other countries 
(5,7). A long-term paradoxical effect of mass vaccination concerns the gap in immunity in 
unvaccinated groups; these groups may be worse off than in the prevaccination era. This could 
result in outbreaks in these groups similar to those observed for congenital rubella syndrome 
among Amish people in the United States and for poliomyelitis in orthodox reformed groups in 
the Netherlands (10,14,15). 
'Co-sponsoring agencies of Children's Vaccine Initiative: United Nations Children's Fund, United Nations 
Development Programme, World Bank, World Health Organization, Rockefeller Foundation 
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The Dutch National Immunisation Programme 
The Dutch National Immunisation Programme was introduced in 1952, offering diphtheria, 
tetanus and pertussis vaccination (DTP), and since 1957, poliomyelitis vaccination (IPV) to all 
children born from 1945 onwards. Nowadays, vaccination against measles, mumps, rubella 
(MMR) and Haemophilus influenzae type b (Hib) are also included in the programme (Table 1). 
Table 1. Diseases, year of introduction and vaccine included in the Dutch National 
Immunisation Programme 
Disease Year of introduction in the 
National Immunisation 
Programme 
Vaccine 
Diphtheria 
Tetanus 
Pertussis 
Poliomyelitis 
Rubella 
Measles 
Mumps 
Haemophilus influenzae type b 
1952 
1952 
1952 
1957 
1974 (for girls) 
1976 
1987 
1993 
DTP, since 1962 DTP-IPV 
DTP, since 1962 DTP-IPV 
DTP, since 1962 DTP-IPV 
IPV, since 1962 DTP-IPV 
R, since 1987MMR 
M, since 1987MMR 
MMR 
Hib 
The vaccination schedule till 1999 is given in Table 2. Since January 1999, children are offered the 
first three vaccinations for DTP-IPV and Haemophilus influenzae type b at 2, 3 and 4 months of 
age instead of 3, 4 and 5 months of age (16). Advancing the programme will protect children 
earlier in life, which is particularly relevant to the prevention of pertussis and invasive H. 
influenzae type b infections. 
Table 2. Vaccination schedule of the Dutch National Immunisation Programme till 
January 1999* 
Vaccine Primary course Booster vaccination 
(in months) (in years) 
DTP-IPV, Hib 3,4, 5 and 11 
DT-IPV 4 and 9 
MMR 14 9 
Since January 1999 the schedule for the first three vaccinations has been accelerated by 1 month, starting at 2 
months of age 
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The vaccination coverage amounts to 97% for all 12-month-old children for at least three 
vaccinations against DT(P)-IPV and 94% of all 2-year-old children for one vaccination against 
MMR (17). The high coverage is a result of a very effective organisation of vaccination in the 
Netherlands (18,19). Every child is offered vaccination from birth to 13 years on a voluntary basis 
and free of charge. The Dutch National Immunisation Programme is implemented mainly by the 
network of Maternal and Child Health Clinics for children up to the age of 4 years and by Public 
Health Services for school-aged children. The provincial immunisation administrations each 
maintain a database of vaccination records for each child younger than 13 years of age living in 
the province and process data on births, deaths and removal from municipal population records 
(18,19). Parents receive an invitation for vaccination with information on the importance of 
vaccination. If the provincial immunisation administration has not received a notice that the child 
has been vaccinated within a specified time, a reminder is sent. 
Despite the average high vaccination coverage, in some municipalities or villages the vaccination 
coverage is less than 90%, sometimes even only 60% (17). These municipalities are in a belt from 
the southwest to the northeast of the country. There are several communities in these 
municipalities who refuse vaccination on religious grounds. These pockets of unvaccinated 
orthodox reformed persons are particularly important because they form a closely knit 
sociogeographical network and therefore could escape herd immunity (10,18,20). The remaining 
unvaccinated groups live scattered all over the country and appear to have various reasons for not 
being vaccinated, such as ignorance of the health system, socioethnic problems in immigrant 
populations and 'illegal' residency (17,18,21). A small group of anthroposophically oriented 
people resists immunisation, especially against measles, mumps and rubella, because of nature-
based attitudes towards life (18,21). 
Evaluation of the Dutch National Immunisation Programme: seroepidemiology 
of diphtheria, tetanus, poliomyelitis and pertussis 
Before the licensing of a vaccine, the safety and efficacy of the vaccine must be established in 
controlled trials (22,23). However, post-licensing evaluation is of equal importance for the 
success of a vaccination programme. Epidemiological methods play an important role in this 
continuous evaluation to assess the safety of the vaccine, vaccination coverage, disease incidence, 
disease severity and the immunity of the population (22,23). 
A passive surveillance system for monitoring adverse events following vaccinations, with a 24-
hour telephone service, was instigated in the Netherlands in 1962 (24-26). In 1994, 712 adverse 
events were reported with about 2 million vaccinations administered. The interval between 
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vaccination and the event is established and the likelihood of causality with the administered 
vaccine is assessed for all reported adverse events (24). 
The vaccination coverage in the Netherlands is reported annually by the Inspectorate of Health 
(17). As already stated, this coverage is consistently high with the exception of the groups 
mentioned. 
The reduction in disease incidence achieved after a vaccine has been introduced into routine use is 
the best measure of success of a programme. In the Netherlands, most information on the 
incidence of vaccine-preventable disease is derived from notifications, laboratory reports, data on 
hospital admissions and registration of deaths (27). These data show that the incidence of vaccine-
preventable diseases and their complications decreased considerably after the introduction of 
vaccination (27). 
Since this thesis covers studies on diphtheria, tetanus, poliomyelitis and pertussis, the numbers of 
reported cases of these diseases are given in Figures 1 to 4. The numbers of notifications of 
diphtheria, tetanus and poliomyelitis in recent years are very small, while pertussis is endemic in 
the Netherlands and epidemics occur. Pertussis surveillance is useful for studying trends and 
detecting epidemics; it could possibly help identify factors involved in disease occurrence. 
The small numbers of diphtheria, tetanus and poliomyelitis cases certainly do not mean that 
surveillance should be omitted for these diseases. For example, in view of the initiative of the 
World Health Organization to eradicate poliomyelitis, countries should detect at least 1 case of 
nonpolio acute flaccid paralysis per 100,000 inhabitants to confirm the absence of poliomyelitis. 
This nonpolio acute flaccid paralysis rate is a measure of the sensitivity of the surveillance, or, in 
other words, the ability of a country's surveillance system to detect a poliomyelitis case if it were 
to occur in the population (28). 
However, with smaller numbers of cases, the role of serological surveillance as an epidemiological 
method for the evaluation of the National Immunisation Programme becomes more evident. 
Immunisation programmes aim to replace, naturally acquired immunity by vaccine-induced 
immunity. Neither history of disease nor vaccination is necessarily an accurate marker of true 
immunity (22). Therefore, if a serological correlate of protective immunity against a vaccine-
preventable disease exists, serological surveys are useful. Assessment of specific antibodies offers 
the opportunity to identify groups with little immunity that might require changes in vaccination 
strategy to prevent (re)emerge of the disease (22,29). In order to make reliable estimates of the 
immunity of the population, the sample of sera used for serosurveillance should be representative 
of the total population. A population-based serum collection with extensive information on study 
subjects would be ideal. A rare example is the National Health and Nutrition Examination Study 
(NHANES) in the United States (30). 
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Figure 1. Numbers of diphtheria cases reported from 1940 to 1998. 
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Figure 2. Numbers of tetanus cases reported from 1952 to 1998. 
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Figure 3. Numbers of poliomyelitis cases reported from 1924 in 1998. 
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Figure 4. Numbers of pertussis cases reported from 1976 to 1998. 
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Antibodies that correlate with protection are known for diphtheria, tetanus and poliomyelitis, but 
not for pertussis (31-36). Thus, for diphtheria, tetanus and poliomyelitis, serological surveillance 
is a useful tool for providing insight into the long-term effects of mass vaccination. Serological 
data for pertussis are more difficult to interpret regarding population protection. However, 
serological data on pertussis give valuable information on the antibody distribution in the general 
(healthy) population, which can be used to improve the serodiagnosis of pertussis. Laboratory 
methods are required to confirm the clinical diagnosis of pertussis. Since pertussis diagnosis is 
hampered by low sensitivity, improvement of the diagnostic tools are beneficial for both the 
individual patient and for disease surveillance (37). 
Outline of the thesis 
In view of the evaluation of the Dutch National Immunisation Programme, the main objective of 
the studies described in this thesis was to provide insight into the immunity to diphtheria, tetanus 
and poliomyelitis and into the occurrence of pertussis in the Netherlands and to improve the 
serodiagnosis of pertussis. 
This thesis is based mainly on two studies. In the first study, a population-based serum bank was 
established by collecting sera from the general population together with questionnaire data on 
infectious disease determinants. This nationwide study includes individuals from the general 
population in all age groups from 0 to 79 years. Furthermore, sera were also collected from the 
general population in municipalities with a lower vaccine coverage. Differences in immune status 
of individuals from the nationwide sample and the latter sample are of particular interest in the 
Netherlands with its specific unvaccinated groups. 
In the second study data on the number of pertussis patients from various surveillance sources 
such as notifications, sérodiagnostic data and hospital admissions, were analysed. 
This thesis consists of three parts. The first part is entitled "A population-based serum bank". 
Chapter 2 describes the role of serological surveillance as an epidemiological method in the 
evaluation of a national immunisation programme and the design of the population-based serum 
bank. Chapter 3 described the results of the nonparticipation study that is a part of the first study. 
In the second part of the thesis, entitled "Immunosurveillance for diphtheria, tetanus and 
poliomyelitis", the prevalence of diphtheria antitoxin antibodies (Chapter 4), of tetanus antitoxin 
antibodies (Chapter 5) and of neutralising antibodies against poliovirus types 1, 2 and 3 
(Chapter 6) are studied with respect to the Dutch general population as well as to orthodox 
reformed groups who refuse vaccination in the municipalities with low vaccine coverage. 
The last part of the thesis is entitled "Surveillance and seroepidemiology of pertussis". Chapters 
7 and 8 describe surveillance data of pertussis, which were studied to obtain insight into the 
17 
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pertussis epidemic in 1996 and 1997 and to find possible explanations for this outbreak. Chapter 
9 investigates whether high levels of IgG antibodies against pertussis toxin in a single serum 
sample provide a specific laboratory tool for the diagnosis of pertussis. Finally, in the general 
discussion (Chapter 10), the main findings of the studies and possible implications for public 
health and further research are discussed. 
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Abstract 
Chapter 2 
Mass vaccination can change the epidemiological dynamics of infectious diseases. It may 
result in a limited persistence of natural and vaccine-induced immunity and a higher mean 
age of infection, which may lead to a greater risk of complications. The epidemiological 
situation should be monitored and immunosurveillance based on the assessment of 
specific antibodies against vaccine-preventable diseases in human serum is one of the 
tools. In order to estimate the immunity of the Dutch population reliably, a large-scale, 
population-based, collection of serum samples was established (8359 sera in a nationwide 
sampling and 1589 sera from municipalities with low vaccine coverage). In contrast to 
collecting residual sera from laboratories, this approach gains extensive information by 
means of a questionnaire regarding the determinants of the immune status and the risk 
factors for the transmission of infectious diseases in general. The population-based 
approach gives a better guarantee that the data are representative than collecting sera from 
laboratories does. 
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Introduction 
In the Netherlands, we have established a bank of sera from the general population for public 
health research. This article describes the use of seroprevalence data for the evaluation of the 
National Immunisation Programme (NIP), the design used for the data collection and the 
advantages of a population-based approach. Such an approach may be useful for future sero-
epidemiological studies in other countries. Results drawn from seroprevalence data from this 
study on vaccine-preventable diseases will be published separately. 
Long-term epidemiological effects of mass immunisation 
As in other countries, the incidence of most vaccine-preventable diseases (and their 
complications) in the Netherlands decreased considerably after the introduction of immunisation 
with diphtheria, tetanus and pertussis (DTP) vaccine in 1952, inactivated polio vaccine (IPV) in 
1957, rubella vaccine for girls in 1974, measles vaccine in 1976, measles, mumps and rubella 
(MMR) combination vaccine in 1987 and Haemophilus influenzae type b vaccine in 1993. The 
vaccine coverage is high and amounts to 97% of all 12-month-old children for three 
immunisations against DTP-IPV and 94% of all 14-month-old children for one immunisation 
against MMR (1). 
However, despite this high vaccine coverage, epidemics still occur (e.g measles and pertussis), 
and the (re)emergence of diphtheria is possible (2-5). Furthermore, mass vaccination may have 
some secondary effects in the longterm, as the epidemiological dynamics of infectious diseases can 
change. Once a pathogen has been pushed back to a large extent and its circulation is limited, the 
force of infection (the rate at which those who are susceptible acquire infection) decreases (6). 
This means that the chance of infection will decrease, which will result in delaying the infection of 
susceptible (unvaccinated) individuals. The expected increase in mean age for some vaccine-
preventable diseases is related to a greater chance of complications. For example, the frequency of 
orchitis due to mumps infection increases with age, the case fatality rate for measles was highest 
for unvaccinated individuals in older age groups and the shift in rubella infections to childbearing 
age could result in a greater risk of congenital rubella syndrome (CRS) (7-9). 
The lower force of infection also results in lack of boosting opportunities of both natural and 
vaccine-induced immunity. In contrast to the past, natural immunity may not persist lifelong, and 
vaccine-induced immunity may be lost even faster (10,11). This may also result in a shorter 
duration of passive immunity due to maternal antibodies in infants (12). Therefore, in order to 
assess the long-term effects of mass immunisation, insight into the (possibly changing) duration of 
vaccine-induced immunity and natural immunity is necessary. 
Herd immunity implies that non-immune individuals are protected from infection by the presence 
of immune individuals (13). Thus, in order to prevent the further spread of an infection, a 
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proportion of immune individuals in the population below 100% is sufficient. The threshold value 
is dependent on the contact rate between individuals and the probability of transmission. This was 
estimated (homogenous mixing assumed) at 82%-87% for diphtheria, poliomyelitis and rubella, at 
85%-90% for mumps and at 90%-95% for measles and whooping cough (6). Nevertheless, even 
in countries with high vaccine coverage, infections are still a threat, since high coverage on the 
average does not, warrant sufficient herd immunity. For example, in the Netherlands, groups who 
reject vaccination on religious ground, are sociodemographically and geographically clustered. In 
such situations where the condition of homogeneous mixing is not fulfilled, herd immunity can 
break down and epidemics can occur as a result. Such an event took place during the polio 
epidemic in 1992-3 (14). This epidemic was restricted to religious groups in a closely knit social 
network. The high incidence of CRS after a rubella epidemic among the Amish people in the 
United States is another example of insufficient herd immunity. Due to the low vaccine coverage 
and social clustering in combination with the absence of regular contacts outside their own 
community, the number of susceptible individuals had increased (8). 
Potential long-term secondary effects of mass immunisation should be anticipated by surveillance 
and possible adaptations of vaccination policy should be considered. 
Evaluation of immunisation programmes from seroprevalence data 
Epidemiological methods play an important role in the evaluation of an immunisation programme. 
These methods include monitoring vaccine coverage, surveillance of the occurrence of vaccine-
preventable diseases, case investigations, outbreak investigations, vaccine efficacy and 
effectiveness studies, surveillance of vaccine safety and serological surveillance (15,16). 
Important information on vaccine-preventable diseases can be derived from the latter method 
known as serosurveillance, which is the assessment of specific antibodies in serum as a sign of 
previous contact with the pathogen (17). These antibodies could have been induced either by 
natural infection with the virulent pathogen or by immunisation with the inactivated or live, 
attenuated pathogen. However, in general no serological methods are yet available to distinguish 
between natural and vaccine-induced immunity for vaccine-preventable diseases. Nevertheless, for 
some diseases the distinction can be made indirectly. Combining anti-Hbs and anti-Hbc tests the 
presence of the former in absence of the latter indicates vaccine-induced immunity against 
hepatitis B virus. Poliovirus specific IgA antibodies seem to discriminate between natural or OPV-
induced and IPV-derived immunity (18,19). For most vaccine-preventable diseases, specific 
antibodies can be used as an indicator of protection against the disease (for instance the presence 
of neutralizing antibodies against poliomyelitis). 
Antibodies induced by natural infection give information about both clinical and subclinical 
infections. Thus, this surveillance source is not limited to individuals with diseases that are 
otherwise considerably underreported (20-23). For example, evidence was found of subclinical 
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pertussis infections in which one-fifth of the youngest children had antibodies to pertussis toxin, 
even though they had no history of whooping cough (24). 
Serosurveillance offers an opportunity to look for clustering of susceptible individuals within 
specific age, social or geographical groups based on serological profiles. Ideally, identifying these 
groups should result in preventive interventions (for example, efforts to increase vaccine coverage 
in such groups or to adapt the vaccination strategy) before more cases (re)emerge. Low antibody 
levels for diphtheria and tetanus found in adults stress the need for revaccination of adults (25-
28). Seroprevalence studies support the two-dose immunisation strategy for MMR to prevent the 
disease from shifting to older age groups (29-31). 
Seroprevalence data can also benefit modelling studies (6). On the one hand, seroprevalence data 
derived from serological surveys can be used to estimate input parameters in modelling studies. 
The dynamics of the disease occurrence can then be predicted. For example, the data can help 
estimate the force of infection, the average age of infection and the minimum proportion of 
immune individuals needed to prevent transmission (the herd-immunity threshold). On the other 
hand, serological data are important in modelling studies to test the accuracy of the model 
predictions and epidemiological assumptions. Differences in the predicted serological profile and 
the observed serological profile may indicate the (in)correctness of the model assumptions (9,32-
34). Results from serological surveillance in England reveal that the proportion of school children 
susceptible to measles was increasing after the introduction of the MMR vaccination programme 
in 1988. Mathematical models were used to interpret these data. As the models predicted an 
epidemic of measles in 1994, a national campaign for measles and rubella vaccination was held in 
the United Kingdom (9). In the Netherlands in 1987, the selective vaccination strategy against 
rubella and CRS was changed to a mass vaccination strategy with MMR vaccine. Seroprevalence 
data were used as an input parameter in the mathematical models. These models played a major 
role in the decision-making process for changing the strategy (35). 
In order to make reliable estimates of the immunity of the population, the sample of sera used for 
serosurveillance should be representative for the total population in age and sex structure. The 
sample should also be representative for other demographic and socio-economic factors. 
Therefore, ideally, a population-based survey should be repeated periodically to study any 
changes in the population immunity. Sera from blood banks, military recruits or specialist clinics 
are biased towards certain age groups and sections of the community. Many serosurveys use 
serum samples from the more readily accessible sources (26,27,30,31,36-43). Although these 
studies are important in monitoring the effects of immunisation programmes, they may lack or be 
representative to an unknown degree. Stark and colleagues suggest that immunity against 
diphtheria in blood donors might lead to an overestimation of the immunity in the population, as 
blood donors might be more health conscious than the average individual (26). Whether 
individuals attending special clinics are more or less likely to have antibodies for a specific 
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pathogen than those in the general population is unknown. Apart from not being representative, 
another disadvantage is that the information about individuals from whom such sera were derived 
is often limited to age, sex and sometimes vaccination history. 
Serosurveys based on random samples are described, but often limited to a small age range or 
specific region or city (24,44-46). The National Health and Nutrition Examination Study 
(NHANES) in the United States is a rare example with a population-based serum collection and 
with extensive information on study subjects (25). 
In the Netherlands we have also had the opportunity to collect sera from the general population 
together with questionnaire data on determinants. This nationwide study includes individuals from 
the general population in all age groups from 0-79 years. Furthermore, sera were also collected 
from the general population in municipalities with the lowest vaccine coverage. Differences in 
immune status of individuals from the nationwide sample and the latter sample are of particular 
interest in the Netherlands with its specific unvaccinated groups. The data can give some insight 
into the effects of clustering of unvaccinated individuals on herd immunity. 
A population-based collection of serum samples in the Netherlands 
Sampling 
A two-stage cluster sampling technique was used to draw a nationwide sample. In each of five 
geographic regions, with approximately equal numbers of inhabitants, eight municipalities were 
sampled proportionally to their size. Within each municipality, an age-stratified sample of 380 
individuals was drawn from the population register. The population register contains all 
individuals with a home or postal address. Homeless without a postal address and illegal aliens are 
not included in the register. The age strata were 0, 1-4, 5-9, ... 75-79 years. In each of the first 
two strata 40 individuals were sampled, while in each of the following strata 20 individuals were 
sampled. This oversampling was based on an expected lower response (25% instead of 50%) from 
very young children and the importance of sufficient data in these age groups. Otherwise, we 
could not obtain insight into the level of maternal antibodies and the mean age of infection. 
Because of the particular situation in the Netherlands with its geographically clustered groups 
who refuse immunisation, records from the population registers of eight municipalities with a 
consistently low(er) immunisation coverage were also sampled. The vaccine coverage in these 
municipalities for three DTP-IPV immunisations of 12-month-old children ranged from 65-87% in 
1995 (1). The objective was to gain access to more unvaccinated individuals and to obtain more 
accurate estimates of seroprevalence in this subgroup. The expected number of unvaccinated 
individuals in the national sample would be too small to estimate seroprevalence for the diseases 
in the NIP in this subgroup. 
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The number of clusters (municipalities) and units (individuals) per cluster were chosen so that the 
expected accuracy of the seroprevalence estimates would be optimal within financial and logistical 
constraints. The accuracy is determined mainly by the total number of clusters and to a lesser 
extent by the number of units per cluster, as the expected variance between clusters is greater than 
within clusters (47). 
In total, 18 217 individuals were invited: 15 189 in the national sample and 3028 in the sample of 
the municipalities with a low vaccine coverage. 
Data collection 
The data were collected from October 1995 to December 1996 in collaboration with the public 
health services, an organization well known to the local inhabitants. The prospective participants 
were approached by mail and were asked to fill in a questionnaire at home and to visit the special 
clinic to give a blood sample (20 ml). The questionnaire asked for data on gender, occupation, 
level of education, country of birth and nationality, participation in military service, vaccination 
(participation in the NIP, opinion on the necessity of vaccination against DTP-IPV, MMR and 
Hib, (re)vaccination against DTP, tetanus, Hib, hepatitis A, hepatitis B, influenza), religion, travel, 
long-term coughing, pertussis, otitis, diabetes, gardening, contact/keeping animals, recreation in 
fresh waters, sexually transmitted diseases, self-perception of health, chronic diseases, smoking 
and drinking habits. Participants were asked to bring their immunisation certificates. In a pilot 
study in 1994, it turned out that self-reported vaccination history was not reliable (48). Therefore 
the analysis of serological data to investigate waning immunity will be directed toward individuals 
with verified vaccination history. 
An invited individual received a letter of invitation, along with a brochure giving information on 
the study, a questionnaire and a prescheduled appointment time (between 09.00 and 17.00 h). If 
the suggested time was not convenient, the participant could choose another time during the 2 
days when the clinic was held in the municipality. The walk-in clinic was open from 17.00 to 
19.30. An extra clinic appointment could be made 1 week later, or a house-visit could be 
arranged. 
Turkish and Moroccan residents received a letter of invitation in their own language. They were 
told that a Turkish and Moroccan speaking nurse would be present. Special attention was given to 
these nationalities because we expected a lower response rate, considering the results of the pilot 
study. These nationalities were important as the seroprevalence might be different. There might be 
a different force of infection and a different vaccination policy in their countries of birth. Access 
to the NIP and healthy baby clinics could be limited by language problems and frequent change of 
address for those who had not been in the Netherlands long. Before the consultation days, we 
telephoned invited individuals to remind them of the study, to answer any questions and to ask if 
they were willing to participate. In the pilot study, it was shown that the approach by telephone 
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led to a 6% increase in the response rate (49). When individuals declined to participate, they were 
asked to fill in the questionnaire or at least to answer some questions for the non-response survey 
(by telephone or mail). Individuals who could not be reached by phone were sent a written 
reminder. Participants were offered a gift voucher. Participants had to sign a written informed 
consent form that stated that the sera were to be tested for specific antibodies against infectious 
diseases (with the exception of HIV), that the data would be processed anonymously, that the 
serum would be coded and stored for a long time for the purpose of public health research and 
that they would not be informed of the test results. The study proposal was approved by the 
Medical Ethical Committee of Netherlands Organisation for Applied Scientific Research (TNO), 
Leiden, The Netherlands. 
Non-response survey 
Information about the participants regarding age, gender, marital status and nationality was 
available from the population registers. In addition, individuals who declined to participate were 
asked to fill in the original questionnaire or a short non-response questionnaire that contained 
questions about their level of education, religion, participation in the NIP, opinion on vaccination 
against diseases in the NIP and self-perception of health. The information about nonparticipants 
offers us the opportunity of correcting the seroprevalence data for possible selective 
nonparticipation. 
Serum processing and storage 
The blood samples were stored in a refrigerator during the day and at night. The sera were 
harvested the next day and divided into portions of 350 jxl which were stored at minus 86 °C in 
different freezers. 
The methods used are described in more detail in reference number 50. 
The serum bank 
A serum bank of 9948 samples has been established. All public health services and municipalities 
co-operated in the study. The (non)response rates for both samples are given in Table 1. 
The adjustments (reminder before consultation hours, Moroccan and Turkish speaking nurses, 
translated letter of invitation to individuals with Moroccan or Turkish nationality) made on the 
basis of the findings of the pilot study seem to have been successful because the participation rate 
increased from 40% in the pilot study to 55% (49). The participation rate was only slightly lower 
in the sample of municipalities with a low vaccine coverage (52.5%). 
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Table I. (Non)response rates in the nationwide and low vaccine coverage sample, 
Pienter project 1995-6, The Netherlands 
Nationwide 
sample 
Low vaccine 
coverage sample 
N (%) N (%) 
Participants 
Questionnaire and blood sample 8359 (55.0) 1589 (52.5) 
Nonparticipants 
Full questionnaire 1618 (10.7) 375 (12.4) 
Nonresponse questionnaire 1053 (6.9) 187 (6.2) 
Information from the population register 4159 (27.4) 877 (29.0) 
Total invited 15189 (100) 3028 (100) 
The serum bank can facilitate many sero-epidemiological studies. It will mainly be used for 
vaccine-preventable diseases, but the serum bank can also be used to obtain insight into the 
occurrence of infectious diseases with a course that is frequently subclinical and into the 
prevalence of other determinants. A procedure has been set up for release of the sera for further 
research. Research proposals will be judged on the relevance for public health and on scientific 
quality by a team of experts. 
Seroprevalence studies for diphtheria, tetanus, poliomyelitis, mumps, measles, rubella, 
Haemophilus influenzae type b, hepatitis A, B and C are currently in progress. 
Conclusions 
It appeared feasible to establish a serum bank in the Netherlands for public health research 
through a large-scale nationwide population-based cross-sectional study of the general 
population. The data will primarily be used for the evaluation of the effects of the NIP. Therefore, 
following an identical sampling scheme, a parallel study was done in municipalities with low-
vaccine coverage. These municipalities are of particular interest in our country, with its specific 
religious groups who refuse vaccination. A response rate of 55% was achieved. The result was a 
collection of nearly 10 000 sera. In contrast to the collection of residual sera from laboratories, 
this approach allowed for the collection of extensive information by means of a questionnaire 
regarding determinants of the immune status and risk factors for transmission of infectious 
diseases in general. An advantage of the population-based approach is that it gives a better 
guarantee that the data are representative. Besides, the information on non-participants offers an 
opportunity to study the impact of non-participation on seroprevalence estimates. In order to 
monitor changes in the population's immunity the serosurvey should be repeated periodically, 
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perhaps every 5 to 10 years, depending on the postulated rate of loss of immunity. It could also be 
considered to build up the serum bank in a more continuous way by collecting sera every year. 
This allows for the exploration of the effects of intercurrent epidemics (pertussis in 1996/7 or 
poliomyelitis in 1992/3 in our country) and either the introduction of new vaccines or changes in 
the (schedule of the) vaccines applied routinely (5,14). In the Netherlands we are now moving to 
such a continuous population-based serum collection. Although it would be even more interesting 
to include a longitudinal component in the survey it seems up to now not feasible since it would 
increase the already high costs of a population-based survey enormously. 
Despite the high costs of this population-based study compared to the use of residual sera, it 
might be worthwhile for other countries to consider a population-based collection of serum 
samples to study immunity against vaccine-preventable diseases. In 1996, the European Sero-
Epidemiology Network (ESEN) was established to co-ordinate and harmonise the 
serosurveillance of immunity to vaccine-preventable diseases in six European countries (Denmark, 
England, France, Germany, Italy and the Netherlands) (51). Laboratory methods should be 
standardized so that results from each centre are directly comparable. This is one of the major 
aims of the ESEN. However, comparability is also dependent on the representativeness of the 
study populations. In the ESEN, most of the countries had to rely on specimens submitted to 
laboratories for diagnostic purposes. Actually, not only should serological methods be 
standardised, the serum collection should be standardised as well, preferably by random sampling 
as advocated in this article. 
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Abstract 
Chapter 3 
To estimate the immunity of the Dutch population against vaccine-preventable diseases, an 
population-based serum bank was established. Since a multi-tiered approach to enrol 
eligible individuals was used, both the overall nonresponse selection and the effect on this 
selection of including additional participants and of excluding a subgroup of 
nonparticipants (i.e. those without questionnaire data) could be studied. For some 
characteristics associated with nonparticipation, an association with seroprevalence of 
vaccine-preventable diseases is likely (e.g. age, gender). For other characteristics (e.g. 
marital status, reminder, degree of urbanisation) the association with immune status is 
unclear but probably small. If the population's distribution or information on all 
participants and nonparticipants of the characteristic is available, the effect on the 
seroprevalence can be estimated. However, investigators have to be aware that studying 
only a subgroup of nonparticipants might lead to biased insight into nonparticipation 
selection. Furthermore, including additional participants might not always reduce 
nonparticipation selection. 
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Introduction 
To estimate the immunity of the Dutch population against vaccine-preventable diseases, we 
established a serum bank of Dutch individuals in a population-based study (1). Most previous 
serosurveys used residual sera from blood banks, military recruits, or specialist clinics which are 
not representative. Despite an appropriate sampling frame, serum collection may still be biased 
due to selective nonparticipation (2-8). To reduce this bias, one may incorporate information on 
characteristics of nonparticipants into sample estimates (9). In our study, a multi-tiered approach 
to enrol eligible individuals was used. This approach made it possible to study not only the overall 
nonresponse selection in our serum collection which will be used for future seroprevalence 
studies, but also to study the effect of including additional participants and of excluding a 
subgroup of nonparticipants on this selection (10-12). 
Material and methods 
Sampling design 
In each of five geographic regions in the Netherlands with similar population sizes, eight 
municipalities were sampled with a probability proportional to their population size. An age-
stratified sample of approximately 380 individuals was randomly selected within each municipality 
from the municipal vital statistics information (1). The age strata were 0, 1-4, and then by 5-year 
classes up to 75-79 years. Twenty individuals were sampled in each stratum except the first two, 
where 40 individuals were sampled as a lower response rate was observed in these age groups in a 
pilot study (13). Data were collected between October 1995 and December 1996. Subjects were 
contacted by mail and requested to fill out a questionnaire and to visit a clinic for blood sampling 
on one of two preset dates during daytime or evening hours. Before these dates, individuals were 
reminded of the study by telephone, if possible, or in writing. Individuals who were unable to 
attend on either of the two preset dates could visit an extra clinic. Those who refused to 
participate were asked to fill out the full self-administered questionnaire or, failing that, a short 
nonresponse questionnaire. 
Five groups of (non)participants were distinguished: 
1. 7,904 (52.0%) "initial participants" gave blood at the regular clinic and completed the 
questionnaire. 
2. 455 (3.0%) "additional participants" gave blood at the extra clinic and completed the 
questionnaire. 
3. 1,618 (10.7%) nonparticipants only completed the full questionnaire. 
4. 1,053 (6.9%) nonparticipants only completed the nonresponse questionnaire. 
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5. 4,159 (27.4%) "absolute nonparticipants" neither gave blood nor completed a 
questionnaire. 
For all groups, data on an individual level were available on age, gender, marital status (with the 
exception of one municipality), nationality (with the exception of two municipalities) from the 
municipal database; municipality and degree of urbanization of the municipality were assigned 
based on the place of residence of the individuals ("nonquestionnaire" variables). Missing data on 
nationality and/or marital status were imputed with data from other municipalities. Information on 
educational level, self-perception of health, religion, and opinion of the importance of 
immunisation were collected with both questionnaires ("questionnaire" variables). 
Definition of variables and statistical analysis 
The 17 age strata were grouped into five classes: 0-4, 5-14, 15-29, 30-64, and 65-79 years, which 
corresponded well with participation rates. Marital status was classified as "married", 
"unmarried", and "widowed or divorced". Nationality was classified as "Dutch", 'Turkish", 
"Moroccan", or "other". Although the numbers of Turks and Moroccans were small, they were 
analysed separately as a special effort was made to improve their response. Self-perception of 
health was classified as "(very) good" and "less than good" and reminder status as "by 
telephone", "by mail", or "other" (i.e., no reminder or unknown). The following categories for 
degree of urbanization were made: "very high" (>2,500 addresses/km2), "high" (1,500-2,500), 
"moderate" (1,000-1,500), "low" (500-1,000), and "none" (< 500). The geographical regions 
were based on the provinces in the Netherlands: "Central" (Utrecht and Gelderland), "Southeast" 
(Brabant and Limburg), "Northwest" (Noord-Holland and Flevoland), "Southwest" (Zeeland and 
Zuid-Holland) and "Northeast" (Groningen, Drente, Overijssel, and Friesland). 
The highest educational level achieved by those aged 17 years or older and by one of the parents 
for those younger than 17 years were classified as "low" (primary school, lower vocational or 
lower general secondary education), "intermediate" (intermediate vocational or intermediate 
general secondary and higher general secondary education), and "high" (higher vocational 
secondary education and university education). Three religious groups were distinguished: 
"Orthodox Reformed" for those who are known to be opposed to vaccination, "Reformed Bond" 
of whom about a quarter reject vaccination, and "other or no religion" (14). 
For the opinion of "importance of immunisation" the following groups were distinguished: 
1. Diphtheria (D), pertussis (P), tetanus (T), poliomyelitis (IPV), Haemophilus influenzae 
type b (Hib), mumps (M), measles (Me), and rubella (R) immunisation were considered 
necessary. 
2. Seven of the eight immunisations just mentioned were considered necessary. 
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3. All immunisation was considered unnecessary. 
4. D,T,P,IPV, and Hib were thought necessary and M,Me, and R unnecessary. 
5. M,Me,R were thought necessary and D,T,P,IPV, and Hib "'otherwise" (less than four 
necessary) 
6. D,T,P,IPV, and Hib were considered necessary and M,Me,R "otherwise" (less than 
two necessary). 
7. The remaining group had some other opinion. 
Although the number of subjects in the categories "D,T,P,IPV,Hib,M,Me, and R unnecessary" 
and "Orthodox Reformed" were small, these were considered separately because these groups 
decline immunisation often, which might affect our evaluation of the national immunisation 
programme. 
All participants were compared to all nonparticipants in the first dichotomous logistic regression 
and "non-questionnaire" variables that were associated with (non)participation were identified. 
Variables remained in the multivariate model if either the likelihood ratio test was significant (p < 
0.05) or the estimates of the beta coefficients for other variables in the model changed by at least 
ten percent. These variables were included in the polytomous logistic regression model. 
The second dichotomous logistic regression analysis was restricted to (non)participant groups 
with questionnaire data. "Nonquestionnaire" variables from the first dichotomous logistic model 
were included. "Questionnaire" variables were included in the dichotomous and polytomous 
models according to the procedure described. Participants were used as reference group in the 
dichotomous logistic models; initial participants, in the polytomous logistic models. 
Results 
The univariate and multivariate analyses showed that several subgroups were less likely to 
participate: men aged 15-29 and 30-64 years versus women in these age groups, girls or women 
aged 0-4, 15-29, or 65-79 years versus women aged 30-64 years, boys or men aged 0-4 and 15-
29 years versus men aged 30-64 years, women aged 15-29 versus men aged 15-29 years and 
women aged 30-64 versus men aged 30-64 years, unmarried or widowed/divorced versus married 
individuals, individuals with Turkish or "other" nationality versus Dutch individuals, individuals 
who did not receive a reminder by telephone versus those who did and individuals from 
municipalities with (very) high or moderate versus no degree of urbanization (Table 1). More 
likely to participate were: boys aged 5-14 versus men of 30-64 years, girls aged 5-14 years versus 
women aged 30-64 years, Moroccans versus Dutch, and individuals from the southeast versus 
northeast region (Table 1). The likelihood of participation was similar for men and women aged 
0-4, 5-14 and 65-79 years. 
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Table I. Odds ratios (ORs) and 95 percent confidence intervals (95% CI) for characteristics 
("Nonquestionnaire" variables) comparing all nonparticipants with participants; Pienter 
Project, 1995-1996, The Netherlands 
Numbers in Crude (95%' CI) Adjusted (95% (!) 
subgroup ORs ORs 
Age group (years) by 
gender 
Male 
0-4 1,636 1.34 (1.18- 1.51) 1.00 (0.85 - 1.18) 
5-14 820 0.48 (0.40 • 0.56) 0.36 (0.29 - 0.44) 
15-29 1,194 1.65 (1.44 • 1.89) 1.35 (1.14-- 1.59) 
30-64* 2,842 1.0 1.0 
65-79 1,017 1.01 (0.88 • 1.17) 1.06 (0.92 - 1.23) 
Female 
0-4 1,551 2.06 (1.82 - 2.34) 1.62 (1.37- 1.91) 
5-14 785 0.78 (0.66 • 0.93) 0.58 (0.47 - 0.71) 
15-29 1,205 1.47 (1.28 • 1.68) 1.22 (1.03-- 1.43) 
30-64* ' 2,756 1.0 1.0 
65-79 1,383 2.02 (1.78 •2.31) 1.88 (1.64--2.16) 
Marital status 
Married* 6,012 1.0 1.0 
Unmarried 7,769 1.42 (1.33 - 1.52) 1.44 (1.27- 1.63) 
Widowed/divorced 1,408 1.86 (1.66 - 2.09) 1.59 (1.40 - 1.80) 
Country of nationality 
Netherlands* 14,568 1.0 1.0 
Turkey 128 1.33 (0.94 - 1.89) 1.12 (0.78 - 1.61) 
Morocco 128 0.80 (0.56 - 1.15) 0.65 (0.45 -- 0.95) 
Other 365 2.52 (2.03 -3.15) 2.41 (1.91 - 3.03) 
Reminder 
By telephone* 7,348 1.0 1.0 
By mail 7,386 1.38 (1.29 - 1.47) 1.31 (1.22-- 1.40) 
Other 455 6.56 (5.16 - 8.35) 6.38 (4.99 -8.15) 
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Table I continued 
Numbers in Crude (95% CI) Adjusted (95% CI) 
subgroup ORs ORs 
Degree of 
urbanization 
Very high 2,280 2.03 (1.83 -2.25) 1.92 (1.72-2.15) 
High 1,900 1.20 (1.07- 1.34) 1.20 (1.06- 1.35) 
Moderate 3,798 1.07 (0.98-1.17) 1.10 (1.00- 1.22) 
Low 3,040 1.01 (0.92-1.11) 1.03 (0.92- 1.14) 
No* 4,171 1.0 1.0 
Region 
Central 3,040 0.98 (0.89 - 1.09) 0.93 (0.83- 1.05) 
Southeast 3,040 0.90 (0.81 - 1.00) 0.84 (0.76 - 0.94) 
Northwest 3,038 1.06 (0.96- 1.18) 1.00 (0.90-1.13) 
Southwest 3,033 1.10 (0.99- 1.21) 0.95 (0.84- 1.07) 
Northeast* 3,038 1.0 1.0 
* Reference group 
t Women aged 30-64 years versus men aged 30-64 year crude OR 0.64 (95% CI 0.58 - 0.72) and adjusted 
OR 0.62 (95% CI 0.56 - 0.70) 
The results from the multivariate polytomous logistic regression analysis (Table 2), were similar 
to those of the univariate analysis (not presented). For age groups by gender, the odds ratios for 
the various nonparticipant groups over initial participants were different. This was most obvious 
for the youngest age group: for both boys and girls the odds ratio for nonparticipants with full 
questionnaire over initial participants was far above unity, while it was below one comparing 
absolute nonparticipants with initial participants. 
Nationality, kind of reminder, and degree of urbanization affected the types of (non)participation 
differently (Table 2). 
To study the nonparticipation selection for "questionnaire" variables, absolute nonparticipants 
were excluded from the subsequent analysis. In the univariate analysis, educational level, religion, 
importance of immunisation, and self-perception of health were associated with nonparticipation 
(Table 3). 
After adjustment for the "nonquestionnaire" variables, the opinion of the importance of 
immunisation on nonparticipation remained statistically significant. The polytomous logistic 
regression analysis shows that the opinions about the importance of immunisation affected the 
types of (non)participation differently (Table 4). 
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Table 2. Odds ratios (ORs) and 95 percent confidence intervais (95% CI) for characteristics ("Nonquestionnaire" 
variables) comparing additional participants (AP; n=455), nonparticipants with a full questionnaire (OQ; n=l,618), 
nonparticipants with a nonresponse questionnaire (NQ; n=1,053) and absolute nonparticipants (NP; n-4,I59) with 
initial participants (IP); Pienter Project, 1995-1996, The Netherlands 
Adjusted ORs Adjusted ORs Adjusted Adjusted 
A P _ _ _OQ ORsNQ ORsNP 
Age group (years) by gender 
Male 
0-4 0.63 (0.39 -1.01) 3.54 (2.62 - 4.78) 1.11 (0.81 - 1.52) 0.51 (0.42 - 0.62) 
5-14 0.54 (0.32 • -0.91) 0.74 (0.50 -- 1.09) 0.45 (0.30 - 0.68) 0.26 (0.20 - 0.33) 
15-29 1.29 (0.83 - 2.02) 1.72 (1.23 -2.41) 1.49 (1.08 - 2.06) 1.29 (1.07- 1.56) 
30-64* 1.0 1.0 1.0 1.0 
65-79 0.46 (0.27 -- 0.78) 1.04 (0.76 -- 1.41) 0.87 (0.63 -- 1.20) 1.07 (0.91 - 1.26) 
Female 
0-4 1.11 (0.69 • - 1.78) 4.07 (3.01 -- 5.49) 1.67 (1.21 - 2.32) 0.94 (0.77 - 1.16) 
5-14 0.86 (0.51 -- 1.46) 1.37 (0.97 --1.95) 0.61 (0.40 - 0.93) 0.38 (0.29 - 0.49) 
15-29 0.92 (0.58 • - 1.48) 1.46 (1.07 -2.01) 1.47 (1.07 - 2.02) 1.06 (0.88 - 1.29) 
30-64*' ' 1.0 1.0 1.0 1.0 
65-79 0.51 (0.30 • - 0.88) 1.83 (1.42 - 2.37) 1.30 (0.96 - 1.77) 1.97 (1.68- 2.31) 
Marital status 
Married* 1.0 1.0 1.0 1.0 
Unmarried 1.33 (0.93 - 1.89) 1.33 (1.03 - 1.71) 1.55 (1.21 - 1.99) 1.46 (1.26 - 1.68) 
Widowed/divorced 1.26 (0.84 -1.88) 1.33 (1.04 - 1.71) 1.70 (1.31 - 2.20) 1.63 (1.41 - 1.88) 
Table 2 continued 
Adjusted ORs Adjusted ORs Adjusted Adjusted 
AP OQ ORs NQ ORsNP 
Country of nationality 
Netherlands* 1.0 1.0 1.0 1.0 
Turkey 0.19 (0.03 - 1.41) 0.33 (0.13- 0.83) 0.21 (0.06 - 0.67) 1.73 (1.18- 2.53) 
Morocco 1.32 (0.62 - 2.83) 0.34 (0.14- 0.79) 0.54 (0.26 - 1.11) 0.83 (0.54 - 1.27) 
Other 1.29 (0.66 - 2.51) 1.09 (0.68 - 1.76) 1.46 (0.93 - 2.29) 3.26 (2.54 - 4.19) 
Reminder 
By telephone* 1.0 1.0 1.0 1.0 
By mail 1.49 (1.22- 1.82) 0.62 (0.55 - 0.70) 2.29 (1.99- 2.64) 1.60 (1.47- 1.73) 
Other 2.58 (1.26- 5.30) 4.97 (3.61 - 6.85) 5.19 (3.36 - 8.02) 8.11 (6.17- 10.7) 
Degree of urbanization 
Very high 2.26 (1.67- 3.06) 1.31 (1.07- 1.59) 2.76 (2.23 - 3.43) 2.21 (1.94- 2.52) 
High 1.42 (1.02- 1.98) 1.04 (0.85 - 1.27) 1.95 (1.54- 2.47) 1.17 (1.01 - 1.35) 
Moderate 1.43 (1.07- 1.91) 1.03 (0.87 - 1.22) 1.75 (1.42- 2.16) 1.07 (0.95 - 1.21) 
Low 1.01 (0.73 - 1.40) 0.99 (0.83 - 1.19) 1.12 (0.89 - 1.40) 1.02 (0.90 - 1.15) 
No* 1.0 1.0 1.0 1.0 
Region 
Central 0.62 (0.44- 0.89) 1.03 (0.85 - 1.25) 0.71 (0.57 - 0.90) 0.92 (0.80 - 1.06) 
Southeast 1.08 (0.79 - 1.48) 1.01 (0.84 - 1.22) 0.63 (0.50 - 0.79) 0.85 (0.75 - 0.97) 
Northwest 1.13 (0.81 - 1.57) 1.11 (0.91 - 1.34) 0.80 (0.63 - 1.00) 1.01 (0.88 - 1.15) 
Southwest 0.89 (0.63 - 1.25) 1.13 (0.93 - 1.37) 0.80 (0.64 - 1.01) 0.89 (0.78 - 1.03) 
Northeast* 1.0 1.0 1.0 1.0 
* Reference group; f Women aged 30-64 years versus men aged 30-64 years: AP adjusted OR 0.68 (95% CI 0.50 - 0.91); 
OQ adjusted OR 0.86 (95% CI 0.68-1.08); NQ adjusted OR 0.64 (95% CI 0.51 - 0.81); NP adjusted OR 0.56 (95% CI 0.49 -0.63). 
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Table 3. Odds ratios (ORs) and 95 percent confidence intervals (95% CI) for characteristics 
comparing nonparticipants with questionnaire data with participants; Pienter Project, 1995-
1996, The Netherlands 
Numbers in Crude (95% CI) Adjusted (95% CI) 
subgroup ORs ORs 
A: "Nonquestionnaire" 
variables 
Age group (years) by gender 
Male 
0-4 1,293 3.01 (2.57 - 3.54) 2.51 (2.00-3.16) 
5-14 689 0.78 (0.61 -0.99) 0.65 (0.49 - 0.86) 
15-29 719 1.94 (1.60-2.37) 1.60 (1.26-2.05) 
30-64* 1,892 1.0 1.0 
65-79 670 0.99 (0.78- 1.23) 0.94 (0.74-1.18) 
Female 
0-4 1,219 3.70 (3.13-4.36) 3.18 (2.52 - 4.00) 
5-14 681 1.31 (1.04- 1.64) 1.06 (0.81 - 1.41) 
15-29 883 1.75 (1.44-2.12) 1.52 (1.20- 1.92) 
30-64*' f 2,110 1.0 1.0 
65-79 874 1.80 (1.48-2.19) 1.58 (1.29-1.94) 
Marital status 
Married* 4,366 1.0 1.0 
Unmarried 5,809 2.23 (2.02 - 2.46) 1.37 (1.14- 1.64) 
Widowed/divorced 855 1.73 (1.45-2.06) 1.49 (1.24- 1.80) 
Country of nationality 
Netherlands* 10,697 1.0 1.0 
Turkey 70 0.40 (0.19-0.84) 0.29 (0.13-0.61) 
Morocco 93 0.60 (0.34- 1.04) 0.42 (0.24 - 0.75) 
Other 170 1.26 (0.90-1.76) 1.14 (0.80-1.63) 
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Table 3 continued 
Numbers in Crude (95% CI) Adjusted (95% CI) 
subgroup ORs ORs 
Reminder 
By telephone* 5,738 1.0 1.0 
By mail 5,066 1.05 (0.96 - 1.15) 1.03 (0.94 - 1.14) 
Other 226 5.55 (4.21 - 7.32) 4.82 (3.61 - 6.44) 
Degree of urbanization 
Very high 1,377 1.66 (1.44- 1.91) 1.67 (1.43- 1.95) 
High 1,384 1.21 (1.05- 1.41) 1.30 (1.11- 1.53) 
Moderate 2,857 1.13 (1.00- 1.27) 1.22 (1.06- 1.40) 
Low 2,275 1.00 (0.88 - 1.14) 1.03 (0.89 - 1.20) 
No* 3,137 1.0 1.0 
Region 
Central 2,215 0.97 (0.84 - 1.11) 0.91 (0.78 - 1.07) 
Southeast 2,253 0.89 (0.77 - 1.02) 0.82 (0.70 - 0.95) 
Northwest 2,174 1.05 (0.92 - 1.21) 0.96 (0.82 - 1.12) 
Southwest 2,181 1.13 (0.99 - 1.30) 0.98 (0.83 -- 1.14) 
Northeast* 2,210 1.0 1.0 
B: "Questionnaire" 
variables 
Opinion of importance of 
immunisation 
D, T, P, IPV, Hib, M, Me, 7,443 1.0 1.0 
R necessary* 
Seven of D, T, P, IPV, Hib, 853 1.12 (0.96 - 1.31) 1.25 (1.06 - 1.49) 
M, Me, R necessary 
D, T, P, IPV, Hib, M, Me, 55 1.97 (1.15- 3.37) 2.33 (1.33 -4.10) 
R unnecessary 
M, Me, R necessary, D, T, 267 1.41 (1.09- 1.83) 1.72 (1.30 - 2.27) 
P, IPV, Hib other 
D, T, P, IPV, Hib 478 1.08 (0.88 - 1.32) 1.16 (0.92 - 1.44) 
necessary, M, Me, R other 
Other 1,934 1.34 (1.20- 1.49) 1.59 (1.41 - 1.79) 
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Table 3 continued 
Numbers in 
subgroup 
Crude 
ORs 
(95% CI) Adjusted (95% CI) 
ORs 
Educational level** 
Low* 
Intermediate 
High 
5,115 
3,308 
2,427 
1.0 
1.26 
1.22 
(1.13- 1.39) 
(1.09-1.36) 
Self-perception of health** 
(Very) good* 
Less than good 
9,085 
1,827 
1.0 
0.90 (0.80- 1.02) 
Religion 
Orthodox Reformed 
Reformed Bond 
Other* 
90 
145 
10,795 
1.62 
0.97 
1.0 
(1.06-2.47) 
(0.67- 1.40) 
Reference group 
t Women aged 30-64 years versus men aged 30-64 years: crude OR 0.78 (95% CI 0.67 - 0.94), adjusted 
OR 0.78 (95% CI 0.66 - 0.93) 
** N < 11,030 due to missing values 
The exclusion of absolute nonparticipants affects the association with nonparticipation for some 
"nonquestionnaire" variables considerably (Tables 1 versus 3). The odds ratios for 0-4 year-olds, 
Turks and Moroccans deviate farther from unity in the model restricted to groups with 
"questionnaire" variables (Table 3) than the odds ratios in the analysis with all (non)participant 
groups (Table 1). In contrast, the odds ratios for 5-14-year-olds, other nationality, and reminder 
by mail were closer to unity in the analysis restricted to (non)participants with questionnaire 
information. 
The effect of considering additional participants as nonparticipants would only slightly affect the 
association with nonparticipation as most of the 95% confidence intervals include unity. For 
degree of urbanization and kind of reminder, the difference between participants and 
nonparticipants is slightly less when additional participants are included, while the difference 
increases slightly for nationality. 
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Table 4. Odds ratios (ORs) and 95 percent confidence intervals (95% CI) for opinion of 
immunisation categories comparing additional participants (AP; n=455), nonparticipants with a 
full questionnaire (OQ; n=l,618) and nonparticipants with a nonresponse questionnaire 
(NQ;1,053) with initial participants (IP; n=7,904) (reference group); Pienter Project, 1995-
1996, The Netherlands 
Adjusted Adjusted Adjusted 
ORs* AP ORs* OQ ORs* NQ 
Opinion of importance of 
immunisation 
D, T, P, IPV, Hib, M, 1.0 1.0 1.0 
Me, R necessaryf 
Seven of D, T, P, IPV, 0.75 (0.50 - 1.13) 1.42 (1.16 - 1.75) 1.04 (0.80 - 1.34) 
Hib, M, Me, R necessary 
D, T, P, IPV, Hib, M, 0.60 (0.08 - 4.48) 2.01 (0.99 -4.10) 2.65 (1.25- 5.62) 
Me, R unnecessary 
M, Me, R necessary, D, 1.10 (0.60 - 2.01) 2.34 (1.68 - 3.26) 1.12 (0.72 - 1.73) 
T, P, IPV, Hib other 
D, T, P, IPV, Hib 0.73 (0.43 - 1.24) 1.25 (0.95 - 1.64) 0.98 (0.71 - 1.37) 
necessary, M, Me, R 
other 
Other 0.99 (0.76 -1.28) 1.81 (1.56 -2.11) 1.32 (1 .11- 1.56) 
Adjusted for age group by gender, marital status, nationality, kind of reminder, degree of urbanization 
and region, 
t Reference group 
Discussion 
The only way to eliminate bias from selection is to take a random sample and to achieve complete 
response, which is impossible in practice (15). The participation rate of 55% in our study was 
higher than expected, but differences found between participants and nonparticipants imply that 
our serum collection might not be representative of the general population (9,16). 
When these differences are also associated with immune status of the disease in question they 
could lead to incorrect estimates of seroprevalence. Since the serum collection will be used for 
many seroprevalence studies - mainly directed to various vaccine-preventable diseases - this 
association should be studied separately for each seroprevalence study. Below we summarize for 
which characteristics differences were found between the (non)participation groups and whether 
associations with immune status are expected. 
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The special efforts to enhance the response rate of the Turks and Moroccans (the largest groups 
with non-Dutch nationality) seemed successful; in contrast to our pilot-study, Turks had a 
participation rate similar to the Dutch, and Moroccans had an even a higher participation rate than 
the Dutch (13). Relatively fewer individuals with another nationality participated. 
Due to differences in force of infection and immunisation programmes in country of origin, 
immune status is likely to depend on nationality. For example the likelihood on protective tetanus 
antitoxin levels for Turkish and Moroccan individuals was lower than for Dutch individuals and 
individuals with other nationalities (26). Since non-Dutch individuals account for only a small part 
of the population the impact on the overall estimate is likely to be small. 
Like others, we found that relatively fewer unmarried individuals than married individuals 
participated (3,4,6,27). The finding that a lower degree of urbanization was associated with more 
participation, is consistent with other reports (18,24). Active refusers accounted for the largest 
part of the group described by "other reminder", which caused the high odds ratio for 
nonparticipation. Consistent with other studies individuals who could be reached and reminded by 
telephone participated more frequently than those who were reminded by mail (11, 16,28). 
Although the associations for these three characteristics with immune status are unclear, we 
expect them to be small. This has recently been supported by the absence of associations with 
tetanus immunity (26). 
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The likelihood of participation was lower for men than women for those aged 15-64 years. Some 
found that the participation rate was not related to gender, others reported that men were more 
difficult to recruit (3,5,10,17-20). The participation rate of the men were lowest among 15-29-
year-olds, while the participation rate of the women was lowest among the oldest and youngest 
age group. Frequently, but not always, it is reported that nonparticipants were older than 
participants (4-7, 20-24). The high participation rate of 5-14-year-olds -an age group recently 
vaccinated- might be explained by the perceived importance of the topic of the study (25). The 
low participation rate of the younger age group is probably related to parents' fear of possible ill 
effects of blood sampling on their young children. 
Age and gender are likely to be associated with immune status for vaccine-preventable diseases. 
Seroprevalence will depend on age as a result of age-specific differences in chance of exposure to 
the pathogen, time since exposure, chance of vaccination and time since last vaccination (1). For 
example those born before the introduction of mass vaccination in 1952 with DTP-IPV are more 
likely to be exposed to diphtheria and poliomyelitis but are less likely to have received 
vaccination. Gender differences in seroprevalence can be expected due for example vaccinations 
given in military service. In our recent study on tetanus antitoxin antibodies men with military 
service history were more likely to have tetanus antitoxin antibodies (26). 
Nonparticipation 
The polytomous logistic regression analysis showed that since additional participants resembled 
nonparticipants more for degree of urbanization and kind of reminder, the nonresponse bias due 
to these characteristics is slightly less than it would have been if these subjects had not 
participated. However, with respect to nationality, additional participants resembled initial 
participants more than nonparticipants, so that the reverse is true for this characteristic. Although 
including additional participants probably affected the nonresponse bias in our study very little, 
our results show that the assumption that additional (late) participants resemble nonparticipants 
more than initial participants as they both participated not in the first stage might be incorrect 
(9,11,19,29,30). 
Some variables affected each form of nonparticipation similarly, while other variables influenced 
each form of nonparticipation differently. Identifying nonresponse bias in our study on the basis of 
completed questionnaires would overestimate the nonresponse bias for 0-4-year-olds and for 
Turks and Moroccans, and underestimate it for individuals of another non-Dutch nationality and 
for those reminded by mail. 
This implies that our results from the analysis restricted to those with questionnaire information 
are also difficult to interpret. In this analysis, opinions about the importance of immunisation 
turned out to be an independent predictor for nonparticipation for those with questionnaire 
information. Individuals who considered none of the immunisations necessary, or M,Me, and R 
necessary and D,T,P,IPV, and Hib otherwise, were most likely to be nonparticipant (with 
questionnaire). In the univariate analysis, the likelihood of being a nonparticipant who filled in a 
questionnaire was higher for individuals with an intermediate or high educational level and who 
were Orthodox Reformed, and slightly lower for individuals who considered their health less than 
good. These findings are inconsistent with those in other studies for educational level and self-
perception of health, while no nonresponse studies on the effect of opinion of importance of 
immunisation and religion are known (3-6,10,20-23). 
Vaccination history and as a result of refusing vaccination orthodox reformed religion is expected 
to be associated with immune status to vaccine preventable diseases. Since the vaccine coverage 
in the Netherlands is high (97% for DTP-IPV, Hib; 94% for M, Me and R) and the group of 
orthodox reformed individuals is small (about 300,000) the impact on the seroprevalence 
estimates are probably limited. Again these expectations were supported by the seroprevalence 
study on tetanus (26). 
In this population-based study addressing vaccine-preventable diseases differences were found 
between participants and nonparticipants as they were in other studies. 
Correction for differential participation can be made by taking the distribution of the concerning 
characteristic in the Dutch population (if known, i.e. as for age) into account in the 
seroprevalence estimates. Furthermore, when information for all participants and nonparticipants 
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is known the effect on the seroprevalence can be estimated by weighting the seroprevalence 
estimate by differential response rate. However, the results of our polytomous logistic regression 
analysis show that when information is available only for a subgroup of nonparticipants it might 
lead to biased insight into nonresponse selection. If such a characteristic is associated with 
immune status of the disease in question, one can not be certain on the exact impact on the overall 
seroprevalence estimate. Furthermore, our study shows that investigators have to be aware that 
including additional participants might not always reduce nonresponse bias. 
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Abstract 
In a population-based study in the Netherlands, diphtheria antitoxin antibodies were 
measured with a toxin-binding inhibition assay in 9,134 sera from the general population 
and of religious communities refusing vaccination. 
The Dutch immunisation programme appears to induce long-term protection against 
diphtheria. However, a substantial number of adults born before the programme was 
introduced had no protective diphtheria antibody levels. Although herd immunity seems 
adequate, long-term population protection cannot be assured. As more than 60% of 
orthodox reformed persons have diphtheria antibody levels lower than 0.01 IU/ml, 
introduction of diphtheria into religious communities refusing vaccination may constitute a 
danger of spread of the bacterium. 
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Introduction 
The recent diphtheria epidemics in Eastern Europe are a warning that diphtheria can make a 
comeback in susceptible populations (1). The World Health Organization recommends the 
implementation of strategies for non-epidemic countries, including the assessment of the 
population diphtheria immunity status, to prevent any indigenous cases in the European Region by 
the year 2000 (2). 
In the Netherlands the last diphtheria epidemic occurred during World War II (220,000 cases 
were reported in 1940 to 1946). Diphtheria vaccination was introduced in 1952 for persons born 
after 1945. Under the current schedule, children are vaccinated at ages 3, 4, 5, and 11 months 
with diphtheria, tetanus, pertussis and inactivated polio vaccine (DTP-IPV) and at ages 4 and 9 
years with DT-IPV. For the past decades, the vaccine coverage for at least three vaccinations at 
the age of 12 months has been 97%. Rare exposure to C. diphtheriae may have led to lack of 
boosting opportunities (1). As in other developed countries, lack of immunity in older persons is a 
reason for concern (3,4). Furthermore, in the Netherlands, the immune status of socio-
geographically clustered members of religious communities who refuse vaccination may be even 
more unfavourable. Inadequate diphtheria herd immunity in these groups could lead to outbreaks 
similar to the poliomyelitis outbreaks in the Netherlands (5). A large population-based serum bank 
allowed us to assess the diphtheria immunity in the Dutch population and in persons refusing 
vaccination (6). 
The study 
In October 1995 through December 1996, a population-based serum bank with specimen from 
9,948 individuals was established (6). Our objective was to select 40 municipalities with sampling 
probabilities proportional to population size. In each of five regions, eight municipalities were 
included. For each of these 40 municipalities, an age-stratified sample of 380 individuals was 
drawn from the population register (7). Participants were requested to have a blood sample 
drawn, complete a questionnaire, and provide immunisation and military service records. 
Participants were also selected from eight additional municipalities with low vaccine coverage to 
assess the immunity of members of religous communities that refuse vaccination. The nationwide 
sample had 8,357 (55%) and the low vaccine coverage sample had 1,589 (52.5%). Sufficient 
serum was available for testing 7,715 of the nationwide participants and for 1,419 of the 
participants in the sample with low vaccine coverage. 
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Methods 
Sera were stored at minus 86 °C. The level of diphtheria antitoxin antibodies was measured with a 
toxin-binding inhibition assay as described earlier (8). In brief, twofold serum dilution series were 
incubated with a fixed amount of toxin and the nonneutralised toxin was measured in an enzyme-
linked immunosorbent assay (ELISA) with equine antitoxin purified from hyperimmune serum as 
coat and peroxidase-labelled horse antidiphtheria IgG as conjugate. International units were 
calculated according to the WHO reference standard serum (10 IU/ml) by the four parameter fit 
method in Kineticalc (KC4, Biolyse) with a Bio-Tek plate reader (EL312d). The minimum level of 
detection was 0.01 IU/ml and samples below this level were set to 0.005 IU/ml for calculating 
geometric mean titres. The good correlation with the Vero neutralisation assay was confirmed 
again recently (r>0.95) (9). 
Antitoxin antibody levels were classified according to international standards < 0.01 IU/ml (no 
protection), 0.01 IU/ml to 0.1 IU/ml (basic protection) and > 0.1 IU/ml (full protection) (10). 
Analysis 
Frequencies and geometric mean titres in each municipality were weighted by the proportion of 
the age group in the population. To produce national estimates, the weighted frequencies and 
geometric mean titres were averaged over the 40 municipalities (7). For the low vaccine coverage 
sample, they were averaged weighting by the population size of the municipality. 
Data on age, sex, marital status, country of nationality, degree of urbanization, region and contact 
information for all participants and nonparticipants was available. The effect of differentia] 
probabilities of response for these variables on both sample estimates was less than one standard 
error and was therefore disregarded. 
Linear regression analysis was used to study the persistence of diphtheria antitoxin antibodies 
after full immunisation in the national immunisation programme. The association between 
diphtheria antibody titre (2log) and age in 2log years was studied in this analysis for persons who 
received th sixth documented vaccination at 8 to 9 years of age, without self-reported or 
documented revaccination or military service history. 
Age-specific dipththeria antitoxin immunity levels 
In the nationwide sample 58.1%, 30.0% and 11.9% of persons < 79 years of age had full, basic, 
or no diphtheria protection, respectively (Table 1). Women had lower levels of full protection and 
geometric mean titres. A greater percentage of persons from the municipalities with low vaccine 
coverage and of members of religous communities in this low vaccine coverage sample had no 
protection (Table 2). When members of religious communities were excluded from this low 
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vaccine coverage sample, i.e. for not orthodox reformed persons, the percentages of full, basic, 
and no protection were 57.3%, 25.2%, and 17.5%, respectively (Table 2). 
For the ages of 1,4 and 8 to 9 years the geometric mean titre and percentages of persons with full 
protection increased (Table 3). The percentage with full protection decreased after the age of 10 
to 14 years, but increased for the 35- to 44-year age group (Figure 1). 
After the age of 40 to 44 years, the percentage with full protection and the geometric mean titre 
decreased. Although the geometric mean titres differed statistically significantly by gender only 
after the age of 30 years, they were slightly lower for females from 5 to 9 years old and older 
(Table 3). 
Both for orthodox reformed individuals less than 50 years and for those at least 50 years of age, 
the proportion with no protection was higher than for persons in the nationwide sample (Table 4). 
Men and women aged 20 to 49 years without a military service history had similar proportions of 
full, basic and no protection, while the proportion with full protection was higher for men with a 
military service history (Table 5). 
Percentage GMT (in IU/ml) 
0 1- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75-
ZZI at least 0.1 IU/ml 1HI 0.01 to 0.1 IU/ml 
mt less than 0.01 IU/ml —--GMT (95% CI) Age (in years) 
Figure I. Age-specific diphtheria immunity in the nationwide sample (n = 7715), 
The Netherlands 
61 
Table 1. Diphtheria immunity in a nationwide sample of persons < 79 years of age, The Netherlands 
Number <0.01 (95% CI) 0.01-0.1 (95% CI) £0.1 (95% CI) GMT (95% CI) 
IU/ml IU/ml IU/ml 
Nationwide sample 
Overall 7715 11.9 (10.7- 13.1) 30.0 (28.3-31.7) 58.1 (56.2-59.9) 0.12 (0.11 -0.13) 
Men 3644 9.3 (8.0-10.6) 28.1 (25.9-30.2) 62.6 (60.1-65.2) 0.14 (0.13 - 0.16) 
Women 4071 14.4 (12.6- 16.2) 31.6 (29.7-33.6) 54.0 (51.9-56.0) 0.10 (0.09-0.11) 
Table 2. Diphtheria immunity in the sample of persons < 79 years of age with low vaccine coverage, The Netherlands 
Number <0.01 
IU/ml 
(95% CI) 0.01-0.1 
IU/ml 
(95% CI) >0.1 
IU/ml 
(95% CI) GMT (95% CI) 
Orthodox Reformed 
Overall 233 60.9 (42.9 - 78.9) 12.4 (6.0- 18.7) 26.7 (13.8-39.7) 0.02 (0.01-0.04) 
Men 116 69.7 (54.2 - 85.2) 10.4 (4.2 - 16.6) 19.9 (8.2-31.5) 0.01 (0.01 -0.03) 
Women 117 52.3 (27.7 -76.8) 15.0 (6.9 - 23.2) 32.7 (15.3-50.1) 0.03 (0.01 -0.06) 
Not Orthodox 
Reformed 
Overall 1259 17.5 (15.5-19.4). 25.2 (21.3-29.2) 57.3 (52.2 - 62.4) 0.10 (0.09-0.12) 
Men 590 11.5 (8.2 - 14.8) 25.5 (20.5 - 30.6) 63.0 (55.4 - 70.5) 0.14 (0.13-0.16) 
Women 669 21.7 (18.0-25.4) 25.0 (21.2-28.9) 53.3 (48.6 - 58.0) 0.08 (0.07-0.10) 
Total low vaccine 
coverage sample 
Overall 1492 24.3 (20.5 - 28.0) 23.6 (20.1 -27.1) 52.1 (48.2 - 56.0) 0.08 (0.07 -0.09) 
Men 706 20.6 (16.6-24.7) 23.4 (18.9-27.8) 56.0 (50.3-61.7) 0.10 (0.08-0.12) 
Women 786 26.7 (21.1 -32.4) 23.3 (19.9-26.7) 50.0 (45.3 - 54.7) 0.07 (0.06 - 0.09) 
Table 3. Age-specific prevalence of diphtheria immunity and geometric mean titres < 14 years of age and for men and women 
less than 79 years op age in the nationwide sample, The Netherlands 
Age group Number <0.01 (95% CI) 0.01-0.1 (95% CI) >0.1 (95% CI) GMT (95% CI) 
(years) IU/ml IU/ml IU/ml 
0 187 3.7 (1.1 -6.4) 25.5 (18.6-32.4) 70.7 (63.4-78.1) 0.19 (0.15-0.24) 
1 185 1.2 (0.0 - 3.0) 9.9 (5.4 - 14.3) 88.9 (84.3 - 93.5) 0.57 (0.45- 0.72) 
2 156 1.9 (0.1 -3.7) 34.9 (24.2 - 45.5) 63.3 (52.9 - 73.6) 0.15 (0.12- 0.19) 
3 215 1.7 (0.1 -3.3) 35.5 (27.7 - 43.3) 62.8 (54.7 - 70.9) 0.16 (0.12- 0.22) 
4 153 0.6 (0.0- 1.7) 8.7 (3 .7- 13.7) 90.7 (85.7 - 95.7) 0.81 (0.60- 1.10) 
5 102 1.4 (0.0 - 3.3) 6.3 (1.9- 10.7) 92.3 (87.7 - 97.0) 0.43 (0.35- 0.52) 
6 121 0.9 (0.0 - 2.6) 20.0 (11.7-28.3) 79.1 (70.9 - 87.4) 0.26 (0.21-0.34) 
7 101 2.3 (0.0 - 5.4) 31.8 (20.3 - 43.3) 65.9 (54.7 - 77.2) 0.16 (0.13- 0.20) 
8 127 0.7 (0.0 -2.0) 23.6 (14.9-32.3) 75.8 (66.9 - 84.6) 0.28 (0.20- 0.38) 
9 97 0.0 (0.0 - 0.0) 11.8 (3.2 - 20.4) 88.2 (79.6 - 96.8) 0.71 (0.51-0.99) 
10 113 0.7 (0.0-2.1) 6.7 (1.9-11.5) 92.6 (87.7 - 97.5) 0.54 (0.42- 0.69) 
11 111 0.7 (0.0- 1.9) 8.3 (3 .5- 13.2) 91.0 (85.8 - 96.2) 0.36 (0.30- 0.44) 
12 122 0.6 (0.0-1.9) 17.0 (9.2 - 24.8) 82.4 (74.2 - 90.5) 0.28 (0.22- 0.35) 
13 126 0.0 (0.0 - 0.0) 27.3 (18.0-36.7) 72.7 (63.3 - 82.0) 0.23 (0.18- 0.29) 
14 102 0.4 (0.0-1.1) 26.7 (14.0-39.3) 72.9 (60.3 - 85.6) 0.22 (0.15- 0.31) 
Men 
0 104 3.5 (0.04 -7.0) 25.2 (15.8 - 34.6) 71.3 (61.4 -81.2) 0.18 (0.13 - 0.24) 
1-4 376 1.8 (0.5 -3.1) 22.9 (17.0 - 28.8) 75.3 (69.1 -81.5) 0.31 (0.25 - 0.38) 
5-9 296 0.6 (0.0 -1.4) 16.9 (12.4 -21.4) 82.5 (77.9 -87.1) 0.34 (0.28 - 0.40) 
10-14 280 0.6 (0.0 -1-7) 16.5 (11.7 -21.3) 83.0 (78.0 - 88.0) 0.32 (0.27 - 0.38) 
15-19 209 1.0 (0.0 -2.4) 25.8 (19.7 -31.9) 73.1 (67.1 -79.1) 0.19 (0.16 - 0.23) 
20-24 139 4.0 (0.4 -7.6) 25.5 (17.8 - 33.2) 70.5 (62.0 - 79.0) 0.15 (0.12 -0.19) 
25-29 150 2.9 (0.0 -6.2) 30.6 (21.7 - 39.5) 66.5 (56.9 -76.1) 0.18 (0.14 - 0.24) 
30-34 188 7.0 (1.6- 12.4) 31.5 (23.0 - 40.0) 61.5 (52.1 - 70.9) 0.14 (0.10 -0.19) 
Table 3 Continued. 
35-39 220 5.1 (1.3 -8.9) 
40-44 230 3.8 (1.1 -6.5) 
45-49 208 13.7 (7 .8- 19.6) 
50-54 228 15.0 (10.4- 19.6) 
55-59 251 8.8 (4.0- 13.6) 
60-64 216 10.3 (6.2- 14.4) 
65-69 200 26.5 (19.6- 33.4) 
70-74 193 46.2 (36.9 - 55.5) 
75-79 156 45.0 (35.8 - 54.2) 
Women 
0 83 4.2 (0.0 -8.9) 
1-4 333 2.2 (0.5 -3.9) 
5-9 252 1.8 (0.0 -3.7) 
10-14 294 0.3 (0.0 -0.8) 
15-19 243 0.7 (0.0 -1.7) 
20-24 199 2.8 (0.4 -5.2) 
25-29 226 5.0 (1.5 -8.5) 
30-34 244 10.0 (5.7- 14.3) 
35-39 282 5.6 (2.5 -8.7) 
40-44 247 8.7 (4.8- 12.6) 
45-49 261 22.0 (15.8- 28.2) 
50-54 264 28.2 (20.2 - 36.2) 
55-59 250 22.3 (16.3- 28.3) 
60-64 237 29.2 (22.9 - 35.5) 
65-69 263 38.0 (30.6 - 45.4) 
70-74 218 58.2 (50.8 - 65.6) 
75-79 175 52.7 (43.8 - 61.6) 
27.4 (20.7 -34.1) 67.5 (60.8 - 74.2) 0.18 (0.14 - 0.23) 
16.3 (11.0 -21.6) 79.9 (73.9 - 85.9) 0.25 (0.20 -0.31) 
26.6 (21.4 -31.8) 59.7 (51.8- 67.6) 0.13 (0.09 -0.18) 
31.1 (24.7 - 37.5) 53.9 (46.5 - 61.3) 0.10 (0.08 -0.13) 
38.8 (32.1 - 45.5) 52.4 (46.0 - 58.8) 0.10 (0.08 -0.12) 
52.3 (43.8 - 60.8) 37.4 (29.9 - 44.9) 0.07 (0.06 - 0.09) 
39.4 (30.4 -48.4) 34.1 (26.2 - 42.0) 0.05 (0.04 - 0.06) 
26.6 (19.2 - 34.0) 27.1 (19.2- 35.2) 0.03 (0.02 -0.04) 
26.2 (17.8 - 34.6) 28.8 (20.8 - 36.8) 0.03 (0.02 -0.04) 
26.6 (13.7 - 39.5) 69.3 (56.7 - 81.9) 0.19 (0.13 - 0.27) 
22.2 (16.7 - 27.7) 75.6 (70.0 - 81.2) 0.30 (0.25 - 0.37) 
23.8 (16.2 -31.4) 74.5 (68.2 - 80.8) 0.29 (0.24 - 0.36) 
18.6 (12.9 - 24.3) 81.1 (75.4 - 86.8) 0.29 (0.24 -0.33) 
28.2 (21.9 - 34.5) 71.1 (64.8 -77.4) 0.17 (0.15 - 0.20) 
31.3 (23.6 - 39.0) 65.9 (58.3 - 73.5) 0.14 (0.12 -0.18) 
27.1 (20.3 - 33.9) 67.9 (60.5 - 75.3) 0.14 (0.11 -0.18) 
36.9 (30.5 - 43.3) 53.0 (47.3 - 58.7) 0.11 (0.09 -0.13) 
37.0 (29.6 -44.4) 57.4 (50.6 - 64.2) 0.13 (0.11 -0.15) 
24.4 (18.5 - 30.3) 66.9 (60.9 - 72.9) 0.16 (0.12 - 0.20) 
37.6 (30.6 -44.6) 40.3 (32.3 - 48.3) 0.06 (0.04 -0.08) 
41.7 (34.5 - 48.9) 30.1 (23.0 - 37.2) 0.04 (0.03 - 0.05) 
49.7 (43.6 - 55.8) 28.0 (22.3 - 33.7) 0.04 (0.03 - 0.05) 
45.9 (39.7 -52.1) 24.8 (19.0- 30.6) 0.03 (0.02 -0.04) 
34.3 (29.0 - 39.6) 27.7 (21.3 - 34.1) 0.03 (0.02 - 0.05) 
25.0 (18.9 -31.1) 16.8 (11.0- 22.6) 0.02 (0.01 - 0.02) 
26.6 (19.4 -33.8) 20.7 (12.7- 28.7) 0.02 (0.01 - 0.03) 
Table 4. Diphtheria immunity in the nationwide sample and in orthodox reformed individuals in municipalities with low vaccine 
coverage, The Netherlands 
Nunibe7~<0()i (95% CI) 0.01-0.1 (95% CI) " >0.1 (95% CI) GMT (95% CI) 
IU/ml IU/ml IU/ml 
Nationwide sample 
0 - 4 9 years 5064 5.3 (4.4-6.2) 27.3 (25.3-29.4) 67.4 (65.2-69.5) 0.17 (0.16-0.19) 
50-79 years 2651 29.2 (26.4-31.9) 37.4 (35.3-39.5) 33.4 (31.3-35.6) 0.04 (0.04-0.05) 
Orthodox reformed 
from low vaccine 
coverage sample 
0 -49years 170 60.8 (40.2-81.4) 7.4 (2.3-12.6) 31.8 ' (13.8-49.7) 0.02 (0.01 -0.05) 
50-79 years 63 59.3 (30.1-88.6) 34.6 (9.5-59.6) 6.1 (0.0-18.2) 0.01 (0.005-0.025) 
Table 5. Diphtheria immunity in the nationwide among persons 20 to 49 years, according to sex and military service, The 
Netherlands 
^ ^ - ^ Q o^Toji (95% CI) >oi (95% CI) GMT (95% CI) 
IU/ml IU/ml IU/ml 
Military service* 
(20-49) 
Men with military 425 2.9 (1.2-4.6) 14.9 (11.1 - 18.7) 82.2 (78.0-86.5) 0.30 (0.25-0.36) 
service history 
Men without military 710 7.8 (5 .2- 10.3) 33.1 (28.0-38.1) 59.2 (54.0-64.4) 0.12 (0.10-0.14) 
service history 
Women without 1456 9.1 (7.0-11.2) 32.5 (29.0-36.0) 58.4 (54.5-62.3) 0.12 (0.10-0.13) 
military service history 
Subgroup of the nationwide sample 
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Persistence of diphtheria antitoxin levels 
The geometric mean titre decreased with age (or time since last vaccination) for persons who had 
received their last and sixth vaccination at 8 to 9 years of age (n=961) from 0.30 IU/ml for 10 to 
14 years to 0.09 IU/ml for 30 to 34 years (Table 6, Figure 2). According to linear regression 
analysis, the decrease corresponds to a decrease of -1.27 2log IU/ml with each 2log increase in 
years in age. The percentage with full protection decreased from 82.5% to 41.7%, and the 
percentage with no protection increased from 0% to 4.3% for these 10 to 14 year olds and 30 to 
34 year olds, respectively (Table 6). 
0.45 
0.4 
0.35 
0.3 
0.25 
0.2 -
0.15 -
0. 
0.05 + 
Titre (in IU/ml) 
IZZ1GMT (95% CI) 
- regression Intercept = 2.75; Beta (2 log age)=-l .27 
10-14 15-19 20-24 25-29 30-34 
Age (in years) 
Figure 2. Diphtheria antitoxin litre (Geometric mean titre (GMT) ± 2 standard error) by age 
group and linear regression of diphtheria antitoxin antibody titre (in 2log) with age (in 2log 
years) for individuals with the sixth and last documented vaccination at the age of 8 or 9 years 
(n = 96/J in the nationwide sample, The Netherlands 
The geometric mean titre for persons 20 to 34 years with documented revaccination (n=37) was 
0.29 IU/ml. Percentages of full (81.0%), basic (19.0%), and no (0.0%) protection were similar to 
recently vaccinated 10 to 14 year olds, without further documented or reported revaccination 
(Table 6). 
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Table 6. Diphtheria immunity for persons in the nationwide sample who were completely vaccinated in the national 
immunisation programme and with the sixth documented vaccination at 8 or 9 years of age, The Netherlands 
Age group Number <0.01 (95% CI) 0.01-0.1 (95% CI) >0.1 (95% CI) GMT (95% CI) 
IU/ml IU/ml IU/ml 
No evidence for 
revaccination 
10-14 392 0.0 - 17.5 (12.8-22.1) 82.5 (77.9-87.1) 0.30 (0.26-0.34) 
15-19 282 0.4 (0.0- 1.3) 30.1 (23.7 - 36.5) 69.4 (63.2 - 75.7) 0.17 (0.14-0.21) 
20-24 155 1.2 (0.0 - 3.0) 29.4 (20.7 -38.2) 69.4 (60.7-78.1) 0.16 (0.12-0.19) 
25-29 80 1.6 (0.0 - 3.7) 28.3 (17.2-39.4) 70.2 (58.7-81.6) 0.14 (0.11-0.18) 
30-34 52 4.3 (0.0 - 9.2) 54.0 (39.3 - 68.8) 41.7 (27.3-56.1) 0.09 (0.07-0.13) 
Evidence for 
revaccination 
20-34 37 0.0 - 19.0 (3.2 - 34.9) 81.0 (65.1-96.8) 0.29 (0.18-0.46) 
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Conclusions 
Our population-based study showed that 58% of the Dutch population had full, 30% basic, and 
12%, no protection against diphtheria. These estimates and the geometric mean titre (0.12 IU/ml) 
are in between findings for other European countries (4,11-20). The Dutch immunisation 
programme appeared to induce long-term protection. However, approximately one third of adults 
aged 50 to 79 years, who born before the introduction of the immunisation programme and 
approximately two-thirds of orthodox reformed persons had no protective diphtheria antibodies. 
The toxin inhibition test to measure diphtheria antitoxin concentrations shows good correlation 
with the in vitro neutralisation test in Vero cells, but is faster, simpler, and combines the 
measurement of diphtheria and tetanus antitoxin antibodies (8,9). 
Although the participation rates in the nationwide sample and low vaccine coverage sample 
amounted to 55% and 52.5% respectively, our population-based estimates of diphtheria immunity 
were considered representative, because they seem to be hardly affected by non-participation. 
Our participants included a large percentage of persons with diphtheria protection who were born 
after the vaccination was introduced in 1952 and after the virtual disappearance of diphtheria in 
1960. High levels of immunity in this group reflect the success of the national vaccination 
programme. 
For persons born before the introduction of vaccination, diphtheria immunity is largely derived 
from natural infection. However, immunity levels in those older than 49 years in the general 
population are higher than those of orthodox reformed persons suggesting that immunity was 
partly induced by vaccinations (e.g., for military service, travel). 
The sharp increase in the percentage of persons older than 44 years with no protective diphtheria 
antitoxin levels is consistent with findings of other studies (4,11,12,14-19). It supports the 
phenomenon of waning immunity after natural infection without boosting. 
In our study, higher immunity levels among men are associated with military service, as previously 
reported (15,19). However, other researchers have found similar immunity levels for men and 
women, while others have reported lower immunity for men (11,16,21). Furthermore, lower 
immunity for women that could not be ascribed to vaccinations during military service has also 
been reported (4,20). Women might maintain immunity after vaccination for a shorter time than 
men (14). The slightly lower geometric mean titres for girls aged 5 to 19 years in our study are 
consistent with the latter possibility. 
As more than 60% of orthodox reformed persons have no protection against diphtheria, 
introduction of diphtheria into this sociogeographically clustered group may constitute a 
substantial danger of spreading the bacterium. 
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Since the Netherlands does not have a mandatory vaccination policy, protection of persons who 
refuse vaccination is problematic. For poliomyelitis the solution seems to be eradication of the 
causative agent (5). For diphtheria such a goal has not yet been formulated by the World Health 
Organization. However, even though systematic assessment has not been performed, no signs of 
persistent circulation of C. diphtheriae exists in the Netherlands. 
When our data are interpreted longitudinally, the decrease in diphtheria antibody level with age 
for individuals completely vaccinated in the national immunisation programme, corresponds with a 
continuous decline of vaccine-induced antibodies (13,22). However, relatively few 30 to 34-year-
old persons (4.3 percent) who received their last vaccination approximately 25 years ago had a 
diphtheria antitoxin level of less than 0.01 IU/ml. This compares favourable with observations in 
other countries (13,21-23). Our immunisation programme, in which children are vaccinated at 3, 
4, 5 and 11 months with 15 Lf diphtheria toxoid, and at the ages of 4 and 9 years with 2.5 Lf 
appears to induce long-term protection against diphtheria. 
In the Netherlands, booster vaccinations are only advised for individuals at increased risk for 
exposure (e.g. travellers to endemic countries, and those who work with injection drug users, 
alcoholic patients). 
The need for routine boosters to guarantee population protection depends mainly on the 
proportion necessary to confer diphtheria herd immunity. This proportion is estimated at 70% to 
80%, but no antitoxin level has been precisely defined for complete protection (10,13, 24-26). 
The Dutch immunity level exceeds this threshold (a minimum level of 0.01 IU/ml [88%]), but is 
below a minimum level of 0.1 IU/ml (58%). 
The absence of cases in the Netherlands associated with the diphtheria epidemic in Eastern 
Europe suggests that herd immunity is sufficient. This herd immunity might be the result from 
sufficient protective levels of antitoxin and/or of immunologic memory. Our results, like those of 
others, indicate good immunologic memory after revaccination for persons who had been 
previously vaccinated (17,27). However, the (memory) response of adults after initial vaccination 
is unknown. Furthermore, unknown protective mechanisms might be involved. Only sporadic 
cases and no outbreaks have occurred, in other European countries where gaps have been found 
in the diphtheria antitoxin levels of adults. The only recent epidemic in Western Europe, which 
occurred before the epidemic in Eastern Europe, was one among alcoholics (23). Perhaps 
unfavourable social conditions, such as appear to have contributed to the epidemics in Eastern 
Europe, play a crucial role in spread of diphtheria (1). 
In conclusion, a substantial percentage of adults born before the introduction of the immunisation 
programme have low diphtheria antitoxin levels. Although herd immunity seems sufficient, long-
term population protection cannot be assured. Possibly vaccination might fill the gaps of 
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diphtheria antitoxin antibodies. Diphtheria vaccination could be efficiently combined with other 
vaccines (e.g., tetanus, influenza) as part of an adult immunisation programme. 
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Abstract 
We assessed the tetanus immunity of the general Dutch population and of religious groups 
refusing vaccination by means of population-based study to evaluate the effect of tetanus 
vaccination. More than 95% of those born after the introduction of routine vaccination 
had tetanus antitoxin levels above the minimum protective level. After the sixth 
vaccination, a fall in tetanus antitoxin levels occurred. Nevertheless, immunisation in 
accordance with the routine programme most likely induces protection for much longer 
than two decades. Not only many members of religious groups who refuse vaccination, 
but also many adults born before the introduction of vaccination lack tetanus immunity. 
These cohorts might benefit most from (re)vaccination. 
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Introduction 
Vaccination with tetanus toxoid, one of the most effective prophylactic procedures, has greatly 
reduced the incidence of tetanus (1). In the past decade, two to three cases has been reported 
annually in the Netherlands; these occurred mainly among individuals born before the introduction 
of childhood vaccination (2). Mass vaccination was introduced in the Netherlands in 1952 for 
people born in 1945 and thereafter. Children are vaccinated at 3 ,4 ,5 and 11 months of age with a 
diphtheria, tetanus, pertussis and inactivated polio vaccine (DTP-IPV) and at 4 and 9 years of age 
with DT-IPV. 
Tetanus is not directly communicable between hosts; therefore, vaccination cannot confer herd 
immunity (3). Effective control requires immunising every individual by vaccination. Although 
some have reported natural immunity, it is believed that immunity to tetanus toxin is induced only 
by vaccination (1). 
The prevalence of specific antibodies can be used as a parameter to evaluate the effects of 
vaccination. It offers us the opportunity of finding clusters of individuals susceptible to tetanus. 
This is particularly important in the Netherlands because of its geographically clustered religious 
groups who refuse vaccination. Furthermore, by studying the persistence of tetanus antibodies 
after vaccination through the national programme, possible vaccination requirements for providing 
continuous immunity to tetanus can be evaluated. 
Our large-scale, population-based, serum bank gave us an opportunity of studying the tetanus 
immunity of the Dutch population and of individuals refusing vaccination (4). 
Material and methods 
Study population 
Eight municipalities with probabilities proportional to their population sizes were sampled within 
each of five geographical Dutch regions with similar population sizes. An age-stratified sample 
(classes 0, 1-4, 5-9 to 75-79 years) of 380 individuals was randomly selected from each 
municipality. These individuals were requested to give a blood sample, fill out a questionnaire and 
bring their vaccination certificates from the national immunisation programme and military 
service, as well as proof of travel vaccinations. Similarly, individuals were selected from eight 
municipalities with low vaccine coverage to assess the immunity in geographically clustered 
orthodox reformed groups that refuse vaccination. The data collection was carried out in October 
1995 to December 1996. The participation rates were 55% and 52.5% in the nationwide sample 
and the low vaccine coverage sample, respectively. The study design and details on the data 
collection have been published elsewhere (4). 
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Antibody assay 
Sera were stored at minus 86 °C. The level of tetanus antitoxin antibodies was measured with a 
toxin binding inhibition (ToBI) assay. The results were standardised with the four-parameter-fit 
method, and the national reference serum calibrated on the WHO international reference serum 
was used. The ToBI assay shows a good correlation with the in vivo neutralisation test, even for 
sera with low titres up to a concentration of 0.01 IU per ml (5-8). Sufficient serum was available 
for 7715 of the 8359 of the participants of the nationwide sample and for 1492 of the 1589 
participants of the low vaccine coverage sample. 
According to internal standards, an antitoxin level of 0.01 IU/ml was considered the minimum 
protective level (1). A titre of less than 0.01 IU/ml was set to 0.005 IU/ml for calculating 
geometric mean titres (GMTs). 
Definition of variables 
Two religious groups were distinguished: "orthodox reformed" (opposed to vaccination), and 
"other" (9). Documented revaccination was defined as any documented vaccination given in 
addition to vaccinations documented on the certificate of the national immunisation programme. 
For those with documented revaccination the median number of revaccinations was two and 
ranged from one to six. 
The questionnaire asked participants of all age groups whether they had received a tetanus 
vaccination after injury, and those aged at least 17 years whether they had received a vaccination 
for diphtheria, tetanus and poliomyelitis (DT-fPV) for military service, travel or profession. 
The educational levels of those aged 17 years or more and of one of the parents for those aged 
less than 17 years, were classified as "low" (primary school, lower vocational or lower general 
secondary education), "intermediate" (intermediate vocational or intermediate general secondary 
and higher general secondary education) and "high" (higher vocational secondary education and 
university education). The following categories for degree of urbanisation were made: "very high" 
(>2,500 addresses/km2), "high" (1,500-2,500), "moderate" (1,000-1,500), "low" (500-1,000), 
and "none" (< 500). The geographical regions were based on the Dutch provinces: "central" 
(Utrecht and Gelderland), "southeast" (Brabant and Limburg), "northwest" (North Holland and 
Flevoland), "southwest" (Zeeland and South Holland) and "northeast" (Groningen, Drente, 
Overijssel and Friesland). 
In logistic regression analysis (see the statistical analysis), evidence of tetanus vaccination was 
coded as 'yes' if the participant: i.) had documented tetanus vaccination, ii.) reported a military 
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service history; iii.) reported participation in the national immunisation programme or iv.) 
reported vaccination against DT-IPV or against tetanus after an injury. 
Statistical analysis 
Frequencies and GMTs within each municipality were weighted by the proportion of the age 
group in the population. To produce national estimates, the weighted frequencies and GMTs were 
averaged over the 40 municipalities (10). For the low vaccine coverage sample, they were 
averaged weighting by the population size of the municipality. The effect of differential 
probabilities of response on both sample estimates was less than one standard error and was 
therefore ignored. 
Linear regression analysis was used to study the persistence of tetanus antitoxin antibodies after 
complete participation in the national immunisation programme. The association between the 
tetanus antibody titre (2log) and the inverse of age was studied in this analysis for individuals with 
the sixth documented vaccination at 8 to 9 years of age, and without self-reported or documented 
revaccination or military service history. This analysis was restricted to those aged 10 to 34 years 
of age, as for older age groups the number of individuals with documentation of six vaccinations 
was too small. 
Logistic regression analysis was conducted to determine whether any of the following variables 
were independent predictors of a tetanus antitoxin level of less than 0.01 IU/ml in the nationwide 
sample after adjustment for age group by sex: marital status, educational level, region, degree of 
urbanisation, evidence of tetanus vaccination, orthodox reformed religion, country of birth and 
self-reported travel to Eastern Europe, Turkey or Greece, Asia, Central America, South America, 
North Africa, and Central Africa or South Africa. Variables remained in the multivariate model if 
either the likelihood ratio test was significant O < 0.05) or the estimates of the beta coefficients 
for other variables in the model changed by at least 10%. 
Results 
(Age-specific) tetanus antitoxin immunity levels 
In the nationwide sample 14.0% had tetanus antitoxin levels of less than 0.01 IU/ml (Table 1). A 
tetanus antitoxin level from 0.01 to 0.1 IU/ml was observed in 13.6% (95% confidence interval 
(CI) 12.5% to 14.7%), from 0.1 to 1 IU/ml, in 37.1% (CI 35.2% to 39.0%); from 1 to 10 IU/ml, 
in 33.6% (95% CI 31.3% to 35.9%); and at least 10 IU/ml, in 1.8% (95 % CI 1.4% to 2.2%). 
The tetanus antitoxin antibody level was higher for men; both the prevalence of tetanus antitoxin 
levels less than 0.01 IU/ml and the GMT were statistically significantly different between men and 
women (Table 1). 
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Table 1. Prevalence of tetanus antitoxin levels and GMT by gender in the nationwide 
sample; Pienter Project J995-1996, The Netherlands 
Number <0.01 IU/ml (95% CI) GMT (95% CI) 
Nationwide 
sample 
Total 7715 14.0 (12.9- 15.1) 0.29 (0.26 - 0.32) 
Men 3644 8.8 (7.9 - 9.7) 0.45 (0.41 - 0.50) 
Women 4071 18.4 (16.8-20.1) 0.19 (0.17-0.22) 
The prevalence of tetanus antitoxin levels varied by age (Figure 1, Tables 2 and 3). Less than 2% 
of those aged up to 35 years and less than 5% of those aged up to 45 years had tetanus antitoxin 
levels less than 0.01 IU/ml, while this percentage increased to 19.5% in 45 to 49-year-olds to 
54.6% in 75 to 79-year-olds. This trend was reflected in the GMT value, which was greater than 
0.4 IU/ml for 1 to 44-year-olds and was 0.10 IU/ml or less for 45 to 79-year-olds. Table 2 show 
elevated tetanus antitoxin levels and GMTs at the ages of one year, 4 years and 9 years. Analysis 
by age in months showed a slightly higher GMT for 6 months-olds and a peak in the GMT for 12-
14-months-olds (data not shown). Furthermore, a not statistically significantly higher GMT was 
observed for 25 to 29-year-olds, particularly for men (Table 3). The GMTs were lower for those 
older than 29 years. 
0 1- 5- 10-15-20-25-30-35-40-45-50-55-60-65-70-75-
Age (years) 
Figure 1. Age-specific prevalence of immunity to tetanus in the nationwide sample 
for 0 to 79-year-olds; Pienter Project, 1995-1996, The Netherlands 
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Table 2. Age-specific prevalence of tetanus antitoxin levels and GMT by gender 
in the nationwide sample for0 to 14-years-olds; Pienter Project, 1995-1996, 
The Netherlands 
Age group (years) Number <0.01 IU/ml (95% CI) GMT (95% CI) 
Men 
0 104 0.7 (0.0 - 2.0) 0.25 (0.19-0.32) 
I 99 1.7 (0.0 - 3.8) 0.91 (0.70-1.19) 
2 83 0.8 (0.0 - 2.3) 0.36 (0.28 - 0.47) 
3 113 0.0 ( - ) 0.40 (0.28 - 0.57) 
4 81 0.0 ( - ) 3.28 (2.17-4.96) 
5 49 0.0 ( - ) 2.10 (1.47-3.0) 
6 66 0.0 ( - ) 1.41 (1.02- 1.93) 
7 53 1.9 (0.0 - 5.9) 0.75 (0.54- 1.05) 
8 71 0.0 ( - ) 1.33 (0.92- 1.90) 
9 57 0.0 ( - ) 3.42 (2.24 - 5.22) 
10 51 1.1 (0.0 - 3.4) 1.91 (1.39-2.64) 
11 61 0.7 (0.0 - 2.2) 1.64 (1.28-2.10) 
12 50 0.0 ( - ) 1.72 (1.25 -2.36) 
13 64 0.0 ( - ) 1.13 (0.90-1.41) 
14 54 0.0 ( - ) 1.20 (0.92-1.57) 
Women 
0 83 1.7 (0.0-5.1) 0.23 (0.15-0.33) 
1 86 0.0 ( - ) 0.79 (0.53-1.19) 
2 73 0.7 (0.0-2.1) 0.35 (0.26 - 0.47) 
3 102 2.0 (0.0 - 4.3) 0.37 (0.25 - 0.56) 
4 72 0.9 (0.0 - 2.6) 3.08 (1.99-4.78) 
5 53 0.0 ( - ) 1.84 (1.26-2.68) 
6 55 1.1 (0.0 - 3.4) 1.45 (1.00-2.11) 
7 48 1.2 (0.0 - 3.6) 0.55 (0.40 - 0.76) 
8 56 0.0 ( - ) 1.14 (0.77- 1.71) 
9 40 0.0 ( - ) 4.93 (3.54 - 6.87) 
10 62 0.0 ( - ) 2.41 (1.84-3.16) 
11 50 0.0 ( - ) 1.47 (1.12-1.93) 
12 72 0.0 ( - ) 1.17 (0.96-1.43) 
13 62 3.1 (0.0 - 9.5) 0.71 (0.46-1.10) 
14 48 0.0 ( - ) 0.99 (0.77 - 1.28) 
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Table 3. Prevalence of tetanus antitoxin levels and GMT by age group (birth cohort*) and 
gender in the nationwide sample for 0 to 79 years-olds; Pienter Project, 1995-1996, The 
Netherlands 
Age group (years) Birth-cohort* Number <0.01 IU/ml (95% CI) GMT (95% CI) 
Men 
0 1995/96 104 0.7 (0.0 - 2.0) 0.25 (0.19-0.32) 
1-4 1991/95 376 1.1 (0.01 - 2.2) 0.75 (0.60 -0.95) 
5-9 1986/90 296 0.3 (0.0 - 0.9) 1.61 (1.33-1.94) 
10-14 1981/85 280 0.4 (0.0-1.6) 1.46 (1.27- 1.68) 
15-19 1976/80 209 1.0 (0.0 - 2.5) 0.93 (0.78-1.10) 
20-24 1971/75 139 0.3 (0.0- 1.0) 0.93 (0.73- 1.20) 
25-29 1966/70 150 1.4 (0.0 - 3.5) 1.35 (1.05- 1.73) 
30-34 1961/65 188 2.5 (0.0 - 5.0) 1.21 (0.95- 1.55) 
35-39 1956/60 220 1.8 (0.0 - 3.7) 0.86 (0.66-1.11) 
40-44 1951/65 230 2.3 (0.0 - 4.7) 0.62 (0.49 - 0.80) 
45-49 1946/50 208 10.4 (6.2 -14.5) 0.24 (0.18-0.32) 
50-54 1941/45 228 17.8 (11.9-23.7) 0.16 (0.11 -0.22) 
55-59 1936/40 251 12.6 (8 .5- 16.8) 0.21 (0.15-0.28) 
60-64 1931/35 216 26.8 (20.5 - 33.2) 0.08 (0.05-0.11) 
65-69 1926/30 200 31.0 (24.5 - 37.4) 0.07 (0.04-0.10) 
70-74 1921/25 193 39.0 (30.5 - 47.5) 0.04 (0.03- 0.06) 
75-79 1916/20 156 47.5 (37.4 - 57.5) 0.02 (0.01-0.03) 
Women 
0 1995/96 83 1.7 (0.0-5.1) 0.23 (0.16-0.33) 
1-4 1991/95 333 1.4 (0.1 -2.6) 0.68 (0.55 - 0.84) 
5-9 1986/90 252 0.5 (0.0-1.3) 1.47 (1.22- 1.77) 
10-14 1981/85 294 0.6 (0.0-1.9) 1.29 (1.12- 1.49) 
15-19 1976/80 243 0.6 (0.0-1.9) 0.74 (0.63 - 0.87) 
20-24 1971/75 199 1.0 (0.0 - 2.7) 0.60 (0.49 - 0.74) 
25-29 1966/70 226 1.0 (0.0 - 2.5) 0.74 (0.59 - 0.93) 
30-34 1961/65 244 1.2 (0.0 - 2.7) 0.59 (0.47 - 0.73) 
35-39 1956/60 282 2.8 (0.0 - 5.7) 0.39 (0.31 -0.48) 
40-44 1951/65 247 6.2 (2.7 - 9.6) 0.26 (0.19-0.36) 
45-49 1946/50 261 27.6 (20.0 - 35.3) 0.05 (0.03 - 0.07) 
50-54 1941/45 264 42.6 (34.5 - 50.7) 0.03 (0.02 - 0.04) 
55-59 1936/40 250 56.0 (49.3 - 62.6) 0.02 (0.01 - 0.02) 
60-64 1931/35 237 55.5 (47.0-64.1) 0.02 (0.01 - 0.02) 
65-69 1926/30 263 58.3 (51.2-65.4) 0.02 (0.01 - 0.02) 
70-74 1921/25 218 62.4 (55.5 - 69.3) 0.01 (0.01 - 0.02) 
75-79 1916/20 175 58.5 (49.3 - 67.6) 0.01 (0.01 - 0.02) 
* Due to the data collection during more than 15 months overall 7% of the participants belonged to one younger 
birth cohort and 0.4% to one older birth cohort than the age group presented. The percentages and GMT with 95% 
confidence intervals were similar for the analyses by birth cohort and by age group. 
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Table 4. Frequency of self-reported and documented tetanus revaccination and participation in 
military service by gender in the nationwide sample for 0 to 79-year-olds; Pienter Project 1995-
1996, The Netherlands 
Men 
Percent 
(n = 3644) 
(95% CI) 
Women 
Percent 
(n = 4071) 
(95% CI) 
Self-reported tetanus 
vaccination after an injury 
Self-reported DT-IPV 
vaccination 
Documented revaccination 
of tetanus 
Military service history 
42.6 (40.4 - 44.9) 
54.7 (52.7 - 56.7) 
12.8 (10.8-14.8) 
33.2 (30.6 - 35.8) 
29.5 
49.7 
3.8 
0.1 
(27.1 -31.8) 
(47.7-51.6) 
(2. - 4.8) 
(0.0 - 0.2) 
Any indication of tetanus 
revaccination" 
74.5 (72.6 - 76.4) 70.4 (68.6 - 72.3) 
" Self-reported tetanus vaccination after an injury and/or self-reported DT-IPV vaccination and/or documented 
revaccination of tetanus and/or military service history 
Table 5. Prevalence of tetanus antitoxin levels and GMT by gender among orthodox reformed 
individuals in the low vaccine coverage sample; Pienter Project 1995-1996, The Netherlands 
Number <0.01 IU/ml (95% CI) GMT (95% CI) 
Orthodox reformed 
Total 233 37.4 (26.7 - 48.2) 0.05 (0.03 - 0.09) 
Men 116 36.4 (29.1 -43.6) 0.05 (0.02-0.10) 
Women 117 42.2 (20.1 -64.4) 0.06 (0.02-0.15) 
The difference between men and women was largest for those at least 45 years of age but for all 
age groups the GMT was higher for men (Table 3). Men documented or reported tetanus 
vaccination more often (Table 4). When the analysis was restricted to those with documented 
tetanus revaccination, no statistically significant difference was found between men (GMT 0.89 
IU/ml; 95% CI 0.70 to 1.14) and women (GMT 0.57; 95% CI 0.35 to 0.92). The difference 
between men and women remained when the analysis was restricted to individuals without 
documented revaccinations and when the analysis was restricted to those without documented or 
self-reported revaccinations. 
Among orthodox reformed individuals the percentage of tetanus antitoxin levels below 0.01 IU/ml 
and GMT were higher than in the nationwide sample (Table 5). The percentage of orthodox 
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reformed individuals with tetanus antitoxin levels below 0.01 IU/ml was 40.7% (95% CI 26.6% 
to 54.8%) for 0 to 19-year-olds, 26.2% (95% CI 8.7% to 43.6%) for 20 to 39-year-olds and 
46.4% (95% CI 33.0 to 59.8%) for 40 to 79-year-olds. 
Among 0 to 19-year-olds 38.0% (95% CI 17.8% to 58.2%) and among 20 to 39-year-olds 28.5% 
(95 CI 9.3% to 47.7%) reported to have participated in the national immunisation programme. 
None of these orthodox reformed individuals had tetanus antitoxin levels below 0.01 IU/ml. For 
those who reported not to have participated in the national immunisation programme the 
percentage of individuals with tetanus antitoxin levels below 0.01 IU/ml amounted to 59.5% 
(95% CI 41.1% to 77.9%) for 0 to 19-year-olds and to 42.4% (95% CI 11.8% to 73.0%) for 20 
to 39-year-olds. 
The percentage of tetanus antitoxin levels below 0.01 IU/ml was somewhat, but not statistically 
significantly lower for men than for women. This difference was due to a lower percentage of 
tetanus antitoxin levels in men aged 20 to 39 years compared to women in this age group and 
remained when the analysis was restricted to individuals without self-reported vaccinations. 
When orthodox reformed individuals were excluded from the low vaccine coverage sample, the 
GMT (0.32 IU/ml; 95% CI 0.26 to 0.39 IU/ml) and percentage of tetanus antitoxin levels below 
0.01 IU/ml (16.5%; 95% CI 13.3% to 19.6%) were not statistically significantly different from 
those in the nationwide sample. The GMT for orthodox reformed individuals with a tetanus 
antitoxin level of at least 0.01 IU/ml was 0.23 IU/ml (0.14 to 0.39 IU/ml), lower than the GMT of 
0.47 IU/ml (0.42 to 0.52 IU/ml) of those with a level of minimally 0.01 IU/ml in the nationwide 
sample. 
Predictors of tetanus antitoxin levels 
As no independent association of country of birth with tetanus antibody levels was found in the 
logistic regression analyses for those born outside the Netherlands, those born in Morocco or 
Turkey excluded, these individuals were pooled with individuals born in the Netherlands. 
Independent predictors of a tetanus antitoxin level below 0.01 IU/ml were: i.) lack of evidence for 
tetanus immunisation (odds ratio (OR) 0.19 (95% CI 0.16 to 0.23) , ii.) orthodox religion (OR 
0.06; 95% CI 0.03 to 0.15), iii.) low degree versus no degree of urbanisation (OR 0.69; 95% CI 
0.55 to 0.87) , iv.) no self-reported travel to Asia (OR 0.38; 95% CI 0.28 to 0.52), to South 
America (OR 0.60; 95% CI 0.38 to 0.94) or to Central or South Africa (OR 0.61; 95% CI 0.39 to 
0.96) v.) born in Morocco (OR 0.17; 95% CI 0.06 to 0.51) versus born in the Netherlands or 
other country. The OR for those born in Turkey amounted to 0.40 (95% CI 0.13 to 1.24) and was 
only statistically significant in a model without the variable 'evidence of tetanus vaccination'. 
Evidence of tetanus vaccination might be an intermediate variable in the association with other 
variables and tetanus antitoxin level. In a model without this variable the effects of religion, self- 4 
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reported travel to South America, Asia and Central or South Africa and country of birth were 
slightly stronger. No independent association with tetanus antibody levels was found for marital 
status, educational level, region, self-reported travel to Eastern Europe, Turkey or Greece, 
Middle East, Central America or North Africa. 
Persistence of tetanus antitoxin antibodies 
For individuals aged 10 to 34 years with the sixth and last documented tetanus vaccination at the 
age of 8 or 9 years (n=635) the GMT decreased from 1.38 IU/ml (95% CI 1.23 to 1.55 IU/ml) for 
10 to 14 year-olds to 0.44 IU/ml (95% CI 0.29 to 0.68 IU/ml) for 30 to 34-year-olds (Figure 2). 
In linear regression analysis with the 2log tetanus antitoxin titre, the intercept was -2.6 and the 
parameter estimate for the inverse of age in years amounted to 36.0. No effect for gender was 
observed. One individual (0.09%) had a tetanus antibody level below 0.01 IU/ml. The percentage 
of individuals with a level between 0.01 and 0.1 IU/ml was 3.2% (95% CI 0.0% to 6.5%) and 
ranged from 0.4% (10 to 14-year-olds) to 5.1% (20 to 24-year-olds). The GMT for individuals 
with documented revaccination (n = 39) was 1.88 IU/ml (95% CI 1.49 to 2.37 IU/ml). None of 
these individuals had a tetanus antitoxin level below 0.1 IU/ml. The median number of 
re vaccinations was one (range 1 to 3). Due to the small numbers, no conclusion could be drawn 
from the number of revaccinations. 
Titre (in U/ml) 
2.0 T 
10-14 15-19 20-24 25-29 30-34 
Age (in years) 
Figure 2. Tetanus antitoxin titre (GMT) by age group and linear regression of tetanus antitoxin 
antibody titre (in 2 log) with the reciprocal of age (in yrs)for individuals with the sixth and last 
documented vaccination at the age of 8 or 9 years (n=635); Pienter Project, 1995-1996, The 
Netherlands 
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Discussion 
Unlike vaccination for other vaccine-preventable diseases such as diphtheria and poliomyelitis, 
tetanus vaccination does not indirectly protect other individuals (1). An important exception, the 
passive antibodies of newborns, offers us an opportunity to diminish the burden of neonatal 
tetanus in developing countries by vaccinating girls and women (11). The lack of indirect 
protection, together with the ubiquity of tetanus spores, means that every individual without 
tetanus protection is at risk of tetanus. 
Although there is no absolute protective level of the antitoxin, 0.01 IU/ml is considered the 
minimum protection level (1). The tetanus antitoxin levels we found in the Dutch population 
(14% below 0.01 IU/ml, 13.6% between 0.01 and 0.1 IU/ml and 72.5% above 0.1 IU/ml) are 
more favourable than in most other studies (12-17). 
Our results show that the Dutch immunisation programme has induced very good protection 
against tetanus. The percentage of individuals with tetanus antitoxin levels above the minimum 
protection level was very high (>95%) for those born after its introduction in 1952 (i.e. aged less 
than 45 years in our study). For those who could have participated in the catch-up campaign 
(born between 1945 and 1952), this percentage was still high (80%). 
When our data were interpreted longitudinally, like others, we found that tetanus immunity 
persisted for at least two decades, and probably even longer, in individuals who had received six 
vaccinations (i.e. they had been completely vaccinated in the Dutch immunisation programme) 
(1). 
The regression analysis predicts a decline according to a hyperbolic curve in tetanus antitoxin 
level after complete participation in the Dutch vaccination programme. It is impossible to tell from 
these cross-sectional data whether age has an independent effect in addition to the time after the 
last vaccination. When a similar slope for the overall time/age effect is assumed outside the 
observed age range of 10 to 34 years, the regression analysis predicts a GMT of 0.22 IU/ml and a 
probability of an antibody level below the minimum protective level of less than 0.0001 at the age 
of 90 years, i.e. about 80 years after the sixth vaccination. In Danish studies a hyperbolic or 
exponential decline in antibody titres after primary vaccination with three doses was found (18-
20). Higher levels were found in our study, which is consistent with a higher degree and longer 
duration of immunity with an increasing number of doses (1). After the moments of the third to 
sixth vaccination, the peak in GMT in each case was higher, and although the antitoxin level 
decreased sharply afterwards, the levels remained higher than before these moments. The Dutch 
vaccine contains 5 Lf tetanus toxoid per dose, which is comparable to the potency of the vaccine 
used in the United States, but 40 percent less potent than reported for the studies in Denmark 
(12,20). The longer duration of protective immunity after three tetanus immunisations in the 
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Danish study compared to a study in the United States might be associated with the higher 
vaccine potency (12,20). 
Longitudinal interpretation of cross-sectional data like ours has been found to be reliable (21). 
One difficulty is that we had to rely on self-reported revaccination in our study. Thus, forgotten 
revaccinations could have led to a slower decrease in antitoxin level (21). However, if a faster, i.e. 
exponential, decline is assumed, the predicted GMT is 0.064 IU/ml and the probability of a 
antibody level below the minimum protective level does not exceed 0.14. Furthermore, we think 
that the self-reported revaccination of those individuals who brought documentation of all six 
vaccinations of the vaccination programme is more reliable than that of other individuals, and 
especially more so than that of those born before the introduction of vaccination. 
The percentage of individuals with tetanus antitoxin levels above the minimum protective level 
decreased sharply for those born before the introduction of vaccination, i.e. above 50 years. It was 
less than 50% for those aged 75 to 79 years, and about 25% had an antitoxin level just above this 
minimum level (between 0.01 and 0.1 IU/ml). The higher percentage at risk of a tetanus infection 
in these age groups explains that of the 34 tetanus patients reported in 1984 to 1996, 30 patients 
(88%) were born before 1945. Only one patient, born in 1930, had been vaccinated during 
childhood. For two of the four tetanus patients born after 1945, the vaccination status was 
unknown, and the other two were not vaccinated. This pattern is consistent with other reports 
(12-14,17,22-28). 
We found higher tetanus antitoxin levels for men. In other studies, these higher immunity levels 
were frequently ascribed to vaccinations given in military service, and they were sometimes 
thought to be due to higher accident rates (12,14-17,22,23,28,29). However, some found similar 
levels for men and women despite booster vaccinations in military service (13,30). 
In our study the difference between men and women was largest for those aged at least 45 years, 
but for all age groups the GMT was higher for men. Although more men than women had 
documented or self-reported revaccination, a real difference between men and women could not 
be excluded. Higher antitoxin levels were found for men without documented or self-reported 
revaccination than for women. However, the difference might be explained by the unreliability of 
self-reported vaccination, especially for those born before or just after the introduction of the 
vaccination programme (16,21,24,25). Some of the revaccinated men might have forgotten that 
they had been revaccinated. For example, the higher tetanus antitoxin levels for men born between 
1946 and 1950 compared to women in these cohorts, probably reflects a lower vaccine coverage 
in the first years after the introduction of the vaccination programme. In contrast to women, men 
who were not reached by the vaccination programme, could have received a primary serie of 
tetanus vaccinations in military service. Furthermore, no information was available on the number 
of revaccinations. In the regression model that was restricted to those with documented 
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vaccinations and without documented or self-reported revaccination, no gender effect was 
observed. 
The lower antitoxin levels in the sample of municipalities with low vaccine coverage were due to 
the lower antitoxin levels for orthodox reformed individuals. It is remarkable that, in spite of the 
fact that these individuals frequently refuse vaccination more than 60% had antitoxin levels above 
the minimum protective level. Indeed, among 0 to 19-year-olds 38% and among 20 to 39-year-
olds 29% reported to have participated in the national immunisation programme and all of these 
orthodox reformed individuals had antitoxin levels above the minimum protective level. However, 
the percentage of orthodox reformed individuals with antitoxin levels below the minimum 
protective level was higher in the youngest age group than in those aged 20 to 39 year-olds. 
Besides, also among orthodox reformed individuals who reported not to have participated in the 
national immunisation programme tetanus antitoxin levels above the minimum protective level 
were found. 
Furthermore, although the estimated percentages of tetanus antitoxin levels below 0.01 IU/ml in 
the nationwide sample were hardly affected by selective nonparticipation, the estimated 
percentage of tetanus antitoxin levels below 0.01 IU/ml for the small subgroup of orthodox 
reformed individuals were probably somewhat underestimated. Orthodox reformed individuals 
who reported that they had participated in the vaccination programme were somewhat 
overrepresented among the participants. Nonparticipants for whom questionnaire data was 
available reported less frequently that they had participated in the vaccination programme 
compared to participants (results not shown). As no information on religion was available for 
nonparticipants who did not answer the questionnaire (29%), the true nonparticipation bias is 
unknown. 
Orthodox reformed individuals with antitoxin levels above the minimum protective level had 
lower GMTs than those individuals in the nationwide sample. This suggests that they received 
fewer vaccinations than others. Perhaps these religious groups consider vaccination against 
tetanus after an injury not to be preventive, but therapeutic. Therapeutic interference is accepted 
by these religious groups. Also the not statistically significantly higher tetanus antitoxin levels for 
men might be explained -as described for the nationwide sample- by the fact that some men have 
received tetanus vaccinations in military service but did not report this. 
Thus, it is impossible to obtain reliable insight into the acceptance of vaccination in this group and 
whether this acceptance has changed over time. However, as tetanus antibodies are only induced 
after vaccination, it is clear that a part of the orthodox reformed individuals were vaccinated. 
Since the Netherlands pursue a non-mandatory vaccination policy, acceptance of vaccination will 
be mainly dependent on decision of the concerning individual. 
In addition to age by sex and religion, we studied whether other variables were associated with 
tetanus immunity. The lack of association of educational level, marital status and geographical 
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region suggests that the vaccination programme reaches different parts of the population equally 
well. However, we could not explain the somewhat higher risk of a tetanus antitoxin level below 
the protective level in municipalities with a low degree of urbanisation. The vaccine coverage in 
these municipalities for at least three DTP-IPV doses by the age of 12 months was even slightly 
higher than in the other municipalities (98.1% versus 97.2% in 1996) in the nationwide sample. 
The greater risk of lower antibody levels for individuals born in Turkey or Morocco suggests that 
they had less vaccination coverage for tetanus. They account for the largest groups with non-
Dutch nationality in our country. In a Canadian and American study, birth outside Canada and 
United States was found to be associated with lower tetanus protection (12,13). The difference 
might be due to varying vaccination schedules or varying administration of tetanus vaccinations in 
the countries. 
The better protection of those who reported travel to Asia, South America, Central or South 
Africa than that of those travelling to Turkey or Greece, to the Middle East and to Eastern 
Europe might be due to the absence of guidelines for vaccination (for example in Greece) or to 
the shorter time since the advice has come into effect (Eastern Europe). 
In conclusion, our results subscribe to the policy in our country in which no routine revaccination 
against tetanus is given. This contrasts with the policy in the United States and Canada. However, 
in the Netherlands the vaccine coverage is high and six doses are given in childhood. These 
factors have to be taken into account in decisions on the policy in other countries. Giving four or 
five doses during childhood followed by booster dose in adolescence might be as effective as our 
vaccination schedule in which the last and sixth vaccination is given at nine years of age. 
According to Dutch guidelines, tetanus revaccination for travel or profession is advised when the 
last vaccination was given at least 15 years ago. This advice could explain the peak in the GMT 
for 25 to 29-year-olds, i.e. 15 to 19 years after the last routine vaccination in the Dutch 
vaccination programme. The interval for revaccination after injury is 1 year. Although proper 
wound care and adequate tetanus prophylaxis after injury will have contributed to the very low 
incidence of tetanus, the high vaccine coverage in connection with the long persistence of tetanus 
immunity for those who completed the Dutch immunisation programme must have been very 
important too. After all, tetanus also develops in wounds so small that no medical care is sought 
and thus no tetanus vaccination is given. The long persistence of tetanus immunity suggests that 
our country would still err on the safe side by adhering to the WHO guidelines, which prescribe 
revaccination after injury only when the last vaccination is more than 5 years old. 
A considerable number of adults born before the introduction of mass vaccination lack protective 
tetanus antibodies, and almost all tetanus cases were observed in these age groups. Since the 
Dutch immunisation programme induces long-term protection, we agree with Gergen et al. that 
offering a primary tetanus vaccination to cohorts born before the introduction of vaccination 
would probably be more effective in preventing tetanus than routine revaccination, e.g. every 10 
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years (12). Vaccination of these groups could be prove particularly efficient if combined with 
other vaccines (e.g. diphtheria). 
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Abstract 
With a view to eradicating polio insight into poliomyelitis immunity is useful, particularly 
when there are pockets of unvaccinated persons in the population. In 1995-1996 in a 
population-based study in the Netherlands, neutralizing antibodies against poliovirus types 
1, 2, and 3 were measured in 9,274 sera of the general population and of 
sociogeographically clustered religious groups rejecting vaccination. In the general 
population, the antibody prevalence (>1:8) was 96.6 (95 percent confidence interval (CI) 
95.9 to 97.2 percent), 93.4 (92.3 to 94.5 percent) and 89.7 percent (88.3 to 91.0 percent) 
for poliovirus types 1, 2, and 3, respectively. Antibody prevalence was greater than 90 
percent for type 1 and greater than 80 percent for types 2 and 3 for all age groups. 
Antibodies persist for long periods in both persons with natural immunity and persons with 
immunity induced by inactivated polio vaccine. Among orthodox reformed individuals, 
antibody prevalence of poliovirus types 1, 2, and 3 was 65.0 (57.2 to 72.9 percent), 59.0 
(40.1 to 77.9 percent) and 68.7 percent (65.2 to 72.2 percent), respectively. For orthodox 
reformed participants, but not for other participants, the seroprofiles showed an effect 
from recent poliomyelitis outbreaks among orthodox reformed groups. Since the 
Netherlands pursues non-mandatory vaccination, global poliovirus eradication is the only 
way to protect these orthodox reformed groups. 
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In the 10 years since the World Health Organization launched the initiative to eradicate 
poliomyelitis by the year 2000, major progress has been made worldwide (1). As a result of 
increased global vaccination coverage, the reported incidence of poliomyelitis has dropped from 
over 35,000 cases in 1988 to approximately 5,000 in 1997 (2-4). Surveillance plays a major role 
in directing vaccination efforts and in the process toward eventually certifying that the world is 
free of poliovirus. The surveillance is based on registration and examination of clinical cases 
compatible with poliovirus infection. Although immunosurveillance is not required by the World 
Health Organization, it will provide insight into the protective immunity of (sub)populations. 
Immunosurveillance will be of added value, particularly in countries where there are pockets of 
unvaccinated persons, for polio eradication (5-7). 
Poliovirus vaccination was introduced in the Netherlands in 1957. Children are vaccinated at the 
ages of 3, 4, 5, and 11 months with diphtheria, tetanus, pertussis, and inactivated polio vaccine 
(DTP-IPV) and at ages 4 and 9 years with DT-IPV. The coverage for at least three vaccinations 
at the age of 12 months has been 97 percent in the past decades (8,9). Despite this extensive 
vaccination coverage, there have been a number of poliomyelitis outbreaks in recent decades. 
These outbreaks were confined to orthodox reformed individuals who refuse vaccination on 
religious grounds. The last outbreaks occurred in 1978 with 110 reported cases, caused by 
poliovirus type 1, and in 1992-1993 with 71 cases, caused by poliovirus type 3 (10,11). The 
majority of unvaccinated persons in the Netherlands have not been vaccinated for various, mostly 
trivial reasons, but are protected because of natural immunity or herd immunity. An orthodox 
reformed minority of approximately 275,000 persons is however, insufficiently protected by herd 
immunity, since they form a sociogeographically closely knit network (12). It should be noted that 
vaccination is accepted to some degree even among the orthodox reformed group. About a third 
of the orthodox reformed participants in our study reported to have indeed received vaccination. 
This matches with the presence of tetanus antitoxin antibodies that we measured in the sera of this 
cohort (13). 
We established a serum bank through a population-based sampling in 1995-1996 to evaluate the 
effects of mass vaccination in the Netherlands (7). This offered us an opportunity to study the 
prevalence of antibodies against poliovirus in the Dutch population and in groups refusing 
vaccination. The objective was to gain insight into the population's immunity. In addition, such 
data could provide insight into the possible waning of natural and vaccine-induced immunity in the 
absence of boosting opportunities. Furthermore, the study enabled us to look for indications of 
poliovirus circulation by comparing the serological profiles of cohorts born before and after recent 
outbreaks, both in the general population and in orthodox reformed groups. 
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Study population 
Eight municipalities with probabilities proportional to their population sizes were sampled within 
each of five geographical Dutch regions with similar population sizes. An age-stratified sample 
(classes 0, 1-4, 5-9, 75-79 years) of 380 individuals was randomly selected from each 
municipality. Subjects were requested to give a blood sample, fill out a questionnaire, and bring 
their certificates of national immunisation programme, military service, and travel vaccinations. In 
addition, individuals were selected similarly from eight municipalities with low vaccine coverage 
(65-87 percent) so that immunity in the orthodox reformed persons who refuse vaccination could 
be assessed. Samples and data were collected in the period from October 1995 to December 
1996. The participation rates were 55 percent in the nationwide sample and 52.5 percent in the 
low vaccine coverage sample. The study design and details on the data collection have been 
published elsewhere (7). 
Antibody assay 
The sera were stored at minus 86 °C. Neutralizing antibodies against poliovirus types 1, 2, and 3 
were determined in a microneutralization assay with the Mahoney strain for poliovirus type 1, the 
MEF-1 strain for poliovirus type 2, and the Saukett strain for poliovirus type 3, as previously 
described (14). The sera were titrated in a twofold dilution range up to 1:4096. The results are 
expressed as 2log reciprocal titers. The titers are expressed as the reciprocal of the greatest 
dilution showing complete neutralization of the cytopathic effect of 100 percent cell culture 
infection doses. A titer of 1:8 (2log titer=3) is defined as indicating full protective immunity; a titer 
of 1:4 or 1:2 (2log titer=l or 2), basic protective immunity; and 1:1 (2log titer=0), as no protective 
immunity. 
Statistical analysis 
Frequencies and geometric mean titers within each municipality were weighted by the proportion 
of the age group in the population. To produce national estimates, the weighted frequencies and 
geometric mean titers were averaged over the 40 municipalities (15). For the low vaccine 
coverage sample, the geometric mean titers were averaged weighting by the population size of the 
municipality. The effect of differential probabilities of response on both sample estimates was less 
than one standard error and was therefore ignored. 
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In the different analyses the following groups were distinguished: 
1. All participants of the nationwide sample (NS; N = 7,773). 
2. All participants of the low vaccine coverage sample (LVC; N= 1,501 ). 
3. Participants who were not orthodox reformed, in the low vaccine coverage sample (NOR-
LVC;N= 1,265) 
4. Orthodox reformed participants of the low vaccine coverage sample who frequently refuse 
vaccination (OR-LVC; N = 236). 
5. The subgroup of orthodox reformed participants of the low vaccine coverage sample who did 
not report to have participated in the national immunisation programme and had no 
documented vaccinations against poliomyelitis (UOR-LVC; N = 167). 
Linear regression analysis was used to determine the persistence of poliovirus type 1, 2, and 3 
antibodies after complete participation in the national immunisation programme. The association 
between poliovirus type 1, 2, and 3 antibody titers and age was studied in this analysis for 
individuals from the nationwide sample with the sixth documented vaccination at 8 to 9 years of 
age, for those without self-reported or documented revaccination or a military service history. 
Since the number of individuals over 34 years of age who met these criteria was very small, this 
analysis was restricted to those aged 10 to 34 years. 
Participants over 16 years of age were asked through the questionnaire whether they had received 
any additional vaccination for diphtheria, tetanus, and poliomyelitis (DT-IPV) after their 
childhood vaccination because of military service, travel, or professional activities, for example. 
Those participants who reported such a vaccination were considered revaccinated. Documented 
revaccination was defined as any documented vaccination with inactivated polio vaccine given in 
addition to vaccinations documented on a certificate of the national immunisation programme. 
Results 
Protective immunity in the nationwide sample (NS) 
The percentages of full, basic, and no protection against poliovirus types 1, 2 and 3 are given for 
the nationwide sample in Table 1. The percentage of full protection was greatest (97 percent) for 
poliovirus type 1 ; it was slightly lower for poliovirus type 2 (93 percent) and amounted to 90 
percent for poliovirus type 3. The percentages of full protection against poliovirus type 2 and 
poliovirus type 3 were observed to be smaller than that against poliovirus type 1 in almost all age 
classes (Figure 1). The percentages of full protection are greatest for those up to 29 years of age 
for all serotypes. A gap in the percentage of full protection was observed in the age groups of 30 
to 44 years for poliovirus type 3. The percentage of full protection for poliovirus type 3 in these 
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age groups ranged from 82.3 to 88.1 percent, while for poliovirus types 1 and 2 this percentage 
remained greater than 90 percent. In the groups over 49 years of age, the percentage of full 
protection ranged from 90.7 to 94.8 percent for poliovirus type 1, from 80.7 to 90.0 percent for 
poliovirus type 2, and from 82.3 to 91.3 percent for poliovirus type 3. 
The geometric mean titer was lower for 0-year-olds than for 1 to 4-year-olds for all poliovirus 
types. For 1 to 14-year-olds, it remained stable for poliovirus types 1 and 2, but a slight increase 
was seen for poliovirus type 3. The geometric mean titers gradually decreased for those from 15 
to 40 years of age for all poliovirus types (Figure 1). The geometric mean titers decreased from 
10.3, 8.6, and 8.2 for 10 to 14-year-olds to 7.7, 6.2, and 5.2 for 35 to 39-year-olds for poliovirus 
types 1, 2, and 3. Thereafter, the geometric mean titers remained stable. The geometric mean titer 
was highest for poliovirus type 1 and lowest for poliovirus type 3 in all age groups. No differences 
were observed between men and women. 
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Figure 1. Age-specific prevalence of antibodies and geometric mean titer (with 95 percent 
confidence intervals) for poliovirus types 1, 2, and 3 in the nationwide sample (NS); Pienter 
Project, 1995-1996, The Netherlands 
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Table I. The percentages of full, basic, and no protective antibodies and geometric mean titers for 0 to 79-year-olds for 
poliovirus types 1, 2, and 3 in the nationwide sample (NS), low vaccine coverage sample (LVC), and separately for orthodox 
reformed individuals from the low vaccine coverage sample (OR-LVC) and others from the low vaccine coverage sample 
(NOR-LVC); Pienter Project, 1995-1996, The Netherlands 
Nationwide sample Low vaccine coverage Low vaccine coverage Orthodox reformed 
(NS) sample (LVC) sample excluding individuals from the low 
orthodox reformed vaccine coverage 
individuals (NOR-LVC) sample (OR-LVC) 
(n = 7,773) ( n = l ,501) (n= 1,265) (n = 236) 
% (95% CI) % (95% CI) % (95% CI) % (95% CI) 
Poliovirus type 1 
Full protection 96.6 (95.9 - 97.2) 92.3 (89.5 - 95.0) 97.2 (96.0 - 98.4) 65.0 (57.2 - 72.9) 
Basic protection 2.3 (1.8 -2.7) 3.5 (1.9-5.2) 1.6 (0.9 - 2.3) 12.5 (7.5 - 17.5) 
No protection 1.2 (0.8 - 1.5) 4.2 (2.2 - 6.2) 1.2 (0.0 - 2.5) 22.5 (16.7-28.3) 
Geometric mean titer 8.6 (8.4 -8.8) 8.4 (7.9-8.8) 8.9 (8.4 - 9.3) 5.6 (4.5 - 6.6) 
Poliovirus type 2 
Full protection 93.4 (92.3 - 94.5) 87.7 (85.1 -90.3) 92.8 (91.4-94.1) 59.0 (40.1 -77.9) 
Basic protection 4.1 (3.4 -4.8) 6.3 (4.9 - 7.7) 4.7 (3.8 - 5.5) 16.3 (2.3 - 30.3) 
No protection 2.4 (1.8 -3.1) 6.0 (3.7 - 8.2) 2.6 (1.8-3.3) 24.7 (17.8-31.6) 
Geometric mean titer 7.0 (6.8 - 7.2) 6.7 (6.5 - 6.9) 7.0 (6.8 - 7.3) 4.5 (3.2-5.9) 
Poliovirus type 3 
Full protection 89.7 (88.3 - 91.0) 85.9 (84.2 - 87.7) 89.8 (87.1 -92.6) 68.7 (65.2 - 72.2) 
Basic protection 7.1 (6.2 -8.0) 7.0 (5.7 - 8.3) 5.5 (4.1 -6.9) 14.2 (9.4-19.1) 
No protection 3.2 (2.4 -4.0) 7.1 (5.2 - 8.9) 4.7 (2.1 -7.2) 17.1 (11.2-23.0) 
Geometric mean titer 6.3 (6.1 -6.5) 6.2 (6.0 - 6.4) 6.6 (6.2 - 6.9) 4.8 (4.4-5.1) 
0_ Chapter 6 
Persistence of poliovirus antibodies after vaccination in the nationwide sample (NS) 
For individuals aged 10 to 34 years in the nationwide sample who had had the sixth and last 
documented vaccination at the age of 9 years, without any evidence of revaccinations (n = 969), 
the overall percentages of full, basic, and no protection in this group were 99.7 (95 percent CI 
99.2 - 100), 0.06 (95 percent CI 0.0 - 0.18) and 0.2 percent (95 percent CI 0.0 -0.6) for 
poliovirus type 1, 98.7 (95 percent CI 97.7 - 99.6), 1.2 (95 percent CI 0.2-2.1) and 0.1 (95 
percent CI 0.0 - 0.3) for poliovirus type 2 and 94.5 (95 percent CI 90.9 - 98.2), 5.1 (95 percent 
CI 1.5 - 8.8) and 0.3 percent (95 percent CI 0.0 - 0.7) for poliovirus type 3. The geometric mean 
titers for poliovirus type 1 decreased from 10.5 (95 percent CI 10.2 to 10.7) for 10 to 14-year-
olds to 8.0 (95 percent CI 7.4 to 8.6) for 30 to 34-year-olds, for poliovirus type 2 from 8.6 (95 
percent CI 8.4 to 8.8) to 5.2 (95 percent CI 4.7 to 5.7) and for poliovirus type 3 from 8.2 (95 
percent CI 8.0 to 8.5) to 4.8 (95 percent CI 4.2 to 5.3) (Figure 2). 
In the linear regression analysis of the relationship between antibody titers and age (Figure 2), the 
intercepts for poliovirus types 1, 2, and 3 were 11.9, 10.8, and 10.1 (in 2log titer), respectively, 
with slopes for age in years of-0.12, -0.18, and -0.16 respectively. 
For the 39 individuals who had received the sixth vaccination at the age of 8 or 9 years and had 
had at least one documented revaccination, the geometric mean titers averaged 10.4 (95 percent 
CI 9.7-11.1) for poliovirus type 1, 9.4 (95 percent CI 8.6 - 10.3) for poliovirus type 2, and 8.2 
(95 percent CI 7.0 - 9.4) for poliovirus type 3. These geometric mean titers were similar to those 
of individuals aged 10 to 14 years who received the last and sixth vaccination at the age of 8 or 9 
years. 
Protective immunity in orthodox reformed individuals (OR-LVC) 
A more detailed analysis was carried out on the low vaccine coverage sample. The orthodox 
reformed individuals within this sample (OR-LVC) were compared with others within this sample 
(NOR-LVC). 
Orthodox reformed individuals showed a smaller percentage of full protection for all three 
poliovirus types than others in the low vaccine coverage sample, as well as those in the 
nationwide sample (Table 1). When orthodox reformed individuals were excluded from the low 
vaccine coverage sample (NOR-LVC), no differences were observed in full, basic, and no 
protection and geometric mean titers for poliovirus types 1, 2, and 3 between the low vaccine 
coverage sample and the nationwide sample (NS) (Table 1). 
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Figure 2. Regression analysis for poliovirus types 1 to 3 for individuals with the 
sixth poliomyelitis vaccination at the age of 8 or 9 years without self-reported or 
documented revaccination in the nationwide sample (NS); Pienter Project, 1995-
1996, The Netherlands 
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The age-specific percentages of full protection for poliovirus types 1, 2, and 3 for the orthodox 
reformed individuals in the low vaccine coverage sample (OR-LVC) are compared with all 
individuals in the nationwide sample (NS) in Figure 3. Due to the small numbers of orthodox 
reformed individuals, the age-specific percentages are less precise; therefore the fluctuations 
shown could be a result of chance. 
For poliovirus type 1, the percentage of full protection in the orthodox reformed individuals (OR-
LVC) increases from 39.1 percent for 15 to 19-year-olds to 88.7 percent for 30 to 34-year-olds. 
This percentage is more or less stable at a level of approximately 90 percent for older individuals. 
An increase in the percentage of full protection for poliovirus type 2 is observed after the age of 
25 to 29 years from 54.4 percent to a level of approximately 80 percent. The percentage of full 
protection increases after the 1 to 4-year-olds (54.2 percent) and then fluctuates around an 
average of 75 percent for poliovirus type 3. 
Effects of recent outbreaks: cohortwise analysis 
We did a cohortwise analysis of the serological profiles in order to study the possible effect of 
poliovirus circulation during recent outbreaks among orthodox reformed individuals, i.e., in 1978 
and in 1992-1993. We compared the percentages of full and no protection in various birth cohorts 
in the nationwide sample (NS) for this purpose, in the low vaccine coverage sample excluding all 
orthodox reformed individuals (NOR-LVC) and in the orthodox reformed individuals who did not 
report to have participated in the national immunisation programme and had had no documented 
vaccinations against poliomyelitis (UOR-LVC) (Table 2). The following birth cohorts within these 
groups were distinguished: those born after 1992, i.e., after the epidemic with poliovirus type 3, 
those born between 1978 and 1992, i.e., after the epidemic with polio virus type 1 in 1978, those 
born between 1945 and 1978, i.e., those who had been offered childhood vaccination, and those 
born before 1945, i.e., those who were not eligible for childhood vaccination. Table 2 summarizes 
the results. 
No statistical significant differences were found in the percentages of full protection for 
individuals in the nationwide sample and the not orthodox reformed individuals from the low 
vaccine coverage sample (NOR-LVC). However, the percentages of full protection were slightly 
smaller for those born between 1978 and 1992 and, in particular, those born after 1992 in the low 
vaccine coverage sample (NOR-LVC), than for those in the nationwide sample (NS). The 
difference was largest for poliovirus type 3, but was not statistically significant. In contrast, 
considering those born before 1945 the percentages of full protection for poliovirus types 1 and 3, 
were slightly larger for those in the low vaccine coverage sample (NOR-LVC) than for those in 
the nationwide sample (NS). There was little difference for type 2. 
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Table 2. The percentages of full and no protection against poliovirus types 1, 2, and 3 according to birth cohort in the 
nationwide sample (NS), the low vaccine coverage sample without orthodox reformed individuals (NOR-LVC), and in a 
subgroup of unvaccinated orthodox reformed individuals from the low vaccine coverage sample (UOR-LVC); Pienter 
Project, 1995-1996, The Netherlands 
Poliovirus type 1 Poliovirus type 2 Poliovirus type 3 
% (95% CI) % (95% CI) % (95% CI) 
Nationwide sample (NS) (n = 7,773) 
Born before 1945 91,8 90.4 - 93.3 84.9 82.9 - 86.9 84.6 82.7 - 86.4 
(n = 2,511) (2.9) (2.0 - 3.8) (6.9) (5.6 - 8.2) (6.0) (4.7 - 7.4) 
Born between 1945 and 97.9 97.2 - 98.6 95.9 94.8 - 97.0 90.2 88.5 - 92.0 
1978 (n = 2,956) (0.5) (0.2 - 0.9) (0.9) (0 .3 - 1.4) (2.6) (1.7-3.5) 
Born between 1978 and 99.4 98.9 - 99.9 99.2 98.5 - 99.9 97.1 96.1 -98.1 
1992 (n = 1,675) (0.2) (0.0 - 0.6) (0.5) (0.0- 1.0) (0.6) (0.2-1.0) 
Born after 1992 98.4 97.2 - 99.6 98.2 97.1 -99.2 93.8 91.7-96.0 
(n = 631) (1-0) (0.0 - 2.0) (1-1) (0.07 - 2.0) (1.3) (0.4 - 2.3) 
Low vaccine coverage sample excluding orthodox reformed individuals (NOR •LVC) (n = 1,265) 
Born before 1945 94.0 91.6-96.4 85.2 83.3 -87.1 87.5 83.5-91.5 
(n = 431) (2.0) (0.4 - 3.5) (7.7) (5.8 - 9.7) (6.7) (4.0 - 9.5) 
Born between 1945 and 98.0 96.8 -99.1 94.3 91.9-96.7 90.1 85.7 - 94.4 
1978 (n=499) (0.8) (0.0-1.7) (1.1) (0.0 - 2.4) (4.4) (0.8-8.1) 
Born between 1978 and 98.3 94 .8-100 98.3 94.8 -100 94.8 91.4-98.2 
1992 (n=248) (1.7) (0.0 - 4.0) (0.3) (0-1 .3) (1.3) (0.0 - 3.4) 
Born after 1992 96.4 90.7 - 100 93.1 85.3 -100 83.4 73.0- 93.8 
(n = 87) (3.0) (0.0 - 8.5) (3.6) (0 - 9.2) (8.6) (0.6 - 16.7) 
Table 2 continued 
Poliovirus type 1 Poliovirus type 2 Poliovirus type 3 
% (95% CI) % (95% CI) % (95% CI) 
Orthodox reformed individuals (UOR-LVC) (n = 167) 
Born before 1945 86.9 76.0 - 97.8 70.0 47.2 - 92.8 61.3 25.7 - 96.9 
(n = 60) (8.8) (0.0 - 20.3) (4.1) (0.0- 12.8) (19.9) (0.0 - 55.2) 
Born between 1945 and 64.0 50.2 - 77.9 60.0 33.2-86.1 54.3 31.3-77.4 
1978 (n = 58) (19.5) (3.3- 35.7) (20.1) (0.0 - 42.8) (28.7) (12.3-45.1) 
Born between 1978 and 12.1 0.0 - 24.4 18.8 0.0 - 42.4 52.8 8.1 -97.4 
1992 (n = 27) (62.4) (22.3 - 100) (71.4) (50.1 -92.6) (27.6) (0.0-63.1) 
Born after 1992 5.8 0 .0- 13.4 5.3 0 .0- 12.7 1.3 0.0 -5.8 
(n = 22) (31.5) (0.0 - 65.5) (75.2) (53.8 - 96.6) (78.8) (51.8- 100) 
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Percent Poliovirus type 1 
• Orthodox reformed individuals 
• Nationwide sample 
0 1- 5- 10- 15- 20- 25- 30- 35-40- 45- 50- 55- 60- 65- 70- 75-
Age (in years) 
Percent Poliovirus type 2 
- Orthodox reformed individuals 
• Nationwide sample 
0 1- 5 - 1 0 - 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75-
Age (in years) 
Percent Poliovirus type 3 
0 1- 5- 10-15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75-
Age (in years) 
Figure 3. Age-specific prevalence of antibodies against poliovirus types 1, 2, and 3 
in the nationwide sample (NS) and in orthodox reformed individuals from the low 
vaccine coverage sample (OR-LVC); Pienter Project, 1995-1996, The Netherlands 
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Within both the nationwide sample (NS) and the low vaccine coverage sample (NOR-LVC), the 
percentages of full protection were the smallest for those born before 1945 (with the exception of 
the smaller percentage for type 3 for those born after 1992 in the low vaccine coverage sample), 
while the greatest percentages were observed for those born between 1978 and 1992. By contrast, 
among the orthodox reformed individuals (UOR-LVC), the percentages of full protection for all 
serotypes were smallest in the cohorts born between 1978 and 1992 and after 1992. For these 
individuals, the difference between those born before and after the two epidemics was much larger 
than in the nationwide sample and the low vaccine coverage sample. Less than 20 percent of the 
orthodox reformed individuals born between 1978 and 1992 and less than 6 percent of those born 
after 1992 were fully protected against poliovirus types 1 and 2. In contrast, 53 percent of those 
born between 1978 and 1992 had full protective antibody levels against poliovirus type 3, as did 
only 1 percent of those born after 1992. 
In all cohorts, whether born before or after the introduction of childhood vaccination (1945), the 
percentages of full protection for poliovirus types 1, 2, and 3 were smaller for orthodox reformed 
individuals than for individuals from the nationwide sample or the low vaccine coverage sample. 
Discussion 
Our study shows that the Dutch population is generally well protected against poliomyelitis. A 
large neutralizing antibody prevalence (> 1:8), often exceeding 90 percent, was found in all age 
groups. With the currently available methods, it is not possible to determine whether these 
antibodies are due to exposure to live, wild virus or to vaccine virus. In general, however, it is 
reasonable to assume that the neutralizing antibodies are mainly due to natural infection in those 
born before 1945, whereas they are mainly induced by vaccination with inactivated polio vaccine 
in those born after the start of childhood vaccination (1957). 
Although the prevalence of antibodies (> 1:8) against poliovirus type 3 is generally somewhat 
lower than for types 1 and 2, it is still close to 90 percent. It can be assumed that even persons 
with a basic level of antibodies (1:4 and 1:2) are protected. It is, however, unclear at present 
whether all those without detectable antibodies are susceptible to infection; some, particularly the 
elderly, may be protected by memory immunity. We are currently performing a study of memory 
response in seronegative elderly persons after challenge with oral polio vaccine. Moreover, the 
potential for poliovirus circulation in the well-protected population vaccinated with inactivated 
polio vaccine is an important issue for polio eradication. 
The age-specific profile of antibodies is mirrored in the age-specific geometric mean titers as 
shown in Figure 1. The geometric mean titers are consistently high. In the cohorts born before 
1945 (i.e., in our study of those aged 50 years or more) with predominantly natural immunity, the 
geometric mean titers are stable without any indication of waning immunity. A seroprevalence 
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study with a different sampling scheme and limited numbers was carried out in the Netherlands in 
1980 and 1985. Comparing the present results with those from the previous studies indicates that 
there is no waning immunity in these naturally infected persons several decades after natural 
infection (16,17). Naturally exposed individuals seem to keep their neutralizing antibodies. This 
would imply that those without detectable antibodies have never been exposed to live, wild virus. 
In contrast, a small decrease in the geometric mean titer with age or time was observed for those 
between 10 and 40 years old with probably predominantly vaccine-induced antibodies. It appears 
that the decrease in geometric mean titer is due to waning immunity after vaccination. No further 
decline was observed in the first cohorts to whom vaccination has been offered (40 to 49-year-
olds). These cohorts are also likely to have been exposed to live polioviruses circulating during 
their childhood, and therefore probably have a combination of natural and vaccine-induced 
immunity. It is remarkable that the differences in antibody prevalence between poliovirus type 3 
and types 1 and 2 are stronger in 30 to 44-year-olds. This might be due to a smaller 
immunogenicity of the poliovirus type-3 antigens. As such, assessment of poliovirus type-3 
antibodies may provide the most sensitive tool to study possible waning immunity after 
vaccination. 
In 10 to 34-year-olds who have been completely vaccinated according to the Dutch vaccination 
programme and do not have evidence of revaccination, regression analysis showed a linear 
decrease in antibody levels for all types. Yet antibody levels were still high, even about 20 years 
after vaccination. We cannot rule out the possibility that the long persistence of high levels of 
vaccine-induced antibodies is partly influenced by boosting through circulating poliovirus. This 
might correspond to the slightly smaller slope for poliovirus type 1 in the model, as poliovirus 
type 1 was most prevalent in the past. However, as we discuss later, virus circulation probably 
stopped in the late 1960s or early 1970s (17-19). In a follow-up study of children vaccinated with 
inactivated polio vaccine in Sweden, Bottiger et al. show that poliovirus neutralizing antibodies 
could persist for more than 18 years after vaccination (20). A more marked decline in antibody 
titer was seen in the first few years, while a very slow decrease was observed afterwards (20). 
Epidemiological data of the recent polio outbreaks in the Netherlands confirm the high level of 
protective immunity against poliomyelitis in the general population. In both the 1978 and the 
1992-1993 outbreaks, cases occurred only among unvaccinated individuals nearly all of whom 
belonged to orthodox reformed groups. Our results, however, show that there is still a high 
potential for outbreaks in these groups, since 23 percent, 25 percent, and 17 percent had no 
measurable antibodies for poliovirus type 1, type 2, and type 3, respectively. The percentage of 
susceptible individuals 1 to 19 years of age is 39 percent for type 1, 44 percent for type 2, and 19 
percent for type 3. As expected, seronegative individuals are seen predominantly in the cohorts 
born after the introduction of vaccination. Actually, this seems to be a paradoxical effect of mass 
105 
Chapter 6 
vaccination, although these unvaccinated groups benefit from the interruption of virus circulation 
that results from widespread vaccination. The Ministry of Health, advised by the Health Council, 
has deliberately refrained from making vaccination mandatory in the Netherlands mainly for 
ethical reasons. Therefore, the ultimate prevention of poliomyelitis in these groups can only be 
attained through global eradication of the causative agents, the polioviruses (21). 
The effect of virus circulation during the outbreaks in 1978 (type 1) and 1992-1993 (type 3) 
among orthodox reformed individuals without evidence of vaccination becomes evident when the 
serological profiles of the birth cohorts born before and after the outbreaks are compared. For 
type 1, the seroprevalence for those born between 1978 and 1992 was only 12 percent, but it was 
64 percent for those born between 1945 and 1978; for type 3, the seroprevalence for those born 
after 1992 was only 1 percent in contrast to 53 percent for those born between 1978 and 1992. 
This indicates that as many as half of the individuals in these unvaccinated groups were infected 
during the epidemic. Remarkably, the cohortwise estimates of the seroprevalence for type 2 show 
the same pattern as for type 1, although there have been no signs of wild poliovirus type-2 
circulation in the Netherlands for decades. The last polio patient with a poliovirus type-2 infection 
in the Netherlands was reported in 1966. Occasionally a wild poliovirus type 2 has been isolated 
from adopted children and, once, from river water in the early 1980s. Thereafter, only a few 
vaccine-derived poliovirus type-2 strains have been isolated (17). The apparently elevated 
poliovirus type-2 seroprevalence in those born after 1978 cannot be ascribed to vaccination with 
oral polio vaccine during the outbreak in 1978, as monovalent type-1 oral polio vaccine was used 
then to control the outbreak. In the 1992-1993 outbreak, however, trivalent oral polio vaccine 
was applied, which may have resulted in poliovirus type-2 circulation (22). There is some cross-
reactivity between poliovirus serotype 1 and 2, but it is improbable that this can explain the 
comparable levels for serotypes 1 and 2 satisfactorily (23). Aylward et al. also conclude from 
sero-epidemiological data from a study in gypsies that wild virus circulation could have influenced 
the prevalence, although the possibility that the high prevalence was caused by the spread of 
vaccine virus could not be ruled out (24). The differences in prevalence in poliovirus type-3 
antibodies in cohorts born before and after the 1992-1993 outbreak in our study must mainly be 
ascribed to wild virus circulation. 
In the nationwide sample and the low vaccine coverage sample excluding orthodox reformed 
individuals we saw no differences in type-1 seroprevalence in the cohorts born before and after 
the 1978 outbreak, and there was only a small difference in type-3 seroprevalence in cohorts born 
before and after the 1992-1993 outbreak. This supports the assumption that there has been little 
or no virus spread outside the orthodox reformed groups, either in the general population or 
among other inhabitants of the municipalities where these groups live. In addition, the age-specific 
geometric mean titers for types 1, 2, and 3 in the nationwide and low vaccine coverage samples 
are very similar, which is another indication of the absence of poliovirus circulation in the general 
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population. We must realize that substantial virus circulation would have to occur to cause a 
significant difference. In those born after 1978 and particularly in those born after 1992 , the type-
3 seroprevalence in the low vaccine coverage sample excluding orthodox reformed persons is 
lower than in the nationwide sample. The reason for this is unclear, but might be explained by the 
study results being influenced by other religious groups who live in these municipalities, some 
whom, as is known, also refuse vaccination, be it less strictly. 
The level of protective immunity of individuals in the orthodox reformed groups without evidence 
of vaccination who were born before the introduction of childhood vaccination is lower than that 
of other persons of the same age. As we expect them to have been exposed to the same extent, it 
is likely that some of the elderly outside the orthodox reformed groups have been vaccinated for 
various other reasons, i.e., travel, military service, professional activities. The same has been 
observed for the prevalence of tetanus antitoxin antibodies (13). 
As we have discussed, there are no signs of waning immunity in cohorts supposed to have 
predominantly natural immunity. The seroprevalence for none of the three types reaches 100 
percent in the oldest cohorts, indicating that the endemic virus in those days never fully depleted 
the pool of susceptible individuals. This is in agreement with the threshold value for the 
percentage of protected persons required to prevent polio virus transmission, which is estimated 
at 82-87 percent under the condition of homogeneous mixing (25). The 1978 and 1992-1993 
outbreaks also appear not to have infected all susceptible individuals among the orthodox 
reformed groups; only 64 percent of those born between 1945 and 1978 have type-1 antibodies, 
and 53 percent of those born between 1978 and 1992-1993 have type-3 antibodies. The large 
percentage of children without measurable antibodies clearly shows a potential for another polio 
outbreak in the Netherlands that will exist as long as polioviruses have not been eradicated 
worldwide. 
Conclusions 
Routine childhood vaccination with inactivated polio vaccine has provided excellent protection 
against poliomyelitis in the general population in the Netherlands. Antibodies persist for very long 
periods, not only in naturally infected persons, but also in persons with vaccine-induced immunity. 
Our study, in the era of polio eradication provides additional evidence of absence of poliovirus 
circulation in the general population during the outbreaks that occurred among orthodox 
reformed groups who refuse vaccination in 1978 and 1992-1993. Since the Netherlands pursues a 
nonmandatory vaccination policy, pockets of susceptibility remain because of their objecting to 
vaccination for religious reasons. Global eradication, therefore, would be the means of protecting 
these individuals against poliomyelitis. 
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Abstract 
In 1996, a sudden increase in pertussis incidence was reported in the Netherlands (2.1 per 
100,000 in 1995, 18 per 100,000 in 1996). Although not all potential surveillance artifacts 
could be excluded, it is highly probable that the data reflect a true outbreak. However, the 
cause of this increase has not yet been determined. Further research is directed to the 
severity of disease and a possible mismatch between the vaccine and the circulating 
Bordetella strains. 
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In 1996, 2771 cases were reported to the Inspectorate of Health in the Netherlands (population 
15 million), compared with 319 cases in 1995. With epidemic cycles expected every 3 to 5 years 
and a recent outbreak in 1994, this rise was unexpected (1). 
After the introduction of pertussis immunisation with a whole-cell vaccine in the National 
Immunisation Programme (1952), the incidence of pertussis in the Netherlands decreased 
significantly. Children are immunized at the age of 3, 4, 5, and 11 months with a diphtheria, 
tetanus, pertussis, inactivated polio vaccine (DTP-IPV), and the vaccine coverage for pertussis, 
for at least three immunisation amounts to 96% at the age of 12 months. Until the 1980s, the 
incidence of pertussis seemed very low, because only incidentally cases were reported. However, 
in the last two decades pertussis has been endemic and epidemic peaks have appeared. 
The surveillance of pertussis is mainly based on notification, which was made obligatory by law in 
1976. Because the availability and interpretation of serologic tests changed in the 1980s and the 
absence of a clear case definition for notification seemed to have influenced the surveillance, a 
restrictive case definition that included criteria for laboratory diagnosis, was introduced in 1988. 
Therefore, we have limited this report to the notification data from 1989 onwards. The annual 
incidence of pertussis notification from 1989 to 1995 is shown in Figure 1. In this period, the case 
definition includes defined clinical symptoms and laboratory confirmation. The clinical symptoms 
include a serious cough lasting more than 2 weeks or cough attacks or cough followed by 
vomiting in combination with at least one of the following symptoms/findings: apnea, cyanosis, 
characteristic cough with whooping, subconjunctival bleeding, leukocytosis, or contact with a 
confirmed or suspected pertussis in the previous 3 weeks. Laboratory confirmation is defined as 
either positive culture of Bordetella pertussis or Bordetella parapertussis, or positive two-point 
serology, i.e., the finding of a significant rise (> 4-fold) of IgG antibodies against pertussis toxine 
and/or IgA antibodies against B. pertussis in paired sera. The case definition for notification is 
highly specific, but results in significant underreporting. 
We compared the number of cases reported per 4-week period in 1996 with the number reported 
in 1994, the year with the highest incidence in recent years (Figure 2). It appears that an 
unexpectedly large number of pertussis cases was reported (18 per 100,000) in 1996. 
The reports came from all over the country. No geographical clustering was observed, even in 
regions with pockets of low vaccination coverage or at the borders of the country (close to 
Germany, where vaccination coverage for pertussis is low). 
The age distribution of the patients in the years 1989 to 1996 shows a significant decrease in the 
proportion of infants less than 1 year old (from 2 1 % in 1989 to 7% in 1996) and a significant 
increase in the proportion of 1- to 4-year-olds (from 21% in 1989 to 30% in 1996). A significant 
decrease (from 42% in 1989 to 30% in 1995) was also observed in 5- to 9-year-old children; 
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however, in 1996, the proportion increased to 39%. No changes were observed for 10- to 14- and 
15- to 19-year-old groups, whereas the proportion of patients 20 years old or older increased from 
5% to 11% (Table 1). 
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Figure 1. Annual incidence of pertussis estimated from notification by registraton date for the 
period 1989-1995 
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Figure 2. Number of cases notified by registration date in 1994 and 1996 (4-week periods) 
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Table 1. Age distribution (percentages) pertussis notification in the period 1989-1996 
Age (years) 1989 1990 1991 1992 1993 1994 1995 1996 
0 21 21 23 21 24 16 13 7 
1-4 21 21 26 19 27 34 33 30 
5-9 42 37 34 30 26 32 30 39 
10-14 10 9 10 17 12 8 10 11 
15-19 1 2 2 2 1 1 1 2 
> 2 0 5 9 6 11 10 8 12 11 
Unknown 0 0 1 1 0 1 1 0 
Total (n) 434 471 164 169 294 536 319 2771 
Whereas the average vaccine coverage did not change, the proportion of vaccinated patients 
increased from 55% in 1989 to 85% in 1996. In all age groups, except that of 6- to 11-months old 
infants, the proportion of vaccinated patients is higher in the years 1994 to 1996 than in the years 
1989 to 1993. 
We estimated the annual incidence of pertussis for vaccinated and unvaccinated children aged 1 to 
4 and 5 to 9 years, on the basis of reporting by registration date (1989 to 1996) (Figure 3). 
Calculation of incidence according to vaccination status was deliberately restricted to those aged 
1 to 4 years and 5 to 9 years (vaccine coverage estimated at 96%) for methodological reasons. 
The changes in age-specific incidence over the years for vaccinated and unvaccinated children are 
identical for 1989 to 1993. However, from 1994 to 1996, and particularly in 1996, the incidence 
among vaccinated 1- to 4-year-olds was considerably higher than in 1989 and 1990. In 
unvaccinated children, the incidence in 1994 and 1995 was lower than in 1989 and 1990. The 
difference in incidence between the period 1989 to 1990 and the year 1996 was much smaller in 
unvaccinated than in vaccinated persons. A similar discrepancy can be seen for 5- to 9-year-old 
group. 
In view of the increase in pertussis reporting in 1996, the first issue to be addressed was whether 
this reporting reflected a true increase in pertussis incidence or was a surveillance artifact. If 
considerable underreporting is assumed, an increase due to improved compliance to the 
notification system or increased alertness should be considered. However, in the first two quarters 
of 1996, there is no apparent reason for such an assumption. Nonetheless, after the first reports of 
the observed rise, both publicity and increased awareness of the disease by physicians and patients 
might have influenced reporting. 
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Figure 3. Estimated incidence of pertussis for unvaccinated and vaccinated children aged 1-4 
years and 5-9 years based on notification records and assuming a coverage of 96% for the 
entire population 
Serodiagnosis for the country as a whole is done by a single reference laboratory at the National 
Institute of Public Health and the Environment; thus, the data provided by the laboratory can be 
used for nationwide surveillance. Furthermore, the reference laboratory collects strains of B. 
pertussis from regional public health laboratories, and the number of strains received also reflects 
the epidemic curve. The epidemiologic curve derived from these various sources over the past 
years is consistent with the notification data. 
Since laboratory confirmation is part of the case definition, changes in sérodiagnostic practice 
might have influenced notification. Frequently, no conclusive results are obtained from serology: a 
second serum sample may not be submitted, or the first serum sample may be taken late after onset of 
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disease, thereby missing the dynamic phase of the immunoresponse. Recently, cut-off values for 
antibody titres characteristic for the acute immunoresponse after natural infection with B. pertussis 
have been determined by comparing the titre distribution in the healthy population, in recently 
vaccinated children, and in sera longitudinally collected after natural infection (2). Since 1993, high 
titres in acute-phase sera are reported to be "suggestive for recent infection with Bordetella pertussis". 
It can be imagined that such cases are reported, albeit not strictly in accordance with the case 
definition. 
To exclude the possibility that the rise in notifications was the result of reporting cases diagnosed 
with positive one-point serology only, we linked the notification database and the serodiagnosis 
database. (The data were taken from January 1993 to September 1996). Special permission to link 
the databases was given by the Inspectorate of Health. It appeared that some notification was 
based on positive one-point serology as early as 1993, and this proportion increased from 20% in 
1993 to 33% in 1994. It remained at this level in the subsequent years. Thus, the 1996 increase in 
notification cannot be attributed to this change in sérodiagnostic practice. 
Our surveillance data suggest a decrease in vaccine efficacy, but estimation of vaccine efficacy 
from surveillance data should be interpreted with caution. However, there are no indications of 
significant biases resulting from physicians' perceptions of vaccine efficacy that could have caused 
selective reporting of vaccinated patients; a higher probability of a positive serologic test result 
due to priming in vaccinated persons; or misclassification of cases with respect to vaccination 
status. 
Although not all potential surveillance artifacts could be excluded, it is highly probable that the 
surveillance data reflect a true pertussis outbreak. 
The outbreak can be caused by (1) decrease in vaccination coverage, (2) decrease in vaccine 
quality, (3) interference with other vaccines, (4) changes in circulating strains of B. pertussis that 
are not covered by vaccine-induced immunity, or (5) a combination of these factors. 
A decrease in vaccination coverage has not been observed in the (accurate) registration system. 
The whole-cell vaccine used was produced in the National Institute of Public Health and the 
Environment and meets international standards. There was no sign of a gradual deterioration of 
the vaccine quality as determined for product release using the mouse protection test. 
In April 1993, vaccination against Haemophilus influenzae type b (Hib) was added to the 
immunisation programme. The polyribosylribitolphosphate tetanus toxoid conjugated vaccine 
(PRP-T) was administered simultaneously with the DTP-IPV, although on different limbs. 
Interference of Hib vaccination with the immunoresponse to pertussis vaccine has been described 
(3). In a prospective serologic study on the potential interference in the Netherlands, this effect 
was not observed (4). Furthermore, the increase of pertussis in 5- to 9-year-old vaccinated 
children, who never received Hib vaccination, was similar to the increase in the 1 - to 4-year-old 
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age group. Decreased vaccine efficacy due to interference of Hib vaccination is, therefore, very 
unlikely. 
Molecular typing of B. pertussis isolates collected since 1945 indicated a shift in population 
structure, possibly due to the introduction of whole-cell vaccine (5). Further, antigenic variants of 
B. pertussis distinct from the strains incorporated in the whole-cell vaccine appear to have 
emerged (6). It might be possible that circulating strains of B. pertussis have become less sensitive 
to vaccine-induced immunity. The abrupt increase in the proportion of vaccinated patients 
reported in all age groups suggests such a change. 
Data from other countries in Europe indicate that the pertussis epidemic is restricted to the 
Netherlands. However, a resurgence of pertussis has been noted in the United States since the late 
1980s and in Canada since 1991. No single factor has been found to explain this resurgence (7-
10). 
The decrease in pertussis notification in the Netherlands at the end of 1996 may indicate a 
seasonal variation in the incidence. The 1996 data, including those on hospital admissions, are still 
being analyzed. These data will give insight into the severity of the pertussis epidemic among 
young infants. Protection of these infants is the main reason for pertussis vaccination. In January 
1997 active (monthly) surveillance by pediatricians of cases among hospitalized children was 
added to the routine surveillance based on notification and laboratory surveillance. 
A prospective study is being considered to assess efficacy of the whole-cell vaccine, including 
differentiation of severity of illness and number of immunisations received, if the outbreak 
continues. Cooperative studies to determine the distribution of restriction fragment length 
polymorphism types and antigenic variants of B. pertussis in various countries in Europe, Asia 
and North-America are underway. Also, the immunogenicity of the Dutch whole-cell vaccine is 
being assessed: whether it has changed over time and how it compares to published 
immunogenicity data of whole-cell vaccines with known, prospectively determined, vaccine 
efficacy (11). 
In conclusion, in the Netherlands a sudden increase of pertussis notification has been observed, 
which seems to reflect a true increase in incidence. Nevertheless, the cause of this increase has not 
been definitively determined. A possible mismatch between the vaccine and the circulating 
Bordetella strains is being investigated. 
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Abstract 
Pertussis notifications, data about deaths, hospital admissions, and positive serodiagnoses 
from 1976-1998 were analyzed to help explain the Dutch pertussis outbreak in 1996. The 
unexpected outbreak in 1996 (as it appeared from notifications) was also observed in the 
other surveillance sources. In 1996, according to notifications and serology data, the 
increase in pertussis incidence among (mostly unvaccinated) children less than 1 year of 
age was similar to the increase in hospital admissions. In older, mostly vaccinated, 
individuals the increase of hospital admissions was relatively small. The increase of 
reported vaccinated patients of all ages was larger than that of unvaccinated patients. We 
postulate that the proportion of pertussis infections resulting in recognizable symptoms 
has increased among vaccinated individuals due to the mismatch of the vaccine strain and 
circulating Bordetella pertussis strains. Perhaps the small immunogenicity profile of the 
Dutch vaccine, has resulted in greater vulnerability to antigenic changes in B. pertussis. 
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Introduction 
Introduction of mass vaccination against pertussis has greatly reduced pertussis incidence, but, 
even in countries with high vaccination coverage, pertussis resurgence has been described (1-4). 
We reported a sudden increase in pertussis notifications in the Netherlands in 1996 that reflected a 
true outbreak (5). The outbreak could not be explained by a decrease in vaccination coverage, 
which remained stable at 96% for at least three vaccinations in the first year of life. The vaccine 
meets international standards. No sign of an abrupt or gradual deterioration of vaccine quality, as 
determined at product release by the mouse protection test, was found. No interference of the 
introduction of vaccination against Haemophilus influenzae type b in 1993 with the 
immunoresponse to pertussis was found (6). No cohort effect in children vaccinated for H. 
influenzae type b was observed either (5). Perhaps a mismatch between the vaccine and 
circulating Bordetella pertussis strains contributed to the re-emergence (5,7-9). 
Insight into pertussis epidemiology based on notification data is hampered by changes in case 
definition for notification, availability of laboratory diagnostic tests, interpretation thereof (mainly 
of serology), notification rate, and diagnostic practice. Therefore, we compare data from various 
surveillance sources, i.e., data regarding deaths, hospital admissions, and positive serodiagnosis 
with notification data from January 1976 to September 1998. This will be helpful in obtaining 
insight into pertussis epidemiology and provides possible explanations for the pertussis epidemic. 
Methods 
Surveillance data 
Notification data 
Data from pertussis notifications, which were made obligatory by law in 1976, were obtained for 
the period 1976 to 1998 from the Inspectorate of Health. In the period 1976 to 1987, there was 
no case definition for notification. In 1988, a case definition was introduced; it includes clinical 
symptoms and laboratory confirmation (or close contact with a laboratory-confirmed pertussis 
case). 
Since the introduction of the case definition the clinical symptoms are a serious cough, lasting 
more than two weeks, coughing attacks, or coughing followed by vomiting in combination with at 
least one of the following symptoms/findings: apnea, cyanosis, characteristic cough with 
whooping, subconjunctival bleeding, or leucocytosis. 
From 1988 to April 1997, laboratory confirmation was defined as either a positive culture of B. 
pertussis or B. parapertussis, or positive two-point serology. Two-point serology was considered 
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positive if a significant rise of IgG antibodies against pertussis toxin and/or IgA antibodies against 
B. pertussis in paired sera was found. 
In April 1997, the Inspectorate of Health decided that, in addition to these laboratory results, a 
positive polymerase chain reaction (PCR) and positive one-point serology were acceptable as 
laboratory confirmation. Positive one-point serology was defined as high IgG and/or IgA antibody 
titers in a single serum sample as described under the heading Pertussis serology. 
For the period 1976 to 1988, only aggregated data were available regarding certain points. They 
are: the total number of patients per year based on the notification date, the number of vaccinated 
(at least three vaccinations) and unvaccinated or incompletely vaccinated (0 to 2 vaccinations) 
patients and the number of patients with unknown vaccination status with age at notification in 
age groups ( 0, 1-4, 5-9 and > 10 years). For the period 1989 to 1992, the date of notification and 
age in years at notification were available on an individual level in a database, while the 
aggregated data on vaccination status was similar to that for the period 1976 to 1988. Only since 
1993 have the following data been included in the database: the date of onset of symptoms, date 
of birth, age in years at notification, vaccination status, method of laboratory diagnosis, and 
whether there had been contact with a laboratory confirmed case (i.e., epidemiologically 
confirmed cases). The method of laboratory diagnosis was differentiated as "microbiological" 
(positive culture or PCR), "serological", "epidemiological" (i.e., contact with a laboratory-
confirmed case), and "unknown". 
As a consequence of the available data, the case distribution over the years 1976 to 1988 could 
only be assessed by date of notification. For the period 1989 to 1992, the date of onset of 
symptoms was estimated by finding the median duration between the first day of illness and the 
date of notification for patients in the period 1993 to 1994. This median duration (81 days) was 
then substracted from the notification date of the case at hand. The distribution of cases over the 
years 1989 to 1992 was based on this estimate, while it was based on the date of first symptoms 
available in the database for the period 1993 to September 1998. For 1989 to 1992, the age 
distribution was based on the age at notification, while for 1993 to September 1998, it was based 
on the age at onset of symptoms. 
Hospital admissions 
The number of hospital admissions with pertussis as the main diagnosis (ICD-9-CM 033) in the 
years 1976 to 1997 were obtained from the registry of the Foundation Information Center for 
Health Care. For the period 1989 to 1997, data by age group (0, 1-4, 5-9, 10-14, 15-19, > 20 
years) were available. 
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Pertussis deaths 
The number of deaths by age in 5-year classes due to pertussis in the period 1976 to 1997 were 
obtained from the Central Bureau of Statistics. 
Pertussis serology 
Data on pertussis serology were obtained from our National Institute of Public Health and the 
Environment. From the introduction of routine serology in the period 1982 to 1 January 1998, 
this was the only laboratory in the Netherlands that performed pertussis serology for patients with 
suspected whooping cough. The few other laboratories that also perform pertussis serology since 
1998 are estimated to cover 10 to 15% of pertussis serology of the population. 
Serology consisted of measuring IgA antibodies against a crude cell-wall preparation of B. 
pertussis (available since 1981) and IgG antibodies against purified pertussis toxin (available since 
1984) in ELISAs according to previously described methods (10,11). The interpretation of 
serology has varied over the years. In the period 1982 to 1988, mostly single sera were submitted. 
Since it had been established that vaccination with the Dutch whole cell vaccin only induced low 
levels of IgG against pertussis toxin (IgG-PT) and no IgA against B.pertussis (IgA-Bp), detection 
of IgA-Bp or moderate, high or very high IgG-PT was reported as "supportive for pertussis". 
Around 1987 it became clear that low and moderate IgG-PT and IgA-Bp levels were present in a 
large proportion of the population and that the prevalence increased with age. Therefore, in 1988 
the interpretation of serology in single sera was abandoned; paired sera were requested and only 
the finding of a significant increase of IgG-PT and/or IgA-Bp in such paired sera was reported to 
confirm the diagnosis of pertussis. As mentioned earlier, at the same time point the strict case 
definition for notification was introduced and "positive two-point serology" was included in the 
laboratory confirmation criteria of that case definition. However, in 1993 sera from the 
population, vaccinees, and patients with pertussis were tested. It was shown that high IgG-PT 
and/or high IgA-Bp levels greater than a (age-specific) cut-off value were very rare in the 
population (<2.5%). Such levels were not induced by vaccination, were present in the majority of 
patients with PCR- or culture-confirmed pertussis and decreased again within 6 months to levels 
below that cut-off value (12,13). Since 1994 the laboratory reported detection of such high values 
in a single serum or in both sera of a serum pair to indicate "possible pertussis" although the case 
definition for notification remained unchanged. From April 1997, the detection of such high levels 
in sera from patients was formally defined as "positive one-point serology" and included in the 
case definition for notification as being acceptable as laboratory confirmation of pertussis. 
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We were able to retrieve from the serological database patient data of patients with the day of 
onset in the period January 1989 to September 1998 and of patients with date of serology result 
registered in the period January 1986 to December 1987. Patients with positive two-point 
serology in the period 1989 to 1998 and patients with positive one-point serology in the period 
1994 to 1998 were selected. Furthermore, the criteria we recently defined for positive one-point 
serology were retrospectively applied to the serological data of the periods 1986 to 1987 and 
1989 to 1993. The distribution of cases in 1986 and 1987 was based on the year of the test result 
and, in the period 1989 to 1998, on the year of first symptoms. 
Data analysis 
We used the screening method and assumed an average vaccine coverage in the Dutch population 
of 96% to estimate the vaccine efficacy for those aged 1 to 4 and 5 to 9 years with notification 
data from 1976 to 1997. We compared completely vaccinated individuals (at least three 
vaccinations) with incompletely vaccinated or unvaccinated individuals (less than three 
vaccinations) (14). 
For the period 1993 to 1997, the notification database and the database with records of 
serodiagnosis were linked on the level of individual patients to verify on which type of 
serodiagnosis (positive two-point serology or positive one-point serology) the notification was 
based. The coverage of the notification system was calculated from the proportions of reported 
patients with positive two-point serology and with positive one-point serology. We used the 
statistical package SAS to analyze the data. We calculated the vaccine efficacy in EPI INFO 
version 6.04. 
Results 
Pertussis notifications from 1976 to September 1998 
In the first years after the introduction of notification by law, the reported number of cases was 
smallest (Table 1). From 1983 to 1987, that is, after immunoassays for pertussis serology became 
available, the number of reported patients rose yearly. In 1988, the year in which a case definition 
for notification was introduced and positive serology was restricted to the finding of an increase in 
titer in paired sera, the reported number of cases declined sharply. Between 1989 and 1995 
somewhat greater numbers of cases were reported in the periods 1989-1990 and 1993-1994. In 
1996, the number of cases was 12-times the number in 1995, while a twofold decrease of the 
1996 number was observed in 1997. 
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The number of notifications from January to September 1998 (N = 1582) was smaller than that of 
the same periods in 1996 (N = 2171) and 1997 (N = 2004), but about six times larger than the 
average number of notifications in the same months of the years 1989 to 1995 (N= 269). 
Comparison with hospital admissions 
Although the trend for hospital admissions was similar to that of notifications, the ratios of 
notifications to hospital admissions varied for various periods (Table 1). This ratio was below 1 
from 1976 to 1984, rose to 5.7 in 1987, and decreased sharply to 1.2 in 1988. It remained 
relatively stable from 1989 to 1995, but increased to 8.2 in 1996 and 6.1 in 1997. 
Comparison with positive serology 
Positive one-point serology 
The cases with positive one-point serology followed a trend similar to that of the notifications in 
the years 1986 to 1987 and 1989 to 1998, for which data were available (Table 1). In 1986 and 
1987, the ratio of notifications to cases with positive one-point serology was highest (0.8); it 
decreased in 1989, and remained relatively stable from 1989 to 1996 (0.2 to 0.4). This proportion 
increased in the period 1996 to 1998 from 0.5 to 0.7. 
Positive two-point serology 
The trend for cases with positive two-point serology and the trend in notifications were 
comparable (Table 1). From 1989 to 1995, the number of cases were similar (ratio 0.7 to 1.5), 
according to both notifications and positive two-point serology, while in 1996 and 1997 (ratio 2.2 
and 2.9) and particularly in 1998 (ratio 5.4) the number of notifications was greater than the 
number of cases with positive two-point serology. 
Comparison with deaths 
In the period 1976 to 1997, seven deaths due to pertussis were registered: one in 1981, two in 
1993, two in 1996, and two in 1997. They occurred among children less than 1 year old with the 
exception of one death in 1993 in the age group of 5 to 9 years. 
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Table I. Absolute numbers of pertussis notifications, hospital admissions, cases with positive two-point serology, cases with 
positive one-point serology and ratio of notifications to hospital admissions in the period 1976 to 1997 
Year Notifications Hospital Positive Positive Ratio of Ratio of Ratio of 
admissions two-point one-point notifications notifications notifications 
serology serology and hospital 
admissions 
and positive 
two-point 
serology 
and positive 
one-point 
serology 
1976 Introduction of 
notification law 
4 52 * 0.1 * 
1977 25 93 
* * 0.3 * 
* 
1978 1 32 * * 0.0 
* * 
1979 26 43 * * 0.6 * 
« 
1980 30 65 * * 0.5 * 
1981 Introduction of IgA-assay 50 76 * * 0.7 * 
X 
1982 80 98 * 0.8 * * 
1983 200 223 * * 0.9 * 
1984 Introduction of IgG-assay 534 200 
* 
2.7 
* * 
1985 1522 313 * * 4.9 * 
1986 2159 388 * 2717 5.6 * 0.8 
1987 2709 474 * 3295 5.7 0.8 
1988 Case definition for 112 92 * * 1.2 * 
notification (including 
strict criteria for 
interpretation of serology) 
Table 1 continued 
Year Notifications Hospital Positive Positive Ratio of Ratio of Ratio of 
admissions two-point one-point notifications notifications notifications 
serology serology and hospital 
admissions 
and positive 
two-point 
serology 
and positive 
one-point 
serology 
1989 523 221 350 1760 2.4 1.5 0.3 
1990 397 157 278 1204 2.5 1.4 0.3 
1991 145 82 110 411 1.8 1.3 0.4 
1992 160 101 238 861 1.6 0.7 0.2 
1993 346 288 482 1489 1.2 0.7 0.2 
1994 519 276 498 1867 1.9 1.0 0.3 
1995 341 162 272 1070 2.1 1.3 0.3 
1996 4231 513 1885 7854 8.2 2.2 0.5 
1997 Formal acceptance of 
positive one-point 
serology 
2671 436 924 4107 6.1 2.9 0.7 
1998§ 1582§ * 294§ 2187§ * 5.4 0.7 
Not available 
8 Data from January to September 1998 
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Age-specific incidence according to notifications from 1989 to 1997 
In the period 1989 to 1995, the average annual incidence according to notifications was greatest 
for infants less than 1 year old. Notification data for the years 1993 to 1995 show that the age-
specific peak incidence occurred among 0 to 5-month-olds (Table 2). For infants less than 1 year 
old, according to notifications, the incidence in 1996 is a fourfold of the average incidence from 
1989 to 1995, while it shows at least a 13-fold increase for older age groups. The age-specific 
peak incidence shifted to 4-year-olds in 1996 and 1997. 
Notifications stratified by method of diagnosis 
In the period 1993 to 1997, for which the method of laboratory diagnosis was available for the 
notifications, similar shifts in age distribution were observed for those cases confirmed by 
microbiological method, for cases with positive two-point serology and for cases with positive 
one-point serology. However, reported cases confirmed microbiologically (i.e., culture and/or 
PCR) were those of the relatively youngest patients, and cases confirmed with one-point serology 
were those of the oldest. 
Comparison of notifications with hospital admissions 
In contrast to notification data, the greatest age-specific incidence of hospital admissions occurred 
among infants less than 1 year old from 1989 to 1997 (Table 2). The increase in incidence in 1996 
was more stable for the various age groups. 
Comparison of notifications with positive serology 
Positive two-point serology 
Similarly to notifications, as a result of a relatively greater increase among older age groups, the 
peak incidence occurred among 0 to 5-month-olds from 1989 to 1995 and among 4-years-olds in 
1996 and 1997 (Table 2). 
Positive one-point serology 
The incidence of cases with positive one-point serology was greatest among 7-year-olds in 1989 
and it shifted towards 4-year-olds from 1992 to 1997. Like notification data, the increase for 
infants less than 1 year old was smaller (fourfold) than that of older age groups (fivefold to 
sevenfold) (Table 2). 
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Table 2. Average annual age-specific incidence (I, number per 100,000) and average 
proportional age distribution (%) in the period 1989-1995, in 1996 and in 1997 
Notifications Hospital admissions 
Period 1989-1995 1996 1997 1989-1995 1996 1997 
I % / % / % / % / % I % 
Age 
(years) 
0 36.9 20.7 160.4 7.3 110.4 7.9 66.2 68.2 184.0 68.4 150.9 65.8 
0-5 m 57.3 14.3 219.2 5.0 725.7 4.5 - - - - -6-11 m 22.2 5.4 101.7 2.3 95.7 3.4 - - - - - -1-4 12.0 26.2 152.8 28.7 90.1 26.5 4.9 21.2 11.6 17.9 12.4 22.2 
5-9 12.6 32.8 162.5 37.2 84.0 30.9 1.3 6.8 4.9 9.2 3.4 7.6 
10-14 3.8 10.5 57.4 12.3 33.0 11.3 0.4 2.5 1.2 2.1 0.5 1.1 
15-19 0.5 1.4 10.3 2.3 8.4 2.9 0.01 0.2 0.3 0.6 0 0.0 
>20 0.3 8.4 4.4 12.2 4.6 20.5 0.02 1.1 0.08 1.8 0.1 3.2 
Total 2.3 100 27.3 100 17.1 100 1.2 100 3.3 100 2.8 100 
Positive two-point serology Positive one-point serology 
Period 1989-1995 1996 1997 1989- 1995 1996 1997 
I % / % / % / % I % / % 
Age 
(years) 
0 43.2 26.1 86.0 8.7 54.1 11.2 41.8 6.6 148.9 3.6 107.8 5.0 
0-5 m 67.6 20.7 134.2 6.8 72.5 7.5 50.7 4.1 159.4 1.9 102.0 2.4 
6-11 m 18.8 5.4 37.7 1.9 35.7 3.7 32.8 2.5 138.4 1.7 113.6 2.6 
1-4 12.2 28.3 74.8 31.4 33.4 28.4 42.1 25.8 281.2 28.3 149.8 28.5 
5-9 10.2 29.7 76.7 39.2 32.8 34.7 47.9 34.1 295.3 36.2 124.9 29.7 
10-14 3.2 9.4 22.0 10.6 9.9 9.7 21.1 16.1 110.9 12.8 52.4 11.6 
15-19 0.3 1.1 3.6 1.8 1.9 2.0 3.4 2.9 24.8 2.9 15.9 3.6 
>20 0.1 5.3 1.4 8.4 1.1 14.1 1.5 14.6 10.8 16.2 7.5 21.5 
Total 2.1 100 12.2 100 5.9 100 8.2 100 50.7 100 26.4 100 
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Seasonal trend of notifications 
In March/April 1996, the number of reported cases started to rise (Figure 1). The largest monthly 
number of cases occurred somewhat later in the year (October 1996) than in the periods 1989 to 
1995 and 1997-1998 (mostly August, sometimes July or September). 
Figure 1. Absolute numbers of pertussis cases per month according to notifications, cases with 
positive two-point serology, and cases with positive one-point serology 
Comparison with positive serology 
The seasonal trend for positive two-point serology and positive one-point serology was similar to 
that of the notification data (Figure 1). 
Vaccination status for notifications 
The vaccine efficacy estimated by the screening method with notification data was great from 
1981 to 1984 (1-4-year-olds: 94% to 99%; 5-9-year-olds: 87% to 100%) and from 1988 to 1993 
(1-4-year-olds: 89% to 95%; 5-9-year-olds: 78% to 89%). The estimates were somewhat smaller 
from 1985 to 1987; they amounted between 72% and 85% for 1-4-year-olds and between 56% 
and 77% for 5-9-year-olds. The estimates decreased after 1993 (Table 3). They were the smallest 
in 1996 and could not be estimated in 1997 since the proportion of vaccinated patients exceeded 
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96%. The vaccine efficacies for almost all strata of diagnosis were greater in 1993 than in the 
period 1994-1997 (Table 3). There was a decreasing trend, although it was not consistent for all 
diagnosis strata. The estimates for cases diagnosed microbiologically tended to be the greatest, 
while the estimates for the cases confirmed by one-point serology tended to be the smallest. 
Method of diagnosis for notification from 1993 to 1997 
The linkage between the notification database and sérodiagnostic database for the period 1993 to 
1997 shows the proportion of reported cases confirmed with a microbiological method, with 
positive two-point serology or epidemiological^, decreased, while the proportion of cases 
confirmed with positive one-point serology increased (Table 4). The proportion of cases that 
were confirmed serologically, but that could not be matched with the serological database, also 
increased. It was not possible to differentiate these cases for positive one-point serology and 
positive two-point serology. During 1996 and 1997, the proportion of cases confirmed 
microbiologically by quarter year was rather similar (8.7-10.2%) with the exception of a smaller 
proportion in the last quarter of 1997 (6.4%). The proportion of cases confirmed by two-point 
serology ranged between 12% and 19%. In the first two quarters of 1996 (34.9-35.6%) and in the 
fourth quarter of 1997 (34.3%), the proportion of cases confirmed by positive one-point serology 
was similar to the proportions of 1994 and 1995. The numbers increased to more than 50% in the 
fourth quarter of 1996 and the first quarter of 1997. The proportion of cases confirmed 
serologically that could not be matched with the sérodiagnostic database was great(est) in the 
fourth quarter of 1997 (35.3%). 
Estimate of the notification rate 
The reported proportion of cases with positive two-point serology increased from 24% in 1993, 
26% in 1994, 28% in 1995 to 42-43% in 1996 and 1997. A similar trend was observed for the 
various age groups. 
For positive one-point serology, the reported proportion increased from 6% in 1993, 10% in 
1994, 12% in 1995 to 27-29% in 1996 and 1997. The discrepancy was somewhat greater with 
increasing age. The increase in the reported proportions of cases with positive two-point serology 
and with positive one-point serology was probably underestimated because the notification 
database contained serologically confirmed cases that could not be matched with the 
sérodiagnostic database. This proportion was greatest in 1997 (Table 4). 
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Table 3. Absolute number of reported cases according to vaccination status and estimate of 
vaccine-efficacy according to method of diagnosis* 
1 -4-year-olds 5-9-year-olds 
Year Method of Number Vaccine efficacy Number Vaccine efficacy 
diagnosis (in percentages) (in percentages) 
1993 Microbiological 14 93 14 94 
Two-point serology 25 91 28 75 
One-point serology 24 79 26 50 
Other§ 35 96 20 90 
Total 98 93 88 84 
1994 Microbiological 23 56 15 42 
Two-point serology 36 67 36 83 
One-point serology 63 71 65 # 
Other§ 37 89 29 91 
Total 159 77 145 72 
1995 Microbiological 14 85 9 67 
Two-point serology 27 82 19 64 
One-point serology 39 64 45 # 
Other§ 37 53 27 67 
Total 117 72 100 45 
1996 Microbiological 116 67 123 3 
Two-point serology 245 # 288 49 
One-point serology 545 # 782 # 
Other§ 290 66 355 40 
Total 1196 34 1548 16 
1997 Microbiological 63 51 68 57 
Two-point serology 110 # 131 # 
One-point serology 283 # 345 # 
Other§ 244 # 260 # 
Total 700 # 804 # 
* A vaccine-coverage of 96% was used to estimate the incidence and vaccine efficacy 
§ Epidemiological, serological (differentiation between positive two-point serology and positive one-point 
serology) not possible, clinical or method of diagnosis unknown 
# Vaccine efficacy could not be estimated as the percentage vaccinated was more than 96% 
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Table 4. Method of diagnosis for reported pertussis cases from 1993 to 1997 
Method of diagnosis* 1993 1994 1995 1996 1997 
Number % Number % Number % Number % Number % 
Microbiological 
Two-point serology 
One-point serology 
Serological 
(not matched) 
Epidemiological 
Other 
Total 
73 21.1 
100 28.9 
87 25.1 
20 5.8 
89 17.1 
116 22.4 
180 34.7 
39 7.5 
51 15.0 
62 18.2 
119 34.9 
59 17.3 
418 9.9 
760 18.0 
2041 48.2 
544 12.9 
235 8.8 
383 14.3 
1172 43.9 
609 22.8 
346 100 
38 11.0 
28 8.1 
40 7.7 
55 10.6 
519 100 341 100 
27 7.9 
23 6.7 
178 4.2 
290 6.9 
4231 100 
96 3.6 
176 6.6 
2671 100 
The method of diagnosis was scored according to the following hierarchy: microbiological, positive two-
point serology, positive one-point serology, serological (not matched), epidemiological, and other 
(clinical, method of diagnosis unknown, negative or inconclusive serology) 
Discussion 
Interpretations from surveillance data: pertussis trends in the Netherlands from 1976 to 
The surveillance data of 1996 show that the unexpected outbreak (as it appeared from 
notifications) (5) was also observed in hospital admissions, cases with positive serology, and even 
deaths. The vaccine efficacy estimates that had already declined in 1994 and 1995 declined further 
in 1996 and 1997. In 1996, according to notifications and serology data, the increase in pertussis 
incidence among (mostly unvaccinated) children less than 1 year of age was similar to the increase 
in hospital admissions. However, in older, mostly vaccinated, individuals the increase in hospital 
admissions was relatively small. Furthermore, we consider it likely that a somewhat smaller 
epidemic occurred in 1986 and 1987. This is in contrast to what was reported at that time (15,16). 
The surveillance data for pertussis in our country were affected by changes in availability of 
serological tests, interpretations thereof, case definition for notification, and notification rate. 
However, we could rely on various surveillance sources, could apply criteria for one-point 
serology used in recent years to serological data of 1986 and 1987 and were able to match our 
notification database with our sérodiagnostic database. This enabled us to gain a better 
understanding whether observed changes in surveillance data represented true changes in the 
underlying incidence of pertussis. 
1998 
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The trend in hospital admissions likely reflects the incidence of severe pertussis. We expect that 
this surveillance source is less sensitive to changes in the previously described factors. Thus, 
increasing or decreasing numbers of pertussis cases according to notifications and data of positive 
serology are likely to reflect (partly) true changes when they are accompanied by similar trends in 
hospital admissions. 
We obtained more insight into the effect of changes in definition of positive serology and case 
definition for notification, on serological data and the notification data. The current more 
restrictive criteria for positivity of one-point serology were applied to sérodiagnostic data of 1986 
and 1987. It was possible to study changes into the notification rate of cases with positive one-
point serology and cases with positive two-point serology in the years 1993 to 1997 by linking 
the notification database with the serodiagnosis. 
Furthermore, stratifying notifications according to method of diagnosis enabled us to conclude 
that the decrease in estimated vaccine efficacy and the shift in 1996 and 1997 towards older age 
groups in the notifications could only partly be explained by the enhanced application of positive 
one-point serology. 
As a result of great variation in case definitions and in type of laboratory confirmation between 
countries, figures from notifications are meaningless in the context of international comparisons. 
For comparison between countries hospital admissions might be more useful, although they are 
limited to severe pertussis cases only. 
Possible factors contributing to the pertussis epidemics 
Our results clearly show that pertussis has remained endemic with epidemic peaks in the 
Netherlands, despite high vaccination coverage. Immunity after infection, as well as after 
vaccination, is not lifelong. Therefore, waning vaccine-induced immunity has been suggested as an 
explanation of the re-emergence of pertussis in other countries and probably has contributed to 
the pertussis epidemic in the 1980s as well as in 1996-1997 (17-19). However, the outbreak in 
1986-1987 may also have been associated with the temporary reduction of the potency of the 
Dutch vaccine from 16 to 10 opacity units per dose in the period 1976 to 1984. Furthermore, the 
somewhat smaller vaccine efficacy estimates in the years 1986 and 1987 might be explained by 
greater exposure to B. pertussis in epidemic periods than in interepidemic periods (20,21). 
As we reported previously, the remarkable increase of reported vaccinated patients over a wide 
age range, starting 2 years before the outbreak of 1996, suggests a role of a mismatch between 
circulating and vaccine strains (5,7-9). Antigenic divergence between vaccine strains and clinical 
isolates was observed for two important protective antigens, pertactin and pertussis toxin (9). 
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Furthermore, data suggest that the whole-cell vaccine protects better against strains with the 
vaccine type of pertactin than against strains with nonvaccine types (9). 
By analyzing serology data and hospital admission data apart from notification data, we were able 
to assess the increase in incidence of pertussis in 1996 among (mostly unvaccinated) children less 
than 1 year of age. The increase in incidence was accompanied by a similar increase in hospital 
admissions for pertussis in the same age group. This indicates that the virulence of B. pertussis 
for unvaccinated and previously unexposed individuals did not change during the outbreak. 
In contrast, for older, mostly vaccinated, individuals, the increase of hospital admissions was 
smaller than the increase found in other surveillance sources. While the incidence of hospital 
admissions was greatest for infants less than 1 year old, the incidence in other surveillance sources 
was greatest among 4-year-olds. Therefore, we postulate that a greater proportion of infected 
vaccinated individuals expressed clinical symptoms due to the antigenic shifts. This probably leads 
to a more intense spread of bacteria and thus a greater force of infection in the population. This is 
shown by the increase of cases in unvaccinated infants. 
Despite the findings of antigenic variants of pertactin and pertussis toxin in other countries, no 
outbreaks similar to those in the Netherlands have yet been observed (22-24). It may be that the 
vaccines in these countries are potent enough to offset antigenic variation (22). It is also possible 
that pertussis vaccines protect less well against strains with particular pertactin profiles, which 
dominate in the Netherlands, but are less common in other countries (22). The Dutch vaccine has 
been used in the National Immunisation Programme since 1953. No sign of an abrupt 
deterioration of vaccine quality as determined for product release by the mouse protection test has 
been found (5). However, the Dutch whole-cell vaccine induces low levels of antibodies against 
pertussis toxin and filamentous haemagluttinin and high levels of antibodies to agglutinogens and 
pertactin (6). Perhaps this immunogenicity profile has resulted in a greater vulnerability of the 
vaccinated Dutch population to antigenic changes in B. pertussis, possibly especially with respect 
to pertactin. We have not yet been able to study a potential effect on the epidemiology of 
pertussis as a result of a slightly higher content of pertussis toxin in the Dutch vaccine since 
November 1997. 
A re-emergence of pertussis has also been observed in Canada. The similarities to the Dutch re-
emergence shed some light on the role of the immunogenicity profile of the vaccine (1,2,5). These 
similarities are the small proportion of infants affected and large proportion of patients aged 1 to 9 
years, estimates of little vaccine efficacy, and lower levels of antibodies against pertussis toxin 
after vaccination with the Canadian whole-cell vaccine (19,25). This contrasts to the pertussis 
emergence in the United States, which is accompanied by greater proportions of affected infants 
and adults and more favorable vaccine efficacy estimates (21,26). The levels of pertussis toxin 
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antibodies after vaccination were found to be higher for an American whole-cell vaccine, than for 
the Canadian whole-cell vaccines (25). 
Conclusions 
We realize that the surveillance data support the hypothesis of the role of antigenic changes in the 
B. pertussis population in the pertussis outbreak, but do not provide a definitive explanation. 
Furthermore, the indisputable role of whole-cell vaccine in protection against severe pertussis is 
clearly shown by the sharp decrease in hospital admissions after 12 months of age, as well as by a 
much smaller pertussis incidence in the past and at present in our country than in unvaccinated 
populations (27). In such an unvaccinated population, 60% of unvaccinated individuals had 
experienced clinical pertussis before the age of 10. This is at least 30 times more, even if we 
assume a notification rate of 25% and an incidence as that observed during the epidemic in 1996. 
Booster vaccination will be helpful in reducing the pertussis incidence. However, it has to be 
taken into account that a number of acellular vaccines do not contain the antigenic variants of 
pertactin and pertussis toxin that dominate in Europe (9,22,23). Furthermore, if pertussis 
infections are to be postponed until adulthood as a result of boosting, there might be a greater 
probability of transmission from adults to young, unvaccinated infants. The effects of booster 
vaccination on the pertussis epidemiology must be monitored carefully, and various surveillance 
sources must be used to distinghuish surveillance artifacts and real epidemiological effects. 
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Abstract 
Laboratory confirmation of pertussis by culture, polymerase chain reaction (PCR), or 
detection of antibody increase in paired sera is hampered by low sensitivity in the later 
stages of the disease. Therefore, we investigated whether, and at which level, 
concentrations of IgG antibodies against pertussis toxin (IgG-PT) in a single serum sample 
are indicative of actual or recent pertussis. IgG-PT, measured by ELISA in U/ml, was 
analyzed in 7756 population-based sera, in sera of 3491 patients with at least a fourfold 
increase of IgG-PT, in paired sera of 89 patients with positive cultures and/or PCRs, and 
in sera of 57 patients with clinically documented pertussis with a median follow-up of 1.4 
years. We conclude that, independently of age, IgG-PT levels of at least 100 U/ml are 
diagnostic of recent or actual infection with B. pertussis. Such levels are present in less 
than 1 % of the population and are reached in most pertussis patients within 4 weeks after 
disease onset and persist only temporarily. 
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Introduction 
Whooping cough is a highly contagious bacterial infection of the respiratory tract, caused by 
Bordetella pertussis. It is most severe in unvaccinated infants. Evidence is increasing that B. 
pertussis infections occur more frequently in older children and adults in vaccinated populations 
than has been commonly recognized (l-7).These individuals may play an important role in the 
transmission to infants too young to be vaccinated (5,8-10). Adequate laboratory diagnosis is 
important for control and prevention of pertussis. 
In the Netherlands, the case definition for notification of pertussis includes defined typical clinical 
symptoms and laboratory confirmation. Laboratory confirmation is defined as either a positive 
culture or a positive polymerase chain reaction (PCR) for B. pertussis or B. parapertussis, or 
positive two-point serology, i.e., a significant increase (at least fourfold) of antibodies against 
(antigens of) B. pertussis. This case definition for notification is highly specific, but it results in 
low sensitivity, especially when laboratory diagnosis is initiated at a late stage of the disease. 
Other countries also report that pertussis diagnosis is hampered by low sensitivity (11-15). 
Culture of B. pertussis is laborious and insensitive; the ability to isolate B. pertussis by culture 
decreases progressively during the disease (16,17). The sensitivity of PCR is superior to that of 
culture; however, this sensitivity, like that of culture, rapidly decreases by the time the paroxysmal 
phase has developed, and with increasing age (18,19). In the Netherlands, confirmation of 
suspected pertussis is attempted often by serology. However, in our sérodiagnostic practice, for 
more than 50% of the suspected cases, only one serum sample is submitted or high titers are 
found in paired sera without a significant increase. Similar problems are also reported by others 
(20-22). 
Because pertussis toxin is expressed only by B. pertussis and cross-reacting antigens have not 
been described (21,23) and because IgG responses occur in most patients with B. pertussis 
infection, we investigated whether, and at which level, titers of IgG-antibodies against pertussis 
toxin (IgG-PT) in a single serum sample are indicative for actual or recent pertussis. 
We analyzed IgG-PT in sera of a large cross-section of the population (N = 7756), in paired sera 
of patients of all ages in whom clinical suspicion of pertussis was confirmed by at least a fourfold 
increase of IgG-PT (N = 3491), and in paired sera of patients in whom pertussis had been 
confirmed by culture of B. pertussis or by positive pertussis PCR (N = 89). The course of IgG-PT 
after natural infection, i.e., the duration of high levels, was assessed in long-term follow-up sera of 
57 patients after pertussis had been clinically documented. 
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Material and methods 
Collection of sera and data from population and patients 
The cross-section of the general population (N = 7756) 
The study design and data collection have been published elsewhere (24). Briefly, eight 
municipalities with probabilities proportional to their population sizes were sampled within each 
of five geographical Dutch regions with similar population sizes. An age-stratified sample (classes 
0, 1-4, 5-9, 75-79 years) of 380 individuals was randomly selected from each municipality. 
These individuals were requested to give a blood sample and to fill out a questionnaire in which 
the participants were asked whether they had had a period with coughing attacks that had lasted 
for more than two weeks. They were also asked whether a physician had diagnosed pertussis, 
either during the past year or more than one year previously. The participation rate was 55%. 
Sufficient serum for pertussis serology was available from 7756 of the 8359 participants. Sera 
were collected in 1995 and 1996 and stored at -70° C until use. 
Patients with serologically confirmed pertussis 
Until 1997, the National Institute of Public Health and the Environment was the only laboratory in 
the Netherlands that performed pertussis serology for patients with a suspected pertussis 
infection. Routinely, the submitted sera were assayed for both IgG-PT and IgA against B. 
pertussis. In all cases, if the date of onset of symptoms and/or date of sampling of serum was 
missing upon submission of serum, a standard questionnaire was sent to collect the data. From 
January 1989 onwards, all data and results were registered in an electronic database. 
For the purpose of this study, patient data and serologic results obtained in the period 1989-1996 
from 3491 patients in whom the clinical suspicion of pertussis had been confirmed by the 
detection, in paired sera, of > fourfold increase of IgG-PT to >20 U/ml. 
Likewise, data were analyzed for 15319 patients whose first submitted serum sample contained 
>100 U/ml IgG-PT without (in case of paired sera) a fourfold IgG-PT increase. 
Patients with typically symptomatic infection with B. pertussis and their longitudinal sera 
During the period 1989-1998, we obtained follow-up serum samples from 57 patients with a 
clinical diagnosis of typical pertussis (paroxysmal cough lasting more than two weeks) so that we 
could study the longitudinal course of IgG-PT after infection. 
Twenty-three patients showed at least a fourfold increase in IgG-PT in paired sera, and 34 
patients had an IgG-PT in a first serum sample of at least 75 U/ml. The IgG-PT level was at least 
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100 U/ml for 31 of these 34 patients. The follow-up period varied from 6.5 months to 6.7 years 
after the acute phase of infection (mean: 1.8 years; median: 1.4 years). The number of serum 
samples collected in the follow-up periods varied from two to seven (mean and median: three). All 
patients were from a single pediatric practice. Only those patients participated who, continued to 
be treated by the pediatrician after the episode of pertussis because of other medical conditions 
(mostly allergic conditions and/or asthma) or who consulted the pediatrician again at a later stage 
because of new medical problems. In addition, sera from parents with clinical pertussis were 
selected. The median age of the patients in which the longitudinal course of IgG-PT was studied 
was 3.5 years (range: 0-35 years). Ten patients were less than 6 months old; 7 patients, 6-11 
months old; 19 patients, between 1 and 4 years old, 16 patients, between 5 and 9 years old; 2 
patients, 11 and 12 years old; and 3 patients, 30 to 35 years old. Thirty-nine of the patients were 
vaccinated, 6 patients were unvaccinated, and for 12 patients the vaccination status was unknown. 
In all cases the follow-up sera used for the study were "left over" from samples obtained for some 
other diagnostic procedure. Informed consent for the study was obtained from the patients or 
their parents. 
Patients with PCR and/or culture-proven pertussis 
In the period 1993-1998, the diagnosis of pertussis for 89 patients had been confirmed by culture 
of B. pertussis and/or a positive pertussis-specific PCR. Paired sera from these patients had been 
submitted for serology. Fifty-eight of the 89 patients had participated in a clinical study to assess 
the sensitivity of the pertussis/parapertussis PCR in comparison with culture and serology (18). 
For each of the remaining patients, a pertussis PCR test was performed in the regional public 
health laboratory in Tilburg, the Netherlands. In all cases, the first serum of the pair had been 
obtained on the same day that material for culture and/or PCR had been obtained; the second 
sample had been obtained 2 to 4 weeks later. Of the 89 patients, 37.1% were 0-5 months old; 
7.9%, 6-11 months; 21.3%, 1-4 years; 25.2%, 5-9 years; 2.2%, 10-14 years, and 5.6%, > 15 
years. 
In house IgG-PT ELISA 
The patient sera had been submitted immediately after sampling and were assayed in the routine 
setting of the serology laboratory of our institute within 4 days after receipt. The population sera, 
which had been collected in 1995/1996, were assayed in 1997/1998 in the same routine setting at 
a rate of approximately 200 sera per week. The IgG-PT was measured by ELISA as previously 
described (18). In short, the procedure was as follows: purified PT (source: National Institute of 
Public Health and the Environment) was coated to 96-well ELISA plates after precoating with 
fetuin (50 mg/1 in phosphate-buffered saline). Peroxidase labeled rabbit antihuman IgG was used 
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as a conjugate, and 3,3',5,5' tetramethylbenzidine (TMB) was used as the substrate. A negative, 
low-positive, and medium-positive control serum with defined IgG-PT content was run on each 
plate. The sera were tested in duplicate in a 1:100 and 1:400 dilution against serial dilutions of a 
positive reference serum with a range of 1.6-100 "local" U/ml. The optical density (OD) of the 
1:100 dilution was used for calculation of the IgG-PT concentration. When the OD of the 1:100 
dilution of a serum was above the range that constituted the steep part of the dose response 
curve, the OD of the 1:400 dilution was used. 
Due to the use of only two dilutions for the sera, the IgG-PT assay has an upper limit (500 U/ml) 
above which the values are not further differentiated. The lower detection limit of the assay is 5 
U/ml. 
Results are expressed in "local U/ml". The reference serum was also calibrated against the FDA 
preparation Lot 3 (FDA, Laboratory of Pertussis, Rockville, MD). The formula for conversion of 
"local" to "FDA" U/ml appeared to be: local U/ml x 0.8 = FDA U/ml within this assay. 
Data analysis 
For the cross-sectional population-based study, frequencies of IgG-PT levels from <5 U/ml (lower 
detection limit) to >500 U/ml (upper differentiation limit) within each municipality were weighted 
by the proportion of the age group in the population. To produce national estimates for the 1, 2.5, 
10, 25, 50, 75, 97.5, and 99 percentiles, these weighted and age-specific frequencies were 
averaged over the 40 municipalities (25). 
The following age groups were separately analyzed: 0-5 months, 6-11 months, 12-17 months, 18-
23 months, 2 years, 3 years, 4 years, 5 to 9 years, 10 to 14 years, and >15 years of age. 
The proportions with IgG-PT <5U/mI, 5-9 U/ml, 10-49 U/ml, 50-99 U/ml, 100-499 U/ml, and 
>500 U/ml were also assessed. The proportion of these groups that reported a pertussis diagnosis 
or a period with coughing attacks during the past year was calculated. The proportion of those 
who had a pertussis diagnosis and/or coughing attacks more than one year ago and the proportion 
without any pertussis diagnosis or coughing attacks were also calculated. 
Likewise, for the patients with serologically proven pertussis (i.e., > fourfold increase of IgG-PT 
in paired sera), the total and (similar) age-specific 1, 2.5, 10, 25, 50, 75, 97.5, and 99 percentiles 
for IgG-PT levels were calculated in the second sera of the serum pairs. The median duration of 
disease at the time of initiation of laboratory diagnosis, i.e., the time of sampling of first sera, was 
assessed for these patients in the age groups 0-5 months, 6-11 months, 1 year, 2 years, 3 years, 4 
years, 5 to 9 years, 10 to 14 years, and >15 years of age. 
The median duration of the disease was also assessed for the same age groups for the selection of 
patients from the serological database with >100 U per ml at the time of the first serum sampling 
without a fourfold IgG-PT increase. 
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The Wilcoxon signed ranked test was used to test differences between age groups in the IgG-PT 
distributions in the patients with positive cultures and/or PCR with a P-value of 0.05 considered 
statistically significant. 
To study the longitudinal course of IgG-PT levels after pertussis infection for patients in the 
follow-up study, the association between the IgG-PT level and time in 2log days after the first day 
of illness (and the effect of age) was analyzed with a mixed linear model (PROC MIXED in SAS 
version 6.12) (26). A 2log transformation of both the IgG-PT level in U per ml and of time in days 
since the first day of illness was performed. This way, linear regression yielded the best fit. 
For those patients with follow-up data 0-5 months, 6-11 months, 12-23 months, 2-3 years, and 4-
7 years after onset of the disease, the proportions with IgG-PT levels <20 U/ml, 20-49 U/ml, 50-
99 U/ml, and >100 U/ml were calculated. If multiple serum samples were available for one patient 
within one follow-up period, the serum sample with the highest IgG-PT level was used. 
Results 
The IgG-PT distribution in the population compared to the IgG-PT distribution in second 
sera of serum pairs of patients with serologically confirmed pertussis: choice of cut-offs to 
be validated 
The IgG-PT levels in individuals of the population-based study were low in comparison to those 
in second sera (i.e., reconvalescence sera) of patients with serologically confirmed pertussis; these 
distributions showed little overlap (Figure 1). 
In the population-based study, the median IgG-PT was 6 U/ml, and the 97.5 and 99 percentile, 
69 U/ml and 97 U/ml, respectively. In the second sera of patients with serologically confirmed 
pertussis, the median IgG-PT was >500 U/ml; the 10 percentile was 66 U/ml (Figure 1). 
In the population-based study, the median IgG-PT was <5 U/ml in the age group <10 years old, 
rose to 5 U/ml for 10 to 14-years-olds, and was 7 U/ml for 15 years old or older (Figure 1). For 
those 0-5 months, 6-11 months, and 18-23 months old, the 97.5 percentile was below 20 U/ml, 
while in the other age groups the values given by the 97.5 percentile ranged from 26 U/ml (4-
year-olds) to 98 U/ml (10 to 14-year-olds). Further differentiation in 5-year age classes from 15-
19 years to 75-79 years showed a stable IgG-PT distribution for those aged >15 years (data not 
shown separately). With the exception of the 10 to 14-year-olds, the age-specific 99 percentile 
was below 100 U/ml. 
The percentages with undetectable IgG-PT (i.e., <5 U/ml) decreased from 85.5% for infants aged 
6-11 months to 67.4% for infants 12-17 months and increased again to 79.4% at the age of 4 
years (Figure 1). The proportion with undetectable IgG-PT decreased to 31.7% in those >15 
years of age. From this age onwards, this percentage remained stable (not shown separately). 
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Figure 1. IgG-PT distribution in the population-based study and in (second sera of) pertussis 
patients with at least a fourfold increase in IgG-PT level in paired sera. 
(Results for the population-based study are given in gray bars and results for second sera of pertussis patients are 
given in white bars; total numbers of patients are given aside the bars) 
The median and 10 percentile of the distributions of IgG-PT in second sera of patients with 
serologically proven pertussis showed little variation in the different age groups; median IgG-PT 
ranged from 316 U/ml to >500 U/ml, and the 10 percentile ranged from 40 U/ml to 87 U/ml 
(Figure 1). The percentage of patients with an IgG-PT level of >500 U/ml ranged from 40.7% to 
57.0% within the various age groups (Figure 1). 
Thus, the IgG-PT distributions in the population differed for the various age categories, but IgG-
PT immune responses in pertussis patients did not. Therefore, for further assessment of specificity 
and sensitivity of certain IgG-PT levels for recent/actual infection with B. pertussis, we chose cut-
offs of IgG-PT levels which were age independent, i.e., based on the comparison of the IgG-PT 
distribution in the total population and the IgG-PT distribution in second sera of the total group of 
serologically confirmed pertussis patients. Cut-offs of 50 U/ml and 100 U/ml were chosen because 
IgG-PT levels >50 and >100 U/ml were detected in respectively 92.7% and 81.0% of (second 
sera of) patients with serologically confirmed pertussis. Such levels were rare: respectively, 3.6% 
and 0.8% in the general population. That is to say, they gave specificities of such values as 96.4% 
and 99.2%, respectively. The specificity of the proposed cut-off of > 100 U/ml was maximally 
100% for the ages of 0-5 months, 12-17 months, 18-23 months, and 2 years old; minimally 97.9% 
for 10 to 14-year-olds; and for the cut-off, >50 U/ml, maximally 100% for the ages of 0-5 months 
and 18-23 months and minimally 96.2% for 10 to 14-year-olds and > 15-years-olds. 
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Validation of the proposed IgG-PT cut-offs as markers for recent or actual infection with 
B. pertussis 
The relation between high IgG-PT levels in the population and recall of pertussis diagnosis 
and/or paroxysmal coughing 
In the population-based study, while 9.6% of those with an IgG-PT level of <5 U/ml reported 
coughing attacks or pertussis during the last year, this percentage was statistically significantly 
greater: 19.9% for those with an IgG-PT level between 50 and 99 U/ml, and 25.5% for those with 
an IgG-PT level >100 U/ml (Table 1). 
The percentage of individuals with a diagnosis of pertussis or who had coughing attacks more 
than one year ago showed a smaller increase with increasing IgG-PT. The differences in the 
percentages were not statistically significant (Table 1). 
The longitudinal course of IgG-PT levels after infection 
In each of the 57 patients with clinical pertussis for whom there were follow-up serum samples, 
the IgG-PT decreased with time after the onset of the disease (Figure 2). In the mixed linear 
model with the IgG-PT in 2log U/ml and time from the onset of the disease in 2log days, the 
intercept amounted to 14.61 and the slope was -1.128. Thus, this model predicts that the mean 
time of persistence of an IgG-PT level >100 U/ml amounts to 134 days (4.4 months) and that 
after 365 days, a level of 32 U/ml is reached. Although IgG-PT levels of >500 U/ml were not 
further differentiated, the slopes did not change statistically significantly assuming that the levels 
of >500 U/ml were 1000 U/ml or restricting the analysis to those samples with IgG-PT levels 
<500 U/ml. No effect of age or vaccination status was shown in the mixed linear model. 
The data points for each individual patient were connected linearly. The resulting lines show that 
the IgG-PT level were below 100 U/ml within 1 year for 47 of the 57 patients. For 7 of the 
remaining 10 patients, the IgG-PT levels decreased below 100 U/ml during the subsequent follow-
up period, which ranged from 1.4 years to 4 years. For 2 of the remaining 3 patients, the follow-
up period was less than 1 year. For these 2 patients, the IgG-PT levels amounted to 160 U/ml and 
304 U/ml after 0.84 and 0.92 years of follow-up, respectively. The remaining patient had an IgG-
PT level of 252 U/ml 1.1 year after the first day of illness. 
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Table 1. Percentages of individuals with a history of pertussis or coughing attacks during the last year, of individuals with pertussis 
or coughing attacks more than 1 year ago, and of individuals without pertussis or coughing attacks according to IgG antibody levels 
in the population-based study 
IgG N <5 
IU/ml 
(95% CI) 5-9 
IU/ml 
(95% CI) 10-49 
IU/ml 
(95% CI) 50-99 
IU/ml 
(95% CI) >100 
IU/ml 
(95% CI) 
Pertussis 886 9.6 (8.0-11.3) 11.6 (9.4-13.8) 11.3 (9.7-12.9) 19.9 (13.0-26.9) 25.5 (12.2-38.8) 
diagnosed and/or 
coughing attacks 
during last year* 
Pertussis 463 5.5 (4.3-6.7) 6.1 (4.6-7.6) 6.7 (5.2-8.5) 7.3 (3.5-11.0) 14.1 (2.7-25.5) 
diagnosed and/or 
coughing attacks 
more than one year 
ago; No pertussis 
diagnosed and no 
coughing attacks 
during last yeart 
No pertussis or 6407 84.9 (82.8-87.0) 82.3 (79.9-84.6) 81.8 (80.1-83.5) 72.8 (65.2-80.5) 60.4 (45.3-75.5) 
coughing attacks 
Total 7756 100% 100% 100% 100% 100% 
* Among the 886 individuals, 15 individuals reported pertussis and 12 of these 15 individuals reported coughing attacks, 
t Among the 473 individuals, 126 individuals reported pertussis and 45 of these 126 individuals reported coughing attacks. 
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As shown in Table 2, the highest IgG-PT level detected between 0 and 5 months after onset of the 
disease was >100 U/ml in 90% of the patients, while the highest IgG-PT level detected in the 
remaining patients was between 50 and 100 U/ml. Six to 12 months after onset of the disease, the 
level had declined to <50 U/ml in 40% of the patients. A decrease to <50 U/ml had occurred in 
72% after 12-23 months, in 86% after 2-3 years, and in 100% after 4-7 years (Table 2). 
Table 2. IgG-PT levels in patients with clinical pertussis versus time elapsed since disease onset 
0-5 months 6-11 months 12-23 months 2-3 years 4-7 years 
Number 57 30 25 14 8 
> 100U/mI 90% 20% 16% 7% 0% 
50-99 U/ml 11% 40% 12% 7% 0% 
20-49 U/ml 0% 13% 28% 36% 13% 
< 20 U/ml 0% 27% 44% 50% 88% 
2 l o g U / m l 365 Days u/ml 
0 2 4 6 8 10 12 2logdays 
1 4 16 64 256 1024 4096 Days 
Figure 2. IgG-PT levels (in 2log U/ml) versus time elapsed (in 2log days) since date of onset for 
57 patients with clinical pertussis 
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Time between onset of the disease and development of high IgG-PT levels 
Sera from patients for all age groups with an IgG-PT level >100 U/ml in the first serum sample 
without a fourfold increase in IgG-PT level had been sampled at a later stage of the disease 
(median 30 days) than the first sera of patients showing a fourfold increase in IgG-PT level 
(median 17 days) (Table 3). The first samples from patients less than 3 years of age were collected 
a few days earlier than the samples from older age groups, particularly for patients with at least a 
fourfold increase in IgG-PT. 
The results given in table 3 also show the number of patients with an IgG-PT level >100 U/ml in a 
first serum that in our sérodiagnostic database of 1989-1996 is considerably larger (4.5-fold) than 
the number of patients with at least a fourfold increase in IgG-PT. This discrepancy increases with 
age from onefold for 0 to 5-months-olds to 13.6-fold for >15 years of age. 
Table 3. Time ( in days) between onset of the disease and first blood sampling for patients with at 
least a fourfold IgG-PT increase and for patients with at least 100 U/ml in the first serum 
sample without a fourfold IgG-PT increase 
Patients with at least a four-fold Patients with at least 100 U/ml in first 
IgG-PT rise serum sample without a four-fold 
IgG-PT rise 
Number Median 2.5 - 97.5 Mean Number Median 2.5 - 97.5 Mean 
(days) percentile (days) (days) percentile (days) 
0-5 months 517 14 (2-53) 17.0 497 30 (4-108) 36.8 
6-11 months 144 14 (2-61) 16.8 305 29 (2-105) 35.4 
1 years 174 15 (2-62) 19.2 426 28 (4-122) 36.3 
2 years 195 15 (4-88) 19.6 763 30 (6-109) 38.1 
3 years 262 18 (3-60) 19.7 966 30 (7-119) 38.5 
4 years 362 21 (5-55) 21.9 1499 31 (7-112) 39.0 
5-9 years 1191 18 (3-58) 20.6 5655 31 (7-103) 37.6 
10-14 years 327 18 (4-61) 21.3 2180 31 (7-111) 40.0 
>15 years 222 16 (3-67) 19.3 3028 30 (6-108) 37.2 
Total 3394* 17 (3-59) 19.8 15319 30 (6-109) 38.0 
N < 3491 due to missing values for time of disease onset 
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Figure 3. IgG-PT distribution in the first and second serum samples of patients with a positive 
culture and/or PCR for Bordetella pertussis 
White rounds indicate sera with at least a fourfold increase in IgG-PT to a level of at least 20 U/ml; Black rounds 
indicate sera without fourfold increase in IgG-PT; pairs of sera are connected with a dotted line; Half black, half 
white rounds indicate sera in which the degree of increase of IgG-PT could not be determined due to the upper 
limit of differentiation of the IgG-PT assay of >500 U/ml; pairs of sera are connected with a dotted line. 
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Sensitivity of the proposed cut-offs for IgG-PT in PCR and/or culture-confirmed pertussis cases 
Among the 89 patients for whom pertussis was confirmed by a positive culture and/or a PCR both 
in the IgG-PT distributions in the first and second serum samples, no statistically significant 
differences were found between age groups. 
The distributions of IgG-PT in first and second sera of the serum pairs of these patients are shown 
in Figure 3. In 3 of the 89 patients, IgG-PT was undetectable (<5 U/ml) in both the first and the 
second serum samples. In two other patients the IgG-PT rose from <5 U/ml to 7 and 8 U/ml. In 
69 patients a > fourfold increase of IgG-PT was detected, in 11 patients the IgG-PT in the first 
serum sample was > 100 U/ml and no fourfold rise was detected, and in 4 patients the rise in IgG-
PT was less than fourfold and the IgG-PT in the first serum sample less than 100 U/ml. Thus, if 
detection of a fourfold increase or more of IgG-PT in paired sera and detection of IgG-PT >100 
U/ml in a single serum sample are used as criteria for serodiagnosis of actual/recent infection with 
B.pertussis, the sensitivity of IgG-PT serology in this golden standard group of patients is 
enhanced from 77.5% (69/89) to 89.9% (80/89). Overall, the sensitivity of an IgG-PT level of 
>50 and >100 U/ml amounted to 88.8% and 76.4%, respectively: i.e., 79 and 68 of the 89 
patients had an IgG-PT level of >50 U/ml and of >100 U/ml in first and/or second serum samples. 
Discussion 
Our results show that an IgG-PT level of at least 100 U/ml is a specific tool in laboratory 
confirmation of patients with a suspected pertussis infection in the Netherlands. The levels of IgG-
PT in the Dutch population are lower than, and overlap only slightly, IgG-PT levels that are 
reached in patients with clinical symptoms of pertussis and a significant immune response to B. 
pertussis. IgG-PT levels of least 100 U/ml were observed in less than 1% of the overall general 
population, varying between maximally 2.5% for 10 to 14-year-olds and less than 0.5% for those 
2 years of age or less. Furthermore, such levels were present in the second serum sample of 80% 
of those patients who had at least a fourfold increase in IgG-PT. 
Our longitudinal study of pertussis patients shows that the levels decreased within less than 1 year 
to a level below 100 U/ml after natural infection with B. pertussis for almost all patients who had 
had high IgG-PT levels. The regression model predicts that a level of 100 U/ml is reached in 4.5 
months; and a level of less than 40 U/ml, 1 year after onset of the disease. For 7 of 8 patients with 
a longer follow-up time, the IgG-PT levels were below 20 U/ml 4-7 years after the disease onset. 
Thus, IgG-PT levels of at least 100 U/ml for patients with suspected whooping cough are 
indicative of recent or actual infection with B. pertussis. 
These results are also important for the interpretation of the serological profile of IgG-PT in the 
general population to assess the infection rate of B. pertussis. Cumulative incidence cannot be 
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calculated directly from the seroprofile as others have done (27). The decline of IgG-PT after 
infection with B. pertussis has to be taken into account. 
In our population-based study, the percentage of individuals who reported pertussis or coughing 
attacks in the last year increased from 10% for those with IgG-PT levels less than 5 U/ml to 26% 
for those with at least 100 U/ml. This finding offers further support for our conclusion that a high 
IgG-PT level is indicative of recent or actual infection with B. pertussis. 
Ten percent of the individuals in the population study with an IgG-PT level less than 5 U/ml 
reported pertussis or coughing attacks in the last year. On the one hand, this may be explained by 
other respiratory tract infections that cause "pertussis-like" symptoms (28), a rapid decline of 
previously high IgG-PT level or the absence of IgG-PT response after B. pertussis infection. It is 
also possible that not all subjects answered the question properly. On the other hand, the large 
percentage (60%) of individuals with high antibody titers who did not report pertussis or long-
lasting coughing attacks might be due to very mild, atypical, or even asymptomatic infection with 
B. pertussis. In a household exposure study, a B. pertussis infection was shown to exist in 46% of 
the exposed subjects who remained well (10). In another study, only 26% of the adults with 
laboratory evidence of a B. pertussis infection reported recent symptoms compatible with 
pertussis (14). 
Among those with an IgG-PT level of at least 100 U/ml, the percentage of individuals who 
reported coughing attacks or pertussis more than 1 year previously was higher (14%), but not 
statistically significant, when compared to those with an IgG-PT level of less than 5 U/ml (6%). 
This supports our finding that IgG-PT decreases after B. pertussis infection. As our population-
based serum bank was not established specifically to study pertussis, but to study vaccine-
preventable diseases (a broader objective), the exact time of illness was not further specified (24). 
Therefore, we could not study more accurately the relation between the level of IgG-PT to the 
time elapsed since the coughing attacks or pertussis. Theoretically, a patient with suspected 
pertussis may suffer from another disease that causes similar symptoms at the moment of blood 
sampling and may have had a B. pertussis infection a few months earlier. 
Although IgG-PT is induced after whole-cell vaccination only in children aged 12-17 months, and 
thus after the fourth dose given at the age of 11 months, a temporary and small increase was 
observed. These results are consistent with observations in a vaccine trial showing very low levels 
of IgG-PT after the first to third vaccinations and a small increase just after the fourth vaccination, 
as Nagel observed (29,30). Thus, it is very unlikely that high levels of IgG-PT are induced by 
previous vaccination with Dutch whole-cell vaccine. However, other vaccines might induce higher 
IgG-PT levels as the response to pertussis toxin varies between different whole-cell vaccines and 
acellular vaccines (31-34). However, even when a level of at least 100 U/ml is reached, it is likely 
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to decline shortly afterwards (32-34). Giuliano et al. (32) show that mean titers were close to the 
limit of detection 15 months after the primary immunization with acellular vaccine. High IgG-PT 
levels must be interpreted more cautiously in children recently vaccinated with a vaccine known to 
induce relatively high levels of such antibodies. 
In addition to specificity, both sensitivity and positive predictive value are important for 
diagnostic tools. Using paired sera of patients with positive PCRs and/or positive cultures (golden 
standard group), a sensitivity of IgG-PT of at least 100 U/ml was 76%. At least a fourfold 
increase was found in most of the remaining patients in whose paired sera the IgG-PT level 
remained below 100 U/ml. One might speculate that a level of at least 100 U/ml may have been 
reached at a later point. Only 6% of all patients had very low IgG-PT levels in both sera without 
significant dynamics. 
With the exception of those aged 10-14 years, a level of IgG-PT of at least 100 U/ml exceeded 
the 99 percentile in the general population. Furthermore - as already described - it was likely that 
individuals in the general population with IgG-PT levels above this value had had a recent or 
actual B. pertussis infection. Based on this 99 percentile, the positive predictive value will still 
amount to 90% and 80%, assuming the proportions of true pertussis patients to be 9% and 4%, 
respectively among those who submitted serum samples (i.e., 9 / ( 9 +1) and 4 / (4 + 1)). 
However, depending on the clinical presentation and the epidemiological situation, the a priori 
chance of true positivity in most cases will be higher. Using a more conservative estimate, i.e., a 
97.5 percentile in the general population, the positive predictive value will not be below 80%, 
assuming a percentage of true positives of 10%. 
Even an IgG-PT level of at least 50 U/ml has some predictive value, as it amounts to 70%, 
assuming a percentage of true positives of 10%. This suggests that the diagnosis of pertussis is 
likely among patients with clinical symptoms of pertussis with such IgG-PT levels. However, we 
interpret such a result as indicative of, but not definite proof of a recent B. pertussis infection and 
we advise submission of a second serum sample. If no further change of IgG-PT level has 
occurred as evidenced by a second serum sample, we conclude that "recent or actual infection 
with B. pertussis is possible". 
Serological data at our laboratory show that using our cut-off value for the IgG-PT level of at 
least 100 U/ml would increase the number of patients with serologically proven pertussis by more 
than fourfold. The increase is smallest for infants and greatest for adults, which is probably related 
to a longer delay in consulting a physician and/or initiating laboratory testing in older children and 
adults. This is supported by the similar median time (28-30 days) between the first blood sampling 
and the onset of symptoms for the various age groups for those with an IgG-PT level of at least 
100 U/ml. 
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For patients with at least a fourfold increase in IgG-PT the median time (17 days) between the 
first blood sampling and the first symptoms is about 2 weeks shorter than that of those without a 
fourfold increase and IgG-PT levels above 100 U/ml. The most useful method for pertussis 
diagnosis depends on the time of initiation. PCRs and cultures are most useful early in the disease. 
However, if they are negative, the diagnosis is indeterminate, and serology tests should be 
initiated. Late in the disease, PCRs and cultures are fairly insensitive (with an exception for infants 
less than 1 year old) and serology is then the first method of choice (12,18,19). 
To diagnose pertussis other investigators have also used single serum samples from a control 
group for defining a cut-off, but most studies were limited to a specific study setting and were not 
meant for routine diagnosis (3,4,6,7,9,11,12,15). Our control group consisted of a large number 
of participants from a population-based study, so that the representativeness is probably better 
guaranteed. 
We do not share the opinion of Cattaneo et al. (35) that including a few individuals with a recent 
B. pertussis infection in the control population refutes the use of this population as a reference 
population. This might lead merely to a somewhat less sensitive cut-off value, as the 99 percentile 
might be slightly overestimated. 
Cattaneo et al. point out that it is unlikely that a single serology value can be used to define 
infected persons in a broad age range because age, geographic area, prevalence of infection, and 
history of vaccination all have to be taken into account (35). Yet, an IgG-PT level of at least 100 
U/ml in a single serum sample might be a specific diagnostic tool for pertussis in other countries 
too. After all, it is likely that such high IgG-PT levels will not or will be reached only temporarily 
no matter which vaccine is used. After the initial increase, the IgG-PT level decreases again after 
B. pertussis infection, high predictive values are calculated under different assumptions on 
prevalence of infection, and finally, a large proportion of individuals with a B. pertussis infection 
show high IgG-PT levels later in the disease. Thus, we believe that high IgG-PT levels could 
provide a useful laboratory tool for diagnosis of pertussis in both the individual patient and 
epidemiological studies (12,15,20). It might be worthwhile to validate our results in other 
countries. 
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Results from a nationwide, population-based, cross-sectional study on diphtheria, tetanus and 
poliomyelitis and results from studies on surveillance and seroepidemiology of pertussis are 
described in this thesis. 
The age-specific prevalence of antibodies has given insight into diphtheria, tetanus and 
poliomyelitis immunity in the general population and in differences in immunity between the 
general population and orthodox reformed groups refusing vaccination in the Netherlands. The 
studies on pertussis surveillance have provided information on the occurrence of pertussis in the 
Netherlands and on possible factors involved in its re-emergence. Finally, seroepidemiological 
studies on pertussis have given insight into pertussis diagnosis based on high levels of IgG 
antibodies against pertussis toxin in a single serum sample. 
The main findings of the studies are summarised in the first part of this chapter. Then some 
methodological considerations and the implications of the findings for public health and future 
research are described. 
Main findings 
Part 1. A population-based serum bank 
Implementation of the population-based design for collecting sera for public health research with 
the primary focus on vaccine-preventable diseases (Chapter 2) resulted in an overall response rate 
of 55.0% for serum collection and questionnaire data in the nationwide sample (7Y= 8359) and of 
52.5% in the low vaccine coverage sample (N = 1589). As a result of this parallel study in 
municipalities with low vaccine coverage, we had access to about 240 members of orthodox 
reformed groups who refuse vaccination. 
The nonparticipation study (Chapter 3) shows that various characteristics of individuals were 
independently associated with (non)participation. Various groups of (non)participants were 
distinguished. There were initial and additional participants, nonparticipants who completed the 
(nonresponse) questionnaire and absolute nonparticipants for whom only data from the municipal 
registry were available. Some variables affected each form of (non)participation similarly; other 
variables affected each form differently. For example, for some variables the difference between 
participants and nonparticipants was slightly smaller when additional participants were included, 
while the difference was slightly larger for other variables. Exclusion of absolute nonparticipants, 
i.e. restricting nonparticipants to those who answered a questionnaire, also affected the 
association with nonparticipation considerably for some variables. 
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Part 2. Immunosurveillance for diphtheria, tetanus and poliomyelitis 
The results for the studies on seroprevalence of diphtheria, tetanus and poliomyelitis are given in 
Chapters 4 to 6. Specific antibodies to these diseases give insight into the immunity of the 
population, since they correlate with protection. 
The age-specific prevalence of diphtheria antitoxin antibodies (> 0.01 IU/ml), of tetanus antitoxin 
antibodies (> 0.01 IU/ml) and of neutralising antibodies against poliovirus types 1 and 2 (> 1:8) in 
our nationwide sample was more than 92.5% for individuals aged less than 45 years. These 
individuals were born after the introduction of mass vaccination. The prevalence of neutralising 
antibodies for poliovirus type 3 was more than 90% for those younger than 30 years and more 
than 80% for 30 to 44-year-olds. For older individuals, namely, those born before the introduction 
of vaccination, a sharp decrease with increasing age was observed in the prevalence of antitoxin 
antibodies against diphtheria and tetanus; for individuals aged 70 to 79 years it amounted to 50% 
or less. The prevalence of neutralising antibodies against poliovirus types 1, 2 and 3 remained at 
80% or more for older age groups. 
Among orthodox reformed individuals often refusing vaccination, the prevalence of antibodies 
was less than that among individuals from the nationwide sample, both for those younger than 45 
years and those aged 45 years and more. It amounted to 40% or less for diphtheria antitoxin 
antibodies and tetanus antitoxin antibodies, while it was 70% or less for neutralising antibodies 
against poliovirus types 1, 2 and 3. The seroprofiles showed an effect of the recent poliomyelitis 
outbreaks in 1978 and in the period 1992-1993 among orthodox reformed groups, but not among 
other participants. 
For individuals aged 10 to 34 years who were completely vaccinated according to the National 
Immunisation Programme standards (i.e. at the ages of 3, 4, 5, 11 months, 4 and 9 years), the 
geometric mean titres for diphtheria, tetanus and poliomyelitis decreased with increasing age. 
However, the prevalence of antibodies in this subgroup was at least 98% for diphtheria, tetanus 
and poliovirus types 1 and 2, and at least 94% for poliovirus type 3. The decline in geometric 
mean titres with age was similar for diphtheria antitoxin antibodies and tetanus antitoxin 
antibodies. However, since the geometric mean titres were higher for tetanus than for diphtheria 
for recently completely vaccinated 10 to 14-year-olds, the tetanus antitoxin antibody levels were 
higher for 30 to 34-year-olds than the levels for diphtheria. For all three diseases, the geometric 
mean titres for individuals aged 20-34 years with evidence of revaccination were similar to those 
for 10 to 14-year-olds who were completely vaccinated, but without evidence of revaccination. 
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Part 3. Surveillance and seroepidemiology of pertussis 
Surveillance data for pertussis are presented in Chapters 7 and 8. The number of pertussis patients 
increased sharply in 1996 and 1997 as compared with the number in the period 1989 to 1995 
according to notifications, serology data and hospital admission data. The increase was largest for 
notifications and smallest for hospital admissions. For children less than 1 year old, the increase in 
notifications and positive serology was similar to the increase in hospital admissions. In older 
individuals, the increase in hospital admissions was smaller than the increase from other 
surveillance sources. From 1994 onwards, the vaccine efficacy estimated from notification data 
was less than that from 1989 to 1993. These estimates were lowest in 1996 and 1997. The 
proportion of reported cases with positive two-point serology increased from 24% in 1993 to 
40% in 1996 and 1997. For cases with positive one-point serology, this proportion increased from 
6% in 1993 to 29% in 1997. 
Finally, Chapter 9 describes the study in which we investigated whether, and at which level, 
concentrations of IgG antibodies against pertussis toxin (IgG-PT) in a single serum sample are 
indicative of actual or recent Bordetella pertussis infection. IgG-PT is specific for B. pertussis 
and responses occur in most patients with a B. pertussis infection. IgG-PT levels of at least 100 
U/ml were present in less than 1 % of the participants in the population-based study, which means 
a specificity of 99%. Such levels were present in more than 80% of second sera of patients with 
serologically proven pertussis, i.e. with at least a fourfold increase in IgG-PT in paired sera. 
Follow-up of patients with clinical pertussis showed that the IgG-PT level was less than 100 U/ml 
in more than 80% of the patients less than 1 year after the onset of symptoms. For patients with 
positive pertussis polymerase chain reaction or culture, the sensitivity of a IgG-PT level of at least 
100 U/ml amounted to 76%. The number of patients with IgG-PT levels in a first serum sample of 
at least 100 U/ml in our sérodiagnostic database was more than fourfold greater than the number 
of patients with positive two-point serology. The increase was smallest for infants less than 6 
months of age and largest for individuals aged 15 years or older. 
Methodological considerations 
There are several methodological issues that should be considered in interpreting the results of the 
studies described. For the population-based studies on diphtheria, tetanus and poliomyelitis, we 
discuss the possible bias due to selective participation, the age-cohort effect in association with 
the persistence of antibodies after vaccination and the validity of vaccination status. The validity 
of pertussis surveillance data and of estimations of vaccine efficacy from these data is discussed 
afterwards. Finally, some issues about interpreting the results from the study on high IgG-PT 
levels as a diagnostic tool for pertussis are discussed. 
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A population-based serum bank and immunosurveillance of diphtheria, tetanus and 
poliomyelitis 
Selective participation 
Inevitably, many serosurveys are being performed on residual sera, i.e. sera from blood donors or 
sera taken for clinical reasons. It is dubious to what extent sera from these sources can be used to 
make valid population estimates. Blood donors might be more health conscious, for example, 
while patients who have a blood sample taken for clinical reasons differ from the general 
population in that they are ill somehow. To overcome this problem and to be able to collect 
additional information about participants, we used a population-based approach. 
Since participants had little personal interest in participating, and since many people dislike blood 
sampling, the participation rate of 55% was satisfactory. However, despite an appropriate 
sampling frame, the percentage of nonparticipants implies that our serum collection may not be 
representative of the general population. Information available about all participants and all 
nonparticipants shows that some variables, such as age and sex, were indeed associated with 
nonparticipation (Chapter 3). However, the effect of differential probabilities of response for these 
variables on the population estimate amounted to less than one standard error for diphtheria, 
tetanus and poliomyelitis (Chapters 4, 5 and 6). They were therefore ignored. The absence of an 
effect of nonparticipation on these estimates was mainly the result of correcting for differential 
response (age), lack of association with prevalence of antibodies (marital status, region) or being 
a small subgroup (nationality). 
The interpretation of the association of other variables with nonparticipation in the analysis 
restricted to those nonparticipants who filled in a questionnaire was more difficult. As described in 
Chapter 3, this might lead to biased insight into nonparticipation selection, since those 
nonparticipants who filled in a questionnaire might not be representative of all nonparticipants. 
The most important determinant on which no information was available for all (non)participants 
was vaccination status. 
Perhaps our nationwide estimates of prevalence of diphtheria, tetanus and poliomyelitis antibodies 
were slightly overestimated for those age groups born after the introduction of vaccination. 
Firstly, in the nonparticipation analysis restricted to those who filled out a questionnaire, 
individuals who considered none of the vaccinations necessary were less likely to participate. 
Secondly, for diphtheria, tetanus and poliomyelitis in the younger age groups, the estimated 
prevalence of antibodies exceeded the vaccination coverage of 97%. With respect to this last 
factor, a greater seroprevalence than vaccination coverage alone provides, could also be due to 
reaching detectable antibody levels after less than three vaccinations [note that vaccination 
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coverage is measured for 12-months-olds for at least three DT(P)-IPV] or by (additional) 
vaccinations given afterwards. 
Although we cannot exclude the possibility that our population-based estimates were slightly 
overestimated as a result of overrepresentation of vaccinated individuals, the effect was probably 
very small and did not interfere with the interpretation of our results. 
Vaccinated individuals were likely overrepresented among orthodox reformed individuals who 
participated in our study. Nonparticipants for whom questionnaire data were available reported 
less frequently that they had participated in the vaccination programme than participants. As no 
information on religion and vaccination status was available for nonparticipants who did not 
answer the questionnaire, the true nonparticipation selection is unknown. Even if the prevalence 
of diphtheria antitoxin antibodies, tetanus antitoxin antibodies and neutralising antibodies against 
poliovirus types 1, 2 and 3 estimated for these groups were overestimated, they were still were 
much smaller than those of the nationwide sample. They should probably be considered as upper 
limits. 
Age-cohort effects 
This type of fallacy quite often pops up in cross-sectional seroprevalence studies (1). The effect of 
age and cohort cannot be distinguished in such a study. The seroprevalence measured in a specific 
age group in a particular year does not imply that other individuals will have a similar prevalence 
of antibodies when they reach this age. For example, when the exposure to a pathogen decreases 
with time, younger birth cohorts will have a smaller prevalence of antibodies at the time they 
reach the same age group as the older birth cohorts in which the prevalence was measured. The 
prevalence estimates of hepatitis A antibodies in a cross-sectional study is affected by such a 
cohort effect for those born before World War II (much exposure) and those born after World 
War II (little exposure) as a result of changes in hygienic conditions. 
For vaccine-preventable diseases, a cohort effect is observed in the antibody prevalence in 
individuals born before and after the introduction of vaccination. In our analysis of antibody levels 
of diphtheria, tetanus and poliomyelitis in 10 to 34-year-olds who were completely vaccinated 
according to the National Immunisation Programme standards, we interpreted the decrease in 
geometric mean titres longitudinally, that is, as a decrease with increasing time since the last 
vaccination. Tetanus antibodies are only induced after vaccination. It is very unlikely that 
individuals from the age groups concerned, those aged 10 to 34 years in the period 1995-1996, 
were exposed to poliovirus or Corynebacterium diphtheriae. Circulation of poliovirus during the 
outbreaks in 1978 and 1992-1993 seemed to be restricted to orthodox reformed groups refusing 
vaccination (Chapter 6) and only very few cases of diphtheria occurred after 1960 (Chapter 4). 
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For these reasons, we consider longitudinal interpretation of the decrease in geometric mean titres 
justified. 
Validity of vaccination status 
In studies evaluating the effects of national immunisation programmes, such as described in this 
thesis, vaccination status is a very relevant determinant. The validity of self-reported vaccination 
status was low in our pilot study (2). For example, many participants who reported to be 
completely vaccinated according to the National Immunisation Programme were not, or were 
incompletely vaccinated according to the vaccination certificate of this programme. For this 
reason we have collected data on vaccinations documented by the National Immunisation 
Programme, and/or military service and travel papers. Although such documentation is probably 
not completely infallible, it is highly unlikely that individuals with documented vaccinations did 
not receive them. 
We restricted the analysis of the persistence of antibodies after vaccination to those individuals 
with complete documentation of vaccinations provided by the National Immunisation Programme. 
Individuals with documented revaccinations and those individuals without documentation who 
claimed to have been revaccinated were excluded from this analysis. It is possible that a few 
individuals in the subgroup might have forgotten that they had been revaccinated. If these 
revaccinations were not documented or if the individual did not show us a document of 
revaccination of some kind, this could have led to an underestimation of the decrease in geometric 
mean titres after complete vaccination. 
Surveillance and seroepidemiology of pertussis 
Validity of notification data 
The most important problem of surveillance data concerns the validity. The number of patients 
reported will be influenced by many factors. If these factors remain constant, comparisons can be 
made to study changes in disease occurrence over time. However, if changes in these factors 
occur over time, the interpretation of surveillance data is hampered. We summarise the most 
important factors known to have influenced our surveillance data on pertussis. 
Firstly, due to the increasing application of serology, the number of notifications increased in the 
1980s. Immunoassays for measurement of IgA antibodies against B. pertussis and IgG antibodies 
against pertussis toxin became available in 1981 and 1984, respectively. 
Secondly, changes in the interpretation of serology have influenced the number of pertussis 
notifications in various periods. Before 1988, the conclusion that serology was positive was 
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mostly based on the detectability of moderate or high titres in one serum sample. From 1988 
onwards, according to notification criteria introduced in that year, serology was defined to be 
positive when an increase in titre in paired sera was detected. This is referred to as "positive two-
point serology". In recent years in addition to positive two-point serology, the clinical pertussis 
diagnosis is confirmed by high titres in one serum sample. An increasing number of these patients 
with "positive one-point serology" was reported. The criteria for positive one-point serology are 
more strict than before 1988: higher titres have to be detected. 
Another factor known to have influenced the number of reported pertussis cases is the notification 
rate. The notification rate has increased in recent years, apparently as a result of the pertussis 
outbreak in the period 1996-1997. 
We could obtain insight into the influence of the factors just mentioned, since we were able to link 
the notification database with the sérodiagnostic database of the National Institute of Public 
Health and the Environment. Therefore, we could rule out the possibility that the increase in 
incidence in 1996 was due to a change in sérodiagnostic practice. Furthermore, we applied the 
present criteria for positive one-point serology retrospectively to serological test results in 1986 
and 1987. We could see from the results of this that it was more likely that a true increase in 
pertussis incidence had occurred in 1986 and 1987. 
As a result of a change in sérodiagnostic practice and in the notification rate, comparison of the 
numbers of notifications at present with those before the pertussis outbreak in 1996 and 1997 is 
difficult. 
The National Institute of Public Health and the Environment was the only laboratory that 
performed pertussis serology until 1998; since then other laboratories also do so. Furthermore, 
the law for notification has changed: now, some information necessary for linking the notification 
database to the sérodiagnostic database is no longer available. Both factors make the surveillance 
and the interpretation of the data even more complicated. 
Hospital admissions of pertussis patients are likely to be less sensitive to changes in the factors 
just described. Therefore, this source is very useful, not only for the interpretation of national 
surveillance data, but also for comparison between countries. Case definitions for notification, 
reporting and diagnostic practice differ greatly among the various countries. Differences in 
hospital admissions will probably vary less, particularly for young infants who suffer the disease 
most severely. However, since hospital admissions are restricted to these severe cases, we should 
not rely only upon this source. 
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Chapter 10 
We used notification data to estimate vaccine efficacy with the screening method in Chapters 7 
and 8 (3). Results obtained by the screening method may be biased towards either a higher or 
lower estimate of vaccine efficacy if the data source does not provide the true vaccination status 
of pertussis patients or pertussis vaccination coverage in the population under study (4). 
Since the vaccination coverage is stable, according to the reliable registration system, we expect 
the estimate of the vaccine efficacy to be influenced only by reliability of the vaccination status 
(5). The reported cases are a selection of all pertussis cases. For example, pertussis vaccines 
appear to protect better against severe disease than against milder disease or asymptomatic 
infection with B. pertussis (6). Asymptomatic, subclinical and mild, unrecognized cases will not be 
reported. This may lead to underrepresentation of vaccinated patients. However, it is also possible 
that physicians in regions with low vaccination coverage, who often diagnose pertussis in 
unvaccinated children, have a lower notification rate. 
Therefore, our objective was merely to study changes in vaccine efficacy. Similarly, as discussed 
for the validity of surveillance data, factors that influence reporting and are associated with 
vaccination status have to remain constant over time if we are to make comparisons over time and 
interpret changes in vaccine efficacy. 
Our surveillance data show a decrease in vaccine efficacy over time. This decrease could have 
resulted from a change in the physician's perception and/or the method of diagnosis that could 
have caused selective reporting of vaccinated patients, a higher rate of misclassification of cases 
with respect to vaccination status than previously, and a change in the severity of the disease. 
However, the decrease could only be nullified assuming unlikely large changes in the selective 
reporting of vaccinated individuals or the rate of misclassification. Furthermore, the decrease 
could only partially be explained by a larger proportion of cases with positive one-point serology 
among the reported cases. These patients were more often vaccinated. Unfortunately, we could 
not verify what the effect of a change in the severity of disease would be. Ideally, a case control 
study to estimate the vaccine efficacy stratified by the severity of disease should have been 
performed. However, for practical reasons, this was not feasible. Instead, we collected data on 
symptoms and vaccination status of reported patients and hospitalized patients (7). These data 
show that typical pertussis also occurs among vaccinated individuals. It seems unlikely that cases 
that occurred before the epidemic were more severe than those reported in our study. Thus, it 
appears the decrease in vaccine efficacy at least partially reflects a true decrease. 
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Methodological issues in the study on high IgG-PT levels as a sérodiagnostic tool for pertussis 
IgG-PT distribution in the general population 
The IgG-PT distribution measured in the nationwide population-based study seems to reflect the 
distribution in the population. The IgG-PT levels were not affected by differential response for 
those variables available for both nonparticipants and participants. Furthermore, even less effect 
on the IgG-PT distribution was expected from differential response by vaccination status than on 
the prevalence of antibodies for diphtheria, tetanus and poliomyelitis. At the ages of vaccination, 
only a very slight effect, or none at all, was observed on the IgG-PT distribution. Furthermore, 
since we show in our study that IgG-PT decreased after natural infection, it is likely that after 
vaccination IgG-PT levels will decrease. 
IgG-PT in pertussis patients 
We considered IgG-PT levels measured in second sera submitted to our sérodiagnostic laboratory 
for those patients who showed at least a fourfold increase in IgG-PT, characteristic for the 
reconvalesence phase of those patients with a B. pertussis infection who showed an IgG-PT 
response. Ideally, we would have measured IgG-PT levels in sera collected from a random sample 
of patients starting at the moment of infection with B. pertussis to the highest IgG-PT level 
reached. However, such a study is not feasible. Our approach seems to be justified, but we cannot 
rule out the possibility that the selection of patients somehow differs in their IgG-PT response. 
This issue also applies to the decrease in IgG-PT after infection, which we studied in follow-up 
sera of patients with clinical pertussis. Most of these patients were less than 10 years of age. 
Ideally, we would have collected sera from a random sample of patients rather than patients 
remaining under treatment of a physician, as was the case here. Furthermore, including patients of 
all ages would have made it possible to study more appropriately whether the decrease in IgG-PT 
depended on age. 
Implications for public health and research 
The major challenge in infectious disease control is eradication of the pathogen. Unless the 
pathogen is eradicated, continuous efforts are needed for disease control, even when the disease 
has been eliminated. The vaccine-preventable diseases described in this thesis seem to be in 
different phases of control in the Netherlands. Some are well on the way to eradication 
(poliomyelitis), or elimination (diphtheria and tetanus) and some, despite great progress, need 
more effective control (pertussis). 
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Here we discuss our findings with regard to possible implications for public health and research in 
making progress towards eradication, elimination or better control of poliomyelitis, diphtheria, 
tetanus and pertussis in the Netherlands and, if possible, worldwide. 
Diphtheria 
The implementation of immunisation has ensured that diphtheria has not been a public health 
problem for a generation in many industrialised countries. At the beginning of the 1990s, there 
was optimism that elimination of indigenous respiratory diphtheria could be achieved in the 
European Region by 1990 (8,9). The elimination of diphtheria is facilitated by the facts that 
humans are the only reservoir and that an effective, safe and inexpensive vaccine exists. Factors 
that might hinder the elimination of diphtheria are the presence of an asymptomatic carrier state 
and the need for three initial doses of vaccine and subsequent booster doses (9). 
Our surveillance data show that diphtheria has virtually been eliminated in the Netherlands (10). 
However, diphtheria has re-emerged since 1990 on a massive scale in the New Independent States 
of the former Soviet Union (11,12). Among other contributing factors such as population 
movement, socioeconomic instability, and a deteriorating health infrastructure, a major reason for 
the epidemic is probably the presence of highly susceptible child and adult populations (12). 
Although a high rate of adult susceptibility might not be a sufficient precondition for the 
development of epidemic diphtheria in adults, it is considered a necessary condition (11). It is 
likely that the susceptibility of children is more important in the dissemination of diphtheria (11). 
The peak in measles following the school opening after vaccination exemplifies the role of 
contacts between children as a important determinant for the overall transmission potential (13). 
In contrast to the situation in the former Soviet Union before the diphtheria outbreak, our 
population-based study shows that the diphtheria immunity level in the Dutch general population 
born after the introduction of vaccination is sufficient. This is the result of a successful vaccination 
programme with high vaccination coverage. However, gaps in immunity might exist among adults 
born before the introduction of vaccination. The prevalence of diphtheria antitoxin antibodies 
decreases sharply with increasing age. Similar findings are reported for other countries (14,15). 
This is evidence of the phenomenon of waning immunity after natural infection in the absence of 
boosting. 
In specific orthodox reformed groups that refuse vaccination and that include many children and 
adults without detectable diphtheria antitoxin antibodies, the immunity level resembles the 
situation of great susceptibility in children and adults in the former Soviet Union. 
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The implications of these findings for public health and research depend on the risk of diphtheria 
spreading in the general population and among orthodox reformed individuals. 
No link was established between two cases reported in the Netherlands since 1991 and Eastern 
Europe. Cases of diphtheria imported from the Newly Independent States have been reported in 
some other European countries (16). No secondary cases were reported following these imported 
cases (16). It was reported that the disease has become rare in the United States, and no 
outbreaks from secondary transmission were observed (17). Another favourable factor might be 
that the basic reproduction number of diphtheria (a measure of maximum transmissibility of the 
pathogen in a population) is smaller than that of other childhood diseases (18). This implies that 
the critical number of susceptible people required for spread of diphtheria is relatively large. 
These observations are reassuring and suggest that the diphtheria immunity in the population of 
the Netherlands, as well as other countries, will suffice, despite the lack of antibodies in a large 
number of adults. 
An outbreak of diphtheria in Mongola, affecting older children and young adults, is suspected to 
be a result of imported index cases (12,16). Two cases of diphtheria were diagnosed in one family 
in Denmark in 1998 (19). One of the patients was unvaccinated, while the other had likely 
received three vaccinations. Neither the patients, the family members, nor close contacts had a 
history of travel. It is suggested that one of the patients died of diphtheria, although it is not 
known how she became infected. Enhanced surveillance of patients with upper respiratory 
symptoms in a Northern Plains community in the United States strongly suggests long-term 
persistence of toxigenic C. diphtheriae in this region (20). These observations should alert us, 
although, or perhaps because, their meaning remains uncertain. 
Such observations show the relevance of studying whether adults with low or undetectable 
antibody levels are sufficiently protected. Insight into the protection of these individuals could be 
obtained by offering diphtheria vaccination and by studying whether these individuals show an 
adequate (memory) response. Like others, our results indicate a good memory response after 
revaccination (21,22). However, the (memory) response to initial vaccination of adults whose 
naturally acquired antibodies have waned is unknown. If a large proportion of adults without 
detectable antibodies show a good memory response, it is likely that an adequate response will 
also occur after contact with C. diphtheriae. The National Health Council recommends studying 
the feasibility of vaccinating all adults with DT-IPV, but, at present, this has not been done (23). 
Considering the great susceptibility in both children and adults among orthodox reformed groups 
and their sociogeographic clustering, there seems to be a real potential risk of spreading C. 
diphtheriae in these groups after the introduction of the bacterium (24). Lack of herd immunity 
resulted in a few outbreaks of poliomyelitis in these orthodox reformed groups (25). It is unclear 
why - fortunately - these groups have remained free of diphtheria.. Acceptance of vaccination in 
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Many factors involved in the occurrence of diphtheria remain obscure. Mathematical modelling 
may provide a little bit more insight into situations in which diphtheria cases can be expected. The 
role of susceptibility of children in addition to that of adults and the amount of import needed for 
spreading C. diphtheriae come to mind here. The standardised data on diphtheria antitoxin 
antibodies in various European countries in the European Sero-Epidemiology Network might be 
useful in this regard to compare countries with different immunity levels (27). 
Tetanus 
Tetanus is unique among the vaccine-preventable infectious diseases in that it is not 
communicable. It cannot be eradicated as a result of the ubiquity of spores in the environment. 
Furthermore, the resulting absence of herd immunity means that every unvaccinated individual is 
at risk of tetanus. 
Our surveillance data show that about two or three cases of tetanus (0.16 per 1,000,000) have 
been reported each year in the Netherlands during the last two decades; an incidence similar to 
that in the United States (10,28). In the Netherlands almost all of these patients were born before 
1945, which was before the introduction of vaccination. These surveillance data, together with the 
results of our study on tetanus antitoxin antibodies, show that the occurrence of tetanus is closely 
associated with the tetanus antitoxin antibody level in the population. Almost all the individuals 
without detectable antibodies were aged 50 years or more; in other words they were born before 
1945. 
The prevalence of tetanus antitoxin antibodies among individuals eligible for mass vaccination 
(those born after 1945) was very large. Antibody levels remain high for at least 20 years after 
complete vaccination in the National Immunisation Programme, but probably much longer. This 
implies that tetanus vaccine induces excellent protection. 
These findings imply that in the case of an injury prescribing revaccination 5 years after previous 
vaccination in accordance with the guidelines of the World Health Organization instead of 1 year 
after previous vaccination - the current policy in the Netherlands - seems appropriate. 
Furthermore, offering a primary tetanus vaccination to unvaccinated individuals born before the 
introduction of vaccination is probably more effective in preventing tetanus than routine 
revaccination. Vaccination of these groups might be most efficient combined with other vaccines 
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these groups is not likely to improve considerably in near future. Although there are no signs of 
persistent circulation of toxigenic C. diphtheriae in our country, it would be worthwhile to assess 
this systematically for these unvaccinated orthodox reformed groups who are sociogeographically 
clustered. Specific media are needed for C. diphtheriae isolation; they are not routinely used 
unless the laboratory concerned is alerted that diphtheria is suspected (26). 
General discussion 
(e.g. diphtheria). Incorporation in the regular influenza vaccination programme is a relevant 
option that could be studied. 
To monitor the effect of such a scenario, information on the number of tetanus cases should be 
obtained. Reliable information on the number of tetanus cases has been obtained by the 
notification system until the present time. However, recently, notification of tetanus is no longer 
obligatory by law. Information on hospital admissions for tetanus has been shown to be invalid, 
probably due to misclassification of the diagnosis 'tetani' (10). As a result of lack of notification 
data on tetanus and since most cases of tetanus are diagnosed by the clinical symptoms and are 
not laboratory confirmed, an effort has to be made to make the surveillance of hospital admissions 
for tetanus more reliable. With a view to the small number of tetanus cases (but also of other 
vaccine-preventable diseases such as diphtheria) a strong appeal is made to physicians to 
recognize the clinical symptoms of a disease they have not seen before. Regular attention to the 
disease and the clinical symptoms in professional journals is helpful in this respect (26,29). 
In developing countries, neonatal tetanus is still a serious problem. The World Health 
Organization estimates that the global number of neonatal tetanus deaths decreased from 408,000 
in 1990 to 248,000 in 1997 (30). It is the second leading cause of death from vaccine-preventable 
diseases among children worldwide. The current goal is to eliminate neonatal tetanus (less than 1 
case per 1000 live births) by the year 2000. Our study shows that tetanus vaccination gives very 
good protection, which indicates that the effectiveness of the vaccine is not the restrictive factor. 
However, since tetanus cannot be eradicated, continuous efforts have to be made to control this 
severe disease. 
Poliomyelitis 
In 1988, the goal of global poliomyelitis eradication by the year 2000 was adopted by the World 
Health Assembly (31). Eradication of poliomyelitis was considered feasible after the eradication of 
smallpox, one of the greatest public health achievements of all time (32). However, the differences 
between smallpox and poliomyelitis are great. Unlike smallpox, most infections with poliovirus 
are asymptomatic, and no sign is visible after infection or vaccination (33). Smallpox virus is less 
able to spread from person to person than poliovirus (34). However, the facts that humans are the 
only natural host of poliovirus, no long-term poliovirus carriers exist and the availability of 
effective vaccines (oral polio vaccine and inactivated polio vaccine) provide favourable conditions 
for eradication (33). 
Great progress has been made towards eradication. Since the start of the initiative 10 years ago, 
the number of reported cases have fallen worldwide from more than 35,000 in 1989 to about 
4000 in 1997. The Americas, are completely free of polio, and two other regions, the Western 
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Pacific and Europe, are close to being free (35-37). However, a recent outbreak of poliovirus type 
3 in Angola clearly shows that the goal has not yet been achieved (38). 
In the Netherlands, the last poliomyelitis cases occurred in an outbreak in the years 1992-1993 
among orthodox reformed individuals, affecting 71 persons (10,25). No cases have been reported 
since then, and the surveillance of acute flaccid paralysis has brought no cases of poliomyelitis to 
light (10,39). 
The results of our study on poliomyelitis immunity in the Netherlands show that all age groups are 
very well protected against poliomyelitis. Immunity seems to wane very little, after natural 
infection. This is more advantageous than diphtheria immunity; diphtheria antitoxin antibodies 
have decline in cohorts born before the introduction of vaccination. 
Vaccination with inactivated polio vaccine seem to induce as many antibodies as natural infection. 
Again, this is more beneficial than the case for some other vaccine-preventable diseases. For 
example, vaccinated individuals were found to have fewer antibodies against measles and rubella 
than individuals with naturally acquired immunity. This may be one of the problems in measles 
elimination (40). For rubella, this may lead to an increased risk of congenital rubella syndrome 
when childbearing women must rely on vaccine-induced immunity obtained in childhood. 
Unfortunately, the poliomyelitis immunity in sociogeographically clustered orthodox reformed 
individuals was much less favourable. Herd immunity in these groups might again turn out to be 
insufficient. Our results indicate that about half of the orthodox reformed individuals were 
infected during the outbreaks of 1978 and 1992-1993. This shows considerable spread of the 
virus among these groups, but since many individuals were not infected, hygiene measures might 
have had some effect in preventing the spread. 
No poliomyelitis cases occurred outside the orthodox reformed groups during the outbreaks in 
the periods 1978 and 1992-1993. Although it had been shown that individuals vaccinated with 
inactivated polio vaccine could be re-infected with poliovirus, the herd immunity in the population 
was sufficient to prevent polio circulation outside the orthodox reformed groups (41). Lack of 
poliovirus circulation was indicated by the comparison of the seroprofiles for those born before 
and after the poliomyelitis outbreaks in the periods 1978 and 1992-1993. 
Currently, the effect of challenge of oral polio vaccine Give attenuated virus) in elderly individuals 
is being studied. This will provide more evidence for the potential for poliovirus circulation in 
individuals vaccinated with inactivated polio vaccine (dead virus) and into the memory response 
of seronegative elderly persons. Information from this study can be used in mathematical 
modelling to determine how and when to stop polio vaccination in strategies for poliovirus 
eradication. 
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The implications of our results for the gaps in immunity of poliomyelitis, but also for diphtheria 
and tetanus, among orthodox reformed groups are limited. Mandatory vaccination is not 
considered an option, partly because this could result in a paradoxical effect of lower vaccination 
coverage in general. Moreover, changing the vaccine strategy from inactivated polio vaccine to 
oral polio vaccine is not recommended. Not only the risk of vaccine-associated paralytic 
poliomyelitis, but also the chance of infection of unvaccinated individuals is considered a 
disadvantage (42). A slight increase of vaccination coverage was observed for DT(P)-IPV in the 
province of Zeeland in cohorts born in the period 1991 to 1994, where many orthodox reformed 
individuals live (43). This increase was thought to be the result of greater acceptance of DT(P)-
IPV of orthodox reformed individuals after the poliomyelitis outbreaks. Despite the secularisation 
in the Netherlands, no indications have been found that orthodox reformed individuals are less 
strict in refusing vaccination in general. Therefore, the effect is expected to be temporary. No 
further increase of the vaccination coverage was observed in cohorts born in 1995. Perhaps the 
initiative of offering vaccination to unvaccinated 16-year-olds, irrespectively of the reason for 
being unvaccinated, will have a beneficial effect on the vaccination coverage in this group (44). 
Furthermore, hygiene measures as recommended in the handbook "Care of poliomyelitis" and 
monitoring of polioviras in sewage of schools with large numbers of orthodox reformed 
individuals might limit the spread of polioviras when circulation occurs (42,45). 
The findings of excellent protection after vaccination and the presence of herd immunity in the 
general population during outbreaks in orthodox reformed groups are important in view of the 
global initiative for polio eradication. The Netherlands is one of the few countries in which 
inactivated polio vaccine has been included in the vaccination programme from the beginning. 
Most other countries use oral polio vaccine, and oral polio vaccine strains may continue to 
circulate. Before a region can be certified 'polio free', the World Health Organization demands 
the documented absence of wild type poliovirus in the population or its sewage. However, small 
amounts of wild type poliovirus are difficult to detect, particularly when circulation of oral polio 
vaccine strains occur (45). 
Furthermore, vaccine-associated poliomyelitis cases will continue to occur. This could not only be 
disadvantageous for the patients involved, but also for the acceptance of vaccination in general. In 
the absence of circulation of wild poliovirus, such as in the United States, these are the only 
poliomyelitis cases occurring (46). Antivaccine media attention has grown, and vaccine-associated 
poliomyelitis has been a major issue (46). A decline in vaccination coverage is also very harmful 
for other vaccine-preventable diseases, such as is shown for pertussis and diphtheria (12,47). 
The Dutch experience with long-term use of inactivated polio vaccine shows that the vaccine 
induces excellent protection. For all these reasons switching from oral polio vaccine to inactivated 
polio vaccine in the late stages of polio eradication might be advisable. It is now recommended 
that children receive IPV for the first two doses in the United States. Either IPV or OPV can be 
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administered for the third and fourth doses (48). An "JTV alone" policy will be implemented in 
2000. 
Pertussis 
As for diphtheria, tetanus and poliomyelitis, more than 40 years of experience with pertussis 
vaccination exists. While the first three diseases have virtually been eliminated in the Netherlands, 
more effective control of pertussis is warranted. This is exemplified by the unexpected pertussis 
outbreak in the Netherlands in the period 1996-1997, which is reported in this thesis (Chapters 7 
and 8). A resurgence of pertussis has also been reported in other countries such as the United 
States and Canada (49,50). 
We have shown that changes in case definition and diagnostic practice may result in a greater 
number of reported pertussis cases. However, neither these changes, nor changes in vaccination 
coverage and vaccine quality, can explain the increased incidence of pertussis. 
Two other factors, waning immunity and a change in B. pertussis strains, might play a role in the 
resurgence of pertussis. Following a discussion of their possible contributions some implications 
for vaccination strategy are discussed. 
Data indicate that neither childhood immunisation nor infection provides long-term immunity 
against B. pertussis. Evidence is increasing that older children and adults are major reservoirs of 
infection due to waning immunity (51). It has been shown that these people play an important role 
in the transmission of infection to unvaccinated young infants, in which pertussis is most severe. 
Pertussis in adults and older children was often overlooked, since the illness is often atypical and 
diagnosis is difficult. Diagnosis is initiated later in the disease, when cultures are unlikely to be 
positive (51). At this stage, serodiagnosis on a single serum sample facilitates the diagnosis of 
pertussis. We have found that high IgG-PT concentrations in a single serum sample are a specific 
and sensitive tool in pertussis diagnosis. Furthermore, our serological data show that detection of 
high IgG-PT levels in a single serum sample could confirm an increased number of pertussis cases, 
particularly for older age groups (Chapter 9). General practitioners and paediatricians should be 
on the alert, not only for the occurrence of pertussis in older (vaccinated) children and adults, but 
also for the possibility of confirming the diagnosis with one-point serology. 
The decrease in vaccine efficacy observed in our surveillance data reflects at least a partly true 
decrease. We postulate that the increased incidence in the Netherlands might partially be caused 
by a mismatch between the vaccine strains and circulating strains of B. pertussis. The rather 
abrupt increase in the proportion of vaccinated patients of a wide age range. 
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A shift has occurred in the population structure of B. pertussis, and antigenic variants of pertactin 
and pertussis toxin of B. pertussis have emerged. They are distinct from the strains incorporated 
in the Dutch whole-cell vaccine (52-54). The analysis of strains from vaccinated and unvaccinated 
individuals indicated that the whole-cell vaccine protects better against strains with the vaccine 
type of pertactin than against strains with nonvaccine types (54). The role of pertactin in 
protection is indicated by a greater protection of a three-component acellular vaccine with 
pertactin (and PT and FHA) than of a two-component acellular vaccine (PT and FHA) in a 
Swedish trial (55). Furthermore, protection against clinical pertussis was found to be associated 
with pertactin antibodies (56,57). 
The vulnerability of the population to antigenic changes in B. pertussis might be enhanced due to 
the small immunogenicity profile of the Dutch whole-cell vaccine (the vaccine induces low levels 
of IgG-PT). In response to the 1996-1997 outbreak, the amount of pertussis toxin in the vaccine 
was somewhat enhanced in November 1997. 
Waning immunity indicates the need for booster vaccinations. Whole-cell vaccine was precluded 
from boosters because of the side effects. In response, modern acellular pertussis vaccines that are 
less reactogenic have been developed. The decisions on age at the time of boosting and on the 
type of vaccine (acellular or whole-cell) should be made carefully. 
Our surveillance data show that cases from all ages were reported. The greatest incidence of 
pertussis, according to serological data and notification data, occurred at 4 years of age. Data on 
hospital admissions show a peak for infants less than 1 year old. Active surveillance of 
hospitalised children by paediatricians was started in 1997, and it has confirmed that pertussis is 
most severe among infants, who are too young to be vaccinated (less than 3 months of age) (7). 
The protection of these vulnerable infants has been the most important reason for pertussis 
vaccination. However, the paediatric surveillance and a study of the symptoms of reported cases 
shows that typical pertussis also occurs among vaccinated children, although very severe disease 
with complications is unlikely (7). Improving the protection of these children seems warranted. 
On the short term, a booster in childhood is expected to prevent (vaccinated) children from 
becoming ill. It is also expected to prevent the disease among young infants by reducing the force 
of the infection. In response to the outbreak in the period 1996-1997 in the Netherlands, the 
National Health Council recommended a study of the effect of a booster vaccination at the age of 
4 years (58). However, since the peak incidence occurred at the age of 4 years, a booster dose at 
an earlier age may be more effective. 
The long-term epidemiological effect of a booster dose in childhood is unclear. If it postpones 
infection with B. pertussis to adult age, this might lead to a greater probability of transmission to 
young infants. Even with the advanced vaccination schedule that has been put into effect in 1999 
(2, 3. 4 and 11 months instead of 3, 4, 5 and 11 months), the young infants can only be protected 
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by herd immunity. Maternal immunisation in pregnancy - if it were feasible - would probably be 
the most effective way of preventing pertussis among the youngest cind most vulnerable infants 
(59). Similarly, maternal tetanus vaccination has been shown to be very effective in preventing 
neonatal tetanus. 
The National Health Council recommends the use of an acellular vaccine for the booster dose 
(58). It is questionable whether the current acellular vaccines are the best choice for booster 
vaccination. Most of these acellular vaccines do not contain the antigenic variant of pertactin and 
pertussis toxin that dominates in the Netherlands. Regularly adapting the vaccines to circulating 
strains, as is done each year for influenza, might solve such a problem. 
However, acellular vaccine contains a limited number of components. When the change in a 
component is only a marker for the true immunological change elsewhere in the bacterium, 
adaptation of the whole-cell vaccine that contains whole dead bacteria might be more effective. 
However, to maintain the wide acceptance of vaccination by the population, the adverse events 
that occur when a booster with whole-cell vaccine is given, should be reduced. 
It is likely that a decision will soon be made on the booster dose in childhood. To study the short 
and long-term epidemiological effects of a such booster dose, routine surveillance should be 
continued. As described previously, this will be more complicated because of the decentralization 
of serology and the change in the law regarding notification. More insight into the major 
reservoirs of B. pertussis infection, particularly for young infants must be obtained. These 
reservoirs may change after the introduction of booster vaccination. The IgG-PT distribution in 
the general population (Chapter 9) in relation to the decline in IgG-PT antibody levels after 
infection makes it possible to study the frequency of B. pertussis infections in various age groups. 
The IgG-PT distribution suggests that B. pertussis infections occur frequently. This is exemplified 
by the increase in IgG-PT from 4 years of age onwards. The constant IgG-PT level for individuals 
15 years old and older suggests that the increases in IgG-PT in infected individuals is in balance 
with the following decline in IgG-PT in other individuals. Differences in IgG-PT distributions in 
various European countries as collected in the European Sero-Epidemiology Network might be 
helpful in understanding the epidemiology of pertussis (27). 
Furthermore, transmission studies should be directed to potential sources of infection for young 
infants. In this way, information can be obtained for more effective control of pertussis. 
General conclusions 
The studies in this thesis confirm the great success of the vaccination programme in the 
Netherlands. The challenge is, first of all, to preserve and enhance this progress by sustaining high 
acceptance of vaccination in childhood. As a result of the enormously decreased incidence of 
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vaccine-preventable diseases, the benefits of immunisation might gain less attention, and the focus 
might turn to real and perceived risks of vaccination. Therefore, it is extremely important to 
maintain the trust in vaccinations. For vaccines that give suboptimal, but still very good, 
protection, such as that for pertussis, this might be even more difficult. Physicians are 
inexperienced with the diseases as a result of low incidence and have to rely on education alone. 
They should be aware of the continuous need for vaccination and pay attention to giving good 
information to parents. 
Furthermore, our studies show that we have to anticipate some long-term effects of mass 
vaccination. As a result of decreased circulation of the pathogens, gaps in immunity to diphtheria 
and poliomyelitis among orthodox reformed individuals were observed. A waning of natural-
acquired antitoxin antibodies against diphtheria as a result of lack of boosting is shown. 
Inadequate levels of tetanus vaccination resulted in susceptibility of adults born after the 
introduction of vaccination and explain why most tetanus cases occur in these unvaccinated 
cohorts. In contrast to diphtheria antibodies, poliovirus antibodies did not wane or wane very 
little, after vaccination and natural infection. Waning pertussis immunity after infection and 
vaccination was reflected in the data on surveillance and seroepidemiology of pertussis. The 
pertussis data support the hypothesis of a mismatch of vaccine strains with the circulating strains, 
which might have occurred as a result of long-term pertussis vaccination. 
These findings imply a need to adapt future vaccination strategies. They could prove relevant for 
countries and vaccine-preventable diseases outside the scope of this thesis. 
We conclude that vaccination for diphtheria, tetanus and pertussis must no longer be directed only 
towards children, but also towards adults. The increased number of elderly people in general 
stresses the need for a more common practice of adult vaccination. The feasibility and positive 
effects are exemplified by the influenza programme directed towards individuals aged 65 years 
and older, which is carried out by general practitioners. 
The Dutch experience of excellent immunity after vaccination with inactivated polio vaccine is an 
example where other countries can partly draw on to decide on change in vaccination strategy. 
Particularly when randomised controlled trials are not feasible, for example due to very great 
vaccination coverage, this may prove efficient. 
Adaptation of vaccines to circulating strains that might be useful for pertussis immunisation, has 
already been proven effective for influenza. 
The results of the studies in this thesis clearly show the role of seroepidemiology and surveillance 
in the evaluation and success of the National Immunisation Programme. Epidemiological studies 
to assess disease incidence and the immunity of the population will have to continue to evaluate 
the (long-term) epidemiological effects of the existing vaccines and new vaccines. 
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Summary 
Vaccination has been one of the most effective interventions in public health. However, despite 
great successes, even in a country with high vaccination coverage like the Netherlands, epidemics 
of some vaccine-preventable diseases still occur, and re-emergence of others is possible. The 
success of a vaccination programme can be improved by continuous evaluation after the licensing 
of a vaccine. Epidemiological methods play an important role in this evaluation to assess, the 
disease incidence and the immunity of the population, in addition to the safety of the vaccine and 
vaccine coverage. 
Reduction in disease incidence achieved after a vaccine has been introduced is the best measure of 
the success of a programme. With fewer cases as a result of an effective programme, the role of 
serological surveillance becomes more evident. Assessment of specific antibodies offers an 
opportunity to identify groups with little immunity that might require changes in vaccination 
strategy to prevent (re)emergence of disease. 
In this thesis, several aspects of surveillance as part of the evaluation of the Netherlands 
immunisation programme were described. These aspects include both disease surveillance (of 
pertussis) and immunosurveillance (of diphtheria, tetanus and poliomyelitis). Furthermore, the 
possibilities of improving pertussis serodiagnosis were studied. The aim was to find a more 
sensitive diagnostic tool for patient and laboratory surveillance. 
The results are mainly based on two studies. In the first study, a population-based serum bank was 
established by collecting sera from the general population and from orthodox reformed groups 
refusing vaccination. In the second study, data on the number of pertussis patients from various 
surveillance sources were analyzed. 
Immunosurveillance is one of the tools for studying the change in epidemiologic dynamics of 
infectious diseases as a result of mass vaccination (Chapter 2). The weaker force of infection can 
result in an increase of the mean age at the time of infection and a lack of boosting opportunities 
of both natural and vaccine-induced immunity. Clustering of unvaccinated individuals might lead 
to gaps in immunity in these groups. Herd immunity might break down, and epidemics can occur 
as a result. In the Netherlands, this could happen to orthodox reformed groups who reject 
vaccination on religious grounds and are sociogeographically clustered. 
In order to estimate the immunity of the Dutch population, a population-based serum bank was 
established in the period 1995-1996. In a nationwide sampling, 8359 sera were collected 
(response rate 55%), and in a sample from municipalities with low vaccine coverage 1589 sera 
(response rate 52.5%) were collected. The sera from the latter sample were collected to gain 
access to orthodox reformed individuals refusing vaccination. In contrast to collecting residual 
sera from laboratories, this approach provided an opportunity for collecting extensive information 
on determinants of the immune status by means of a questionnaire. 
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To identify groups with little immunity, specific antibodies to diphtheria, tetanus and poliomyelitis 
that correlate with protection were assessed for individuals from the nationwide sample and from 
the low vaccine coverage sample that included orthodox reformed individuals. 
Diphtheria antitoxin and tetanus antitoxin antibodies were measured in a toxin inhibition assay 
(Chapters 4 and 5). Neutralising antibodies against poliovirus types 1, 2 and 3 were measured in 
the neutralisation assay (Chapter 6). The effects of differential response of variables available for 
both participants and nonparticipants (Chapter 3) on population estimates for both the 
nationwide sample and the low vaccine coverage sample amounted to less than one standard 
error. They were therefore ignored. 
In the nationwide sample, 58% had diphtheria antitoxin levels of at least 0.1 IU/ml; 30%, between 
0.01 and 0.1 IU/ml; and 12%, less than 0.01 IU/ml. In this sample, 72.5% had tetanus antitoxin 
antibodies of at least 0.01 IU/ml, 14% between 0.01 and 0.1 IU/ml and 14% of less than 0.01 
IU/ml. Neutralising antibodies (titre at least 1:8) against poliovirus types 1, 2, and 3 were 
measured in 97%, 93% and 90% of all individuals, respectively. 
The age-specific prevalence of diphtheria antitoxin antibodies (> 0.01 IU/ml), of tetanus antitoxin 
antibodies (> 0.01 IU/ml) and of neutralising antibodies against poliovirus types 1 and 2 (> 1:8) in 
our nationwide sample was greater than 92.5% for individuals younger than 45 years. These 
individuals were born after the introduction of mass vaccination. For poliovirus type 3, the 
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Information from both participants and nonparticipants was used to identify characteristics of 
individuals associated with (non)participation in our population-based serum collection (Chapter 
3). Five groups were distinguished: 7904 initial participants who gave blood and completed the 
questionnaire, 455 additional participants who gave blood during extra opening hours and 
completed the questionnaire, 1618 nonparticipants who completed the questionnaire, 1053 
nonparticipants who completed a nonresponse questionnaire, and 4159 absolute nonparticipants 
for whom only data from the municipal registry was available. In dichotomous and polytomous 
logistic regression, the following variables were associated with (non)participation: age group, 
gender, marital status, nationality, kind of reminder, and degree of urbanisation. Some variables 
affected each form of (non)participation differently. E.g., comparing nonparticipants who 
completed the questionnaire with initial participants yielded an odds ratio of 3.5 for boys 0-4 year 
olds compared to men 30-64 years old, while the odds ratio was 0.5 comparing absolute 
nonparticipants with initial participants. Other variables affected each form similarly. E.g., 
comparing additional participants with initial participants, or each of the different forms of 
nonparticipation groups with initial participants yielded odds ratios for unmarried individuals 
compared to married individuals of about 1.5. 
We concluded that investigators have to be aware that including additional participants might not 
always reduce nonparticipation selection and that studying only a subgroup of nonparticipants 
might lead to biased insight into nonparticipation selection. 
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prevalence of neutralising antibodies was greater than 90% for younger than 30 years and greater 
than 80% for 30 to 44-year-olds. 
The antitoxin antibody levels for diphtheria and tetanus decreased sharply after 44 years of age, 
i.e. for those born before the introduction of vaccination. More than 50% of the 70 to 79-year-
olds had diphtheria and/or tetanus antitoxin antibody levels below 0.01 IU/ml. For poliomyelitis, 
the prevalence of neutralising antibodies for all three types remained at 80% or more in the older 
age groups. 
For individuals aged 10 to 34 years who were completely vaccinated according to the National 
Immunisation Programme standards (i.e. at the ages of 3, 4, 5, and 11 months, 4 and 9 years), the 
geometric mean titres decreased with increasing age. However, the prevalence of antibodies in 
this subgroup was still more than 98% for diphtheria antitoxin levels, for tetanus antitoxin levels 
of at least 0.01 IU/ml and for neutralising antibodies of poliovirus types 1 and 2. It was at least 
94% for poliovirus type 3. The decline in geometric mean titres with age was similar for 
diphtheria antitoxin antibodies and tetanus antitoxin antibodies. Since the geometric mean titres 
were higher for tetanus than for diphtheria for recently completely vaccinated 10 to 14-year-olds, 
the tetanus antitoxin antibody levels were higher for 30 to 34-year-olds than the levels for 
diphtheria. The geometric mean titre for poliomyelitis decreased only slightly with increasing age. 
For all three diseases, the geometric mean titres for those individuals aged 20 to 34 years with 
evidence of revaccination were comparable to the titres of 10 to 14-year-olds who were 
completely vaccinated, but without evidence of revaccination. 
Only 40% of the orthodox reformed persons had diphtheria and/or tetanus antitoxin antibodies of 
at least 0.01 IU/ml, while 65%, 59% and 69% had neutralising antibodies against poliovirus type 
1, 2 or 3, respectively. The seroprofiles of orthodox reformed participants, but not of other 
participants, showed an effect of recent poliomyelitis outbreaks. 
We concluded that the Dutch immunisation programme induced long-term diphtheria, tetanus and 
poliomyelitis immunity. While adults are very well protected against poliomyelitis, a great number 
of adults lack diphtheria or tetanus antitoxin antibodies. These adults might benefit from 
diphtheria (re)vaccination; however, with the prevention of tetanus in mind, offering a primary 
tetanus vaccination to cohorts born before the introduction of vaccination would probably be 
more effective than routine revaccination. Introduction of Corynebacterium diphtheriae or 
poliovirus in sociogeographically clustered orthodox reformed groups might constitute a 
substantial danger of spreading of these pathogens. Since the Netherlands pursues non-mandatory 
vaccination, global eradication such as envisioned for poliovirus, is the only way to protect these 
orthodox reformed groups. 
While diphtheria, tetanus and poliomyelitis have virtually been eliminated from the Netherlands, 
better control for pertussis is warranted. Pertussis remains endemic, and epidemic peaks occur. 
Surveillance data of pertussis were analysed to obtain insight into the occurrence of pertussis and 
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possible factors involved in its re-emergence (Chapters 7 and 8). Besides notification data from 
1989 to 1996 (Chapter 7), data from positive serodiagnosis, hospital admissions and deaths were 
collected for 1997 and earlier years (Chapter 8). In the period 1996-1997, a sudden increase in 
the number of pertussis cases was observed from notifications, positive two-point serology, 
positive one-point serology and hospital admissions. Comparing the average annual incidence in 
the period 1989 to 1995, the incidence in 1996 increased 12-fold according to notifications (2.3 
versus 27.3 per 100,000), 6-fold according to cases with positive two-point serology (2.1 versus 
12.2), 6-fold according to positive one-point serology (8.2 versus 50.7) and 3-fold according to 
hospital admissions (1.2 versus 3.3). Both in the period 1989 to 1995 and in 1996, two deaths 
were reported. 
In 1996, according to notifications and serology data, the increase in pertussis incidence among 
(mostly unvaccinated) children less than 1 year of age was similar to the increase in hospital 
admissions. In older, mostly vaccinated, individuals, the increase of hospital admissions was 
relatively small. The increase of reported cases of vaccinated individuals of all ages was larger 
than that among unvaccinated individuals. The relatively greater increase in reported cases for 
vaccinated patients than for unvaccinated patients has already begun in 1994 and 1995, that is, 
before the sharp increase in the overall number of cases. The proportion of reported cases with 
positive two-point serology increased from 24% in 1993 to 42-43% in 1996 and 1997. For 
positive one-point serology, a sharp increase occurred in the proportion that was reported; from 
6% in 1993 to 29% in 1997. This increase in the notification rate and the greater number of cases 
reported with positive one-point serology could not explain the sudden rise in pertussis cases. We 
conclude that the increased incidence, as well as the decrease in vaccine efficacy, reflected a partly 
real change. Furthermore, due to a mismatch between the vaccine strain and circulating 
Bordetella pertussis strains, we postulate that the proportion of pertussis infections resulting in 
recognizable symptoms has increased among vaccinated individuals. Perhaps the small 
immunogenicity profile of the Dutch vaccine has resulted in greater vulnerability of the population 
to antigenic B. pertussis changes. 
Laboratory confirmation of pertussis by culture, polymerase chain reaction (PCR), or detection of 
antibody increase in paired sera is hampered by low sensitivity. Therefore, we investigated 
whether, and at which level, concentrations of IgG antibodies against pertussis toxin (IgG-PT) in 
a single serum sample are indicative of actual or recent pertussis (Chapter 9). IgG-PT, measured 
by ELISA in U per millilitre (ml), was analysed in 7756 population-based sera, in sera of 3491 
patients with at least a fourfold increase of IgG-PT, in paired sera of 89 patients with positive 
cultures and/or PCRs, and in sera of 57 patients with clinically documented pertussis with a 
median follow-up of 1.4 years. Levels of IgG-PT of at least 100 U/ml were present in less than 
1 % of the participants in the population-based study. In other words, this gives a specificity of 
99% for positive one-point serology based on this cut-off level. Such levels were present in more 
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than 80% of the sera of patients with clinical pertussis symptoms with at least a fourfold increase 
in IgG-PT in paired sera. The follow-up sera of patients with clinically documented pertussis 
showed that the IgG-PT level had decreased below 100 U/ml in more than 80% of the patients 
within 1 year after the onset of symptoms. The sensitivity of an IgG-PT level of at least 100 U/ml 
amounted to 76% in patients with positive pertussis PCR or culture. The number of patients with 
IgG-PT levels of at least 100 U/ml in a first serum sample in the sérodiagnostic database was 
more than four times greater than the number of patients with positive two-point serology. This 
varied from onefold for 0 to 5-month-olds to 14-fold for individuals aged 15 years or more. 
We conclude that, IgG-PT levels of at least 100 U/ml are a specific and sensitive tool for 
diagnosing a recent or actual B. pertussis infection. Diagnosis on the basis of a single serum 
sample could particularly facilitate the pertussis diagnosis in older children and adults because 
laboratory testing for these children and adults is initiated at a later stage of the disease. 
Therefore, this tool is helpful, not only for the individual patient, but also for epidemiological 
studies. 
In the general discussion (Chapter 10), the methodological issues of selective participation, the 
age-versus-cohort effect and the validity of vaccination status for interpreting the results of the 
population-based studies, are discussed. Regarding the interpretation of pertussis surveillance 
data, validity of notification data and vaccine efficacy with the screening method were described. 
For the study on IgG-PT levels in single serum samples as a diagnostic tool in pertussis, 
methodological issues such as the validity of using IgG-PT levels of patients with at least a 
fourfold increase in titre as characteristic for reconvalenscence sera were discussed. 
Implications for public health and research of the study findings were discussed with regard to 
potential progress in (maintaining) control of the diseases. The diphtheria epidemic in the former 
Soviet Union has shown that this disease can make a comeback in susceptible populations. The 
lack of diphtheria antitoxin antibodies in many adults as a result of waning immunity implies the 
need to study the (memory) response of adults who have low or undetectable antibody levels. 
Such a study would resolve the question whether people have sufficient immunity after exposure 
to C. diphtheriae. Tetanus vaccination induces excellent immunity, showing that prevention of 
tetanus could be made possible by directing vaccination to unvaccinated individuals. Primary 
vaccination of unvaccinated adults born before the introduction of mass vaccination seems to be 
the most effective method. 
The Dutch experience with long-term use of inactivated polio vaccine shows that the vaccine 
induces excellent protection, as well as the ability to maintain herd immunity. Therefore, to 
prevent vaccine-associated poliomyelitis, changing from oral polio vaccine to inactivated polio 
vaccine might be advisable in the late stages of global poliovirus eradication. 
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Potential interventions with respect to gaps in diphtheria, poliomyelitis and tetanus immunity 
among orthodox reformed groups are limited. Monitoring the occurrence of the circulation of the 
pathogens, would detect (re)emergence of the diseases as early as possible. 
Progress towards better control of pertussis could be made by implementing booster vaccination 
after infant vaccination. Adaptation of such a vaccine to circulating strains might also be effective. 
Both the choice of the most appropriate vaccine and the age of boosting are complicated as a 
result of lack of insight into long-term effects on the pertussis epidemiology. Not only surveillance 
data, but also data on the major reservoirs for infection, particularly for unvaccinated young 
infants, are needed to monitor the effect on pertussis epidemiology. 
In general, our results show that the high degree of acceptance of vaccination for children should 
be sustained, and that vaccination should also be directed towards adults. Adaptation of vaccines 
to circulating strains might be useful for pertussis, as has already been proven effective for 
influenza. 
In order to monitor changes in epidemiology of vaccine-preventable diseases after vaccination, 
epidemiological studies such as the ones described in this thesis will have to be repeated 
periodically in order to improve the success of (new) vaccination programmes. 
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Samenvatting 
Vaccinatie is een van de meest effectieve intervenues bij het bevorderen van de volksgezondheid. 
Toch komen nog steeds epidemieën voor van ziekten waartegen gevaccineerd wordt, zelfs in een 
land met een hoge vaccinatiegraad zoals Nederland. Ook is het niet uitgesloten dat andere ziekten 
waartegen gevaccineerd wordt weer zullen gaan optreden. Het succès van een vaccinatie 
programma kan worden verbeterd door continue evaluatie na introductie van een vaccin. 
Epidemiologische methoden speien hierbij een belangrijke rol; niet alleen om de veiligheid van een 
vaccin en de vaccinatiegraad vast te stellen, maar ook om de incidentie van de ziekte en 
immuniteit in de bevolking te bepalen. 
Het succès van een programma na introductie van een vaccin kan goed worden aangetoond door 
het vaststellen van een daling van de ziekte waartegen wordt gevaccineerd. Wanneer door een 
effectief programma het aantal ziektegevallen is verminderd, wordt de rol van serologische 
surveillance duidelijker. Door het bepalen van specifieke antistoffen kunnen groepen met lagere 
immuniteit worden opgespoord. Op grond hiervan kunnen veranderingen in vaccinatiestrategie 
noodzakelijk blijken om het (weer) optreden van de ziekte te voorkomen. 
In dit proefschrift zijn diverse aspecten van surveillance als onderdeel van de evaluatie van het 
Nederlandse vaccinatieprogramma beschreven. Deze betreffen zowel surveillance van ziekte (ten 
gevolge van kinkhoest) als immunosurveillance (van difterie, tetanus en poliomyelitis). Ook werd 
onderzocht of serodiagnostiek van kinkhoest kon worden verbeterd. Een sensitievere diagnostiek 
méthode voor kinkhoest is zowel voor de individuele patient als voor laboratorium surveillance 
waardevol. 
De resultaten zijn hoofdzakelijk gebaseerd op twee onderzoeken. In de eerste Studie is een 
serumbank opgezet van de Nederlandse bevolking waarbij sera zijn verzameld van de algemene 
bevolking en van orthodox gereformeerde personen die vaccinatie afwijzen. In het tweede 
onderzoek werden gegevens van kinkhoest patiënten uit diverse surveillance bronnen 
geanalyseerd. 
Immunosurveillance is een van de methoden waarmee veranderingen in epidemiologische 
dynamiek van infectieziekten na routine vaccinatie bestudeerd kan worden (Hoofdstuk 2). Door 
de lagere infectiedruk kan de gemiddelde leeftijd waarop infectie optreedt, toenemen. Natuurlijke 
en vaccin- ge'induceerde immuniteit kunnen minder goed worden onderhouden. Clustering van 
ongevaccineerden kan leiden tot een groot aantal vatbare individuen binnen zulke 
ongevaccineerde groepen. Als hierdoor de groepsimmuniteit wordt doorbroken kunnen 
epidemieen optreden. In Nederland kan dit voorkomen bij orthodox gereformeerde groepen die 
vaccinatie afwijzen op grond van hun religie omdat zij in sociaal en geografisch opzicht zijn 
geclusterd. 
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Om inzicht te krijgen in de immuniteit van de Nederlandse bevolking werd in 1995-1996 een 
serumbank van de algemene bevolking opgezet. In een nationale steekproef zijn 8359 sera 
verzameld (respons 55%); in een steekproef van gemeenten met een läge vaccinatie graad 1589 
sera (respons 52.5%). De sera uit de laatste steekproef zijn verzameld om toegang te hebben tot 
orthodox gereformeerden die vaccinatie afwijzen. In tegenstelling tot residuele sera van 
laboratoria, kon met deze benadering uitgebreide informatie over determinanten van 
immuunstatus worden verzameld met behulp van een vragenlijst. 
Informatie over deelnemers en niet-deelnemers is gebruikt om karakteristieken te i'dentificeren, die 
geassocieerd waren met (niet)deelname aan onze serum verzameling van de bevolking 
(Hoofdstuk 3). Vijf groepen zijn onderscheiden: 7.094 initiële respondenten gaven bloed en 
vulden de vragenlijst in; 455 additionele respondenten gaven bloed tijdens een extra spreekuur en 
vulden de vragenlijst in; 1.618 nonrespondenten vulden alleen de vragenlijst in; 1.053 
nonrespondenten vulden een nonrespons vragenlijst in, en van 4.159 absolute nonrespondenten 
was alleen informatie uit het bevolkingsregister beschikbaar. In dichotome en polychotome 
logistische regressie waren de volgende variabelen geassocieerd met (non)participatie: leeftijd, 
geslacht, burgerlijke Staat, nationaliteit, soort van herinnering en mate van urbanisatiegraad van de 
gemeente. Sommige variabelen hadden een verschillende invloed op de diverse vormen van 
(non)participatie. Bijvoorbeeld, vergelijking van nonrespondenten die alleen de vragenlijst 
invulden met initiële respondenten leverde een odds ratio van 3,5 voor mannen van 0-4 jaar versus 
mannen van 30-64 jaar, terwijl voor de vergelijking van absolute nonrespondenten met initiële 
respondenten deze odds ratio 0,5 bedroeg. Andere variabelen bei'nvloedden elke vorm van 
(non)participatie overeenkomstig, Zo bedroegen de odds ratios voor ongehuwden versus 
gehuwden ongeveer 1,5 zowel voor de vergelijking van additionele respondenten met initiële 
respondenten als voor de vergelijkingen van elk van de drie groepen van nonrespondenten met 
initiële respondenten. 
We concludeerden dat onderzoekers zieh er van bewust moeten zijn dat het opnemen van 
additionele participanten niet altijd leidt tot een vermindering van nonparticipatie selectie. Ook het 
bestuderen van een subgroep van nonparticipanten kan een verkeerd beeld geven van deze 
selectie. 
Specifieke antistoffen die correleren met bescherming tegen difterie, tetanus en poliomyelitis 
werden bepaald voor deelnemers uit de nationale steekproef en voor deelnemers uit de steekproef 
van gemeenten met een läge vaccinatiegraad. In de laatste steekproef waren orthodox 
gereformeerde personen opgenomen. 
Difterie antitoxine en tetanus antitoxine antistoffen zijn gemeten met een toxine inhibitie test 
(Hoofdstuk 4 en 5). Neutraliserende antistoffen tegen poliovirus type 1, 2 en 3 zijn bepaald in de 
neutralisatie test (Hoofdstuk 6). Het effect van verschillende kansen op deelname voor variabelen 
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die voor participanten en nonparticipanten beschikbaar waren, bedroeg minder dan een standaard 
fout voor de populatie schattingen van beide steekproeven. Dit effect werd daarom genegeerd. 
In de nationale steekproef had 58% van de deelnemers difterie antitoxine antistoffen van 
tenminste 0.1 IU per ml, 30% van 0.01 tot 0.1 IU per ml en 12% van minder dan 0.01 IU per ml. 
In deze steekproef had 72.5% van de deelnemers tetanus antitoxine antistoffen van tenminste 0.01 
IU per ml, 14% van 0.01 tot 0.1 IU per ml en 14% van minder dan 0.01 IU per ml. In 96%, 93% 
en 90% werden neutraliserende antistoffen (titer > 1:8) tegen respectievelijk poliovirus type 1, 2 
en 3 gemeten. 
De leeftijdsspecifieke prevalentie voor personen van jonger dan 45 jaar bedroeg voor difterie 
antitoxine antistoffen (>0.01 IU per ml), voor tetanus antitoxine antistoffen (>0.01 IU per ml) en 
voor neutraliserende antistoffen tegen poliovirus type 1 en 2 tenminste 92.5%. Deze personen zijn 
geboren na de introductie van routine vaccinatie. De prevalentie van neutraliserende antistoffen 
voor poliovirus type 3 was hoger dan 90% voor degenen jonger dan 30 jaar en hoger dan 80% 
voor personen in de Ieeftijd van 30 tot 44 jaar. 
De difterie en tetanus antitoxine antistoffen namen sterk af na de Ieeftijd van 44 jaar; dat wil 
zeggen voor degenen die geboren waren voor de introductie van routine vaccinatie. Meer dan 
vijftig procent van 70 tot 79 jarigen had difterie en / of tetanus antitoxine antistoffen van minder 
dan 0.01 IU per ml. Voor poliomyelitis bleef de prevalentie van neutraliserende antistoffen in 
oudere leeftijdsgroepen voor de drie typen 80% of hoger. 
De geometrisch gemiddelde titers namen af met de Ieeftijd voor personen van 10 tot 34 jaar die 
compleet gevaccineerd waren volgens het Rijksvaccinatieprogramma (dat wil zeggen op de 
leeftijden van 3,4, 5 en 11 maanden, 4 en 9 jaar). De prevalentie van antistoffen in deze subgroep 
was tenminste 98% voor difterie antitoxine antistoffen, tetanus antitoxine antistoffen en 
neutraliserende antistoffen tegen poliovirus type 1 en 2. Voor poliovirus type 3 bedroeg deze 
94%. De afname in geometrisch gemiddelde titer was vergelijkbaar voor difterie en tetanus. 
Doordat de geometrisch gemiddelde titers voor recent gevaccineerde 10 tot 14 jarigen voor 
tetanus hoger waren dan voor difterie, lagen deze niveau's voor tetanus voor 30 tot 34-jarigen 
boven die voor difterie. Voor poliomyelitis was de afname in geometrisch gemiddelde titer gering. 
De geometrisch gemiddelde titers voor die deelnemers van 20 to 34 jaar met bewijs van 
revaccinatie, was voor de drie ziekten vergelijkbaar met de geometrisch gemiddelde titers van 
recent gevaccineerde 10 tot 14 jarigen zonderenig bewijs van revaccinatie. 
Slechts 40% van orthodox gereformeerde personen had difterie en/of tetanus antitoxine 
antistoffen van tenminste 0.01 IU per ml, terwijl respectievelijk 65%, 59% en 69% neutraliserende 
antistoffen had tegen poliovirus type 1, 2 of 3. Voor orthodox gereformeerden is, in tegenstelling 
tot de overige deelnemers, in de seroprevalentie curven een effect te zien van de récente 
poliomyelitis epidemieën. 
We concludeerden dat het Rijksvaccinatieprogramma Iangdurige bescherming induceert tegen 
difterie, tetanus en poliomyelitis. Volwassenen zijn goed beschermd tegen poliomyelitis, maar een 
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aanzienlijk deel heeft geen antistoffen tegen difterie of tetanus toxine. Deze volwassenen zouden 
kunnen profiteren van (re)vaccinatie tegen difterie. Om ziektegevallen ten gevolge van tetanus te 
voorkomen, lijkt het effectiever om een primaire tetanus vaccinatie aan te bieden aan cohorten 
geboren voor de introductie van vaccinatie dan om routine revaccinatie in te voeren. Introductie 
van Corynebacterium diphtheriae of van poliovirus in orthodox gereformeerde groeperingen die 
in sociaal en geografisch opzicht zijn geclusterd, zou mogelijk tot verspreiding van deze 
pathogenen kunnen leiden. Aangezien Nederland vrijwillige vaccinatie nastreeft, zou wereldwijde 
eradicatie zoals wordt voorzien voor poliovirus, de enige manier zijn om deze orthodox 
gereformeerde groepen te beschermen. 
Terwijl difterie, tetanus en poliomyelitis vrijwel uit Nederland zijn geelimineerd, is betere 
beheersing van kinkhoest nodig. Kinkhoest blijft endemisch met epidemische pieken. Om inzicht 
te krijgen in het voorkomen van kinkhoest en in factoren die betrokken zouden kunnen zijn bij het 
weer opkomen van kinkhoest, zijn surveillance gegevens geanalyseerd (Hoofdstuk 7 en 8). 
Behalve gegevens uit aangiften wegens kinkhoest van 1989 tot 1996 (Hoofdstuk 7), zijn 
gegevens van positieve serodiagnostiek, ziekenhuisopnamen en overledenen verzameld van 1997 
en eerdere jaren (Hoofdstuk 8). In 1996-1997 nam het aantal kinkhoest patienten op basis van 
aangiften, bevindingen van positieve tweepuntsserologie, bevindingen van positieve 
eenpuntsserologie en ziekenhuisopnamen plotseling toe. In vergelijking tot de gemiddelde 
jaarlijkse incidentie in de periode 1989 tot 1995, nam de incidentie in 1996 volgens aangiften 
twaalfvoudig toe (2,3 versus 27,3 per 100.000), zesvoudig volgens patienten met positieve 
tweepuntsserologie (2,1 versus 12,2), zesvoudig volgens patienten met positieve 
eenpuntsserologie (8,2 versus 50,7) en drievoudig volgens ziekenhuisopnamen (1,2 versus 3,3). 
Zowel van 1989 tot en met 1995 als in 1996 werden twee overledenen ten gevolge van kinkhoest 
gerapporteerd. 
De toename in de kinkhoest incidentie in 1996 op grond van aangiften en serologische gegevens 
was voor (grotendeels ongevaccineerde) kinderen jonger dan een jaar vergelijkbaar met de 
toename in ziekenhuisopnamen. Voor oudere, grotendeels gevaccineerde personen, was de 
toename in ziekenhuisopnamen relatief klein. De verhoging van het aantal aangegeven patienten 
was groter voor gevaccineerden dan voor ongevaccineerden. De grotere toename in 
gevaccineerde aangegeven patienten ten opzichte van ongevaccineerde aangegeven patienten 
begon reeds in 1994-1995, dat wil zeggen voordat de verheffing in het totaal aantal patienten 
werd waargenomen. Het aandeel patienten met positieve tweepuntsserologie dat werd 
aangegeven nam toe van 24% in 1993 tot 42-43% in 1996 en 1997. Voor positieve 
eenpuntsserologie nam het aandeel dat werd aangegeven sterk toe; namelijk van 6% in 1993 tot 
29% in 1997. Deze verhoging in aangifte discipline en het groter aantal patienten dat op grond 
van eenpuntsserologie werd aangegeven, kon de plotselinge toename in het aantal kinkhoest 
patienten niet verklaren. We concludeerden dat de toegenomen incidentie en de verlaagde vaccin-
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effectiviteit voor een deel werkelijke veranderingen reflecteerden. Ook veronderstelden we dat ten 
gevolge van een mismatch tussen vaccin stammen en circulerende B. pertussis stammen, het 
aandeel van de kinkhoest infecties onder gevaccineerden met herkenbare Symptomen, groter is 
geworden. Misschien dat het smalle immunogeniciteitsprofiel van het Nederlandse vaccin een 
grotere gevoeligheid van de bevolking te weeg heeft gebracht voor antigène veranderingen in B. 
pertussis. 
Bevestiging van kinkhoest in het laboratorium wordt bemoeilijkt door de läge sensitiviteit van 
kweek, polymerase ketting reactie (PCR) en van het aantonen van een toename van antistoffen in 
gepaarde sera. Daarom, onderzochten we, of en op welk niveau, IgG antistoffen tegen pertussis 
toxine (IgG-PT) in een enkelvoudig serum monster indicatief zijn voor actuele of recente infectie 
met B. pertussis (Hoofdstuk 9). IgG-PT is gemeten in een ELISA in U per ml voor 7756 sera uit 
de algemene bevolking, in sera van 3491 patienten met tenminste een viervoudige stijging in IgG-
PT, in gepaarde sera van 89 patienten met positieve kweek of PCR, en in sera van 57 patienten 
met klinisch gedocumenteerde kinkhoest met een mediane follow-up duur van 1,4 jaar. Minder 
dan 1% van de deelnemers uit de Studie in de algemene bevolking had IgG-PT niveau's van 
tenminste 100 U per ml. De specificiteit bij deze afkapwaarde voor positieve eenpuntsserologie 
bedroeg 99%. IgG-PT niveau's van tenminste 100 U per ml werden aangetoond in 80% van de 
sera van patienten met klinische kinkhoest Symptomen met tenminste een viervoudige titerstijging 
in IgG-PT in gepaarde sera. De follow-up sera van patienten met klinisch gedocumenteerde 
kinkhoest, toonden aan dat binnen 1 jaar na het begin van kinkhoest Symptomen bij meer dan 80% 
van de patienten het IgG-PT niveau was gedaald tot minder dan 100 U per ml. In patienten met 
positieve PCR of kweek bedroeg de sensitiviteit van een IgG-PT niveau van ten minste 100 U per 
ml 76%. Het aantal patienten in de serodiagnostiek database met IgG-PT niveau's van tenminste 
100 U per ml was meer dan vier keer groter dan het aantal patienten met positieve 
tweepuntsserologie. Deze toename varieerde van een enkelvoudig stijging bij kinderen van 0 tot 5 
maanden tot een veertienvoudige stijging bij personen van 15 jaar en ouder. We concludeerden 
dat IgG-PT niveau's van tenminste 100 U per ml een specifieke en sensitieve methode is om een 
recente of actuele infectie met B. pertussis te diagnosticeren. Diagnose op grond van een 
enkelvoudig serum monster kan het stellen van de diagnose kinkhoest bij oudere kinderen en 
volwassenen vereenvoudigen. Pas later in het beloop van de ziekte wordt bij hen laboratorium 
diagnostiek geinitialiseerd. Daarom is deze methode niet alleen bruikbaar voor de individuele 
patient, maar ook voor epidemiologisch onderzoek. 
In de algemene discussie (Hoofdstuk 10) zijn methodologische aspecten besproken van selectieve 
participatie, leeftijd versus cohort effect en de validiteit van vaccinatiestatus bij de interpretatie 
van de resultaten van de studies in de algemene bevolking. Voor de surveillance gegevens van 
kinkhoest is ingegaan op de validiteit van gegevens van aangiften en van schattingen van vaccin 
199 
D K 
T P Samenvatting 
effectiviteit op grond van surveillance gegevens. Voor de Studie naar IgG-PT niveau's in een 
enkelvoudig serum monster als diagnostische méthode bij kinkhoest, werden methodologische 
aspecten zoals de validiteit van IgG-PT niveau's van patiënten met een viervoudige titerstijging 
als karakteristiek voor reconvalescentie sera besproken. 
Implicaties van de resultaten uit de diverse onderzoeken werden besproken in het licht van 
(verdere) beheersing van de ziekten. De difterie epidemie in de voormalige Sovjet Unie heeft laten 
zien dat deze ziekte kan terugkeren in vatbare populaties. Het gebrek aan difterie antitoxine 
antistoffen bij een groot deel van de volwassenen ten gevolge van afnemende immuniteit, geven 
aan dat het bestuderen van de (memory) respons van volwassenen zonder detecteerbare of met 
geringe antistof niveau's inzicht kan geven of na blootstelling aan C. diphtheriae vertrouwd kan 
worden op voldoende immuniteit. 
Tetanus vaccinatie induceert zeer goede immuniteit. Dit betekent dat tetanus goed kan worden 
voorkomen door vaccinatie te richten op ongevaccineerden. Primaire vaccinatie van 
ongevaccineerde volwassenen geboren voor de introductie van het vaccinatieprogramma lijkt het 
meest effectief te zijn. 
De jarenlange ervaring van Nederland met gei'nactiveerd polio vaccin toont aan dat dit vaccin zeer 
goede bescherming en voldoende groepsimmuniteit geeft. Om vaccin-geassocieerde poliomyelitis 
te voorkomen kan het in het late stadium van de wereldwijde polio eradicatie zinvol zijn, over te 
gaan van oraal polio vaccin naar gei'nactiveerd polio vaccin. 
De mogelijkheden voor interventie in verband met de hiaten in de immuniteit tegen difterie, 
tetanus en poliomyelitis onder orthodox gereformeerde groepen zijn beperkt. Het bestuderen van 
circulatie van de pathogenen zal het opsporen van de ziekten wanneer zij terugkeren in een zo 
vroeg mogelijk stadium mogelijk maken. 
Door invoering van een booster vaccinatie na de zuigelingen vaccinaties kan kinkhoest beter 
worden voorkomen. Aanpassing van zo'n vaccin op circulerende stammen zou effectief kunnen 
zijn. De keuzes zowel voor het meest geschikte vaccin als voor de leeftijd van boostering worden 
gecompliceerd door gebrek aan inzicht in de lange termijn effecten op de kinkhoest 
epidemiologic Naast surveillance gegevens zijn ook gegevens over de reservoirs voor infecties 
met name voor ongevaccineerde zuigelingen van belang om het effect op de epidemiologic van 
kinkhoest te bestuderen. 
Over het algemeen laten onze resultaten zien dat niet alleen de hoge vaccinatiegraad onder 
kinderen gehandhaafd moet worden maar dat vaccinatie ook gericht zou moeten worden op 
volwassenen. Aanpassing van vaccins op circulerende stammen zou effectief kunnen zijn voor 
andere vaccins dan kinkhoest en influenza. 
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Om veranderingen in epidemiologic van ziekten waartegen wordt gevaccineerd te blijven 
bestuderen, zouden epidemiologische studies zoals beschreven in dit proefschrift periodiek 
herhaald moeten worden om het succes van (nieuwe) vaccinatieprogramma's te verhogen. 
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Iedereen die direct of indirect heeft helpen bouwen aan de blokken uit mijn proefschrift wil ik 
hartelijk bedanken. Een aantal van deze mensen wil graag in het bijzonder noemen. 
Beste Daan Kromhout, de sturing en de adviezen die je vooral in de laatste fase van mijn 
proefschrift hebt gegeven waren waardevol en opbouwend. Ik hoop dat mijn promotieonderzoek 
je verder heeft gei'nspireerd op het gebied van de infectieziekten-epidemiologie. Hopelijk zullen er 
dan ook, na je (naar mijn weten) eerste promovenda op dit gebied van de epidemiologic, nog 
velen volgen. 
Beste Marina Conyn-van Spaendonck, dit proefschrift is voor het grootste deel te danken aan 
jouw ideeen over het opzetten van een serumbank: het Pienter-project. Vanaf de eerste dag dat ik 
bij het Centrum voor Infectieziekten Epidemiologie kwam werken, heb je mij het idee gegeven dat 
ik een eigen en waardevolle inbreng kon leveren. Je geweidige expertise die veel verder gaat dan 
epidemiologisch onderzoek op het gebied van het Rijksvaccinatieprogramma, je vertrouwen, het 
feit dat ik altijd, echt altijd, bij je terecht kan, en je fijne en enthousiaste persoonlijkheid hebben 
mijn promotietijd voor mij erg leerzaam en leuk gemaakt. Ik wil je hiervoor ontzettend bedanken! 
Beste Joop Schellekens, jou wil ik bedanken voor je tomeloze enthousiasme, kennis en ideeen 
vooral in het kinkhoest-onderzoek. Door jou ben ik meer en meer thuis geraakt in de kinkhoest-
epidemiologie. Soms werd ik moedeloos van je steeds maar weer nieuwe ideeen. Maar juist 
daarvan werden de artikelen beter en heb ik erg veel geleerd. 
Marc Sprenger wil niet alleen bedanken omdat hij mij de gelegenheid heeft gegeven aan mijn 
proefschrift te werken, maar ook voor het frequent uitspreken van zijn vertrouwen dat het een 
mooi boekje zou worden. 
De (voormalige) medewerkers uit onze projectgroep collectieve preventie wil ik bedanken voor 
hun bijdrage aan dit proefschrift. Een aantal mensen wil ik hier graag noemen. 
Anita Suijkerbuijk, mede door jouw goede, nüchtere en leuke inbreng al in de pilot voor het 
Pienter-project, is het landelijke Pienter-project een succes geworden. Susan van de Hof, je Staat 
altijd klaar om mij te helpen bij mijn vele plentere (?) al dan niet werkgerelateerde vragen. 
Hopelijk krijg je ook de mogelijkheid promotie-onderzoek te doen, waarbij ik dan graag zal 
proberen jouw vragen te beantwoorden. Sabine Neppelenbroek, je bracht na de kinkhoest-
epidemie in 1996 een enorme verlichting door een groot deel van het kinkhoest-onderzoek op je 
te nemen. Doordat je een fijne collega bent, was onze samenwerking behalve nuttig ook gezellig. 
Evelien Geubbels, Matty de Wit en Irene Veldhuijzen, drie stagiaires die gelukkig zijn blijven 
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'hangen' op het Centrum voor Infectieziekten Epidemiologic wil ik bedanken voor hun hulp bij 
de nonrespons- en 'open velden' problematiek in het Pienter-project. 
Het secretariaat wil ik bedanken voor de antwoorden op al mijn vragen. Hoewel dat formeel niet 
'mocht', was deze informele steun voor mij zeer waardevol. Annet Esser wil ik bedanken voor de 
moeite die zij neemt bij het zoeken naar fondsen voor dit boekje. Eric Elbers en Per Broersen, 
bedankt voor het verhelpen van alle kleine en grote computer problemen. 
Ook wil ik mijn (ex-)kamergenoten bedanken. Zij waren vaak de eersten die mij hielpen bij het 
beantwoorden van allerlei vragen. Lucas Wiessing, ik vond het erg jammer en ongezellig dat je 
naar Portugal vertrok, maar de heerlijke vakantiedagen die Marja Esveld en ik bij jullie hadden, 
maakten veel goed. Heel veel succès met het afronden van jouw proefschrift. 
Door Hedwig Carsauw en Christine Meffre leer(de) ik behalve wat EPEET is, ook wat meer 
Vlaams en Frans (?). Frithjofna Abbink, het is leuk dat je na een paar maanden switchte van 
gastro-enteritis naar poliomyelitis omdat je daardoor in onze gezellige projectgroep kwam. 
Jammer genoeg betekende dat wel dat we geen kamergenoten meer mochten blijven. Hopelijk kan 
ik dankzij jouw tip een feest geven in Spaanse sferen. 
Ook alle andere (ex-)collega's wil ik bedanken. De plezierige sfeer op ons Centrum voor 
Infectieziekten Epidemiologie zorgt ervoor dat ik het nog steeds erg naar mijn zin heb. Ik 
waardeer het zeer dat ik bij mijn collega's altijd binnen kan lopen voor serieuze maar gelukkig 
ook voor minder serieuze zaken (wie gaat er mee borrelen?). 
Bennie Bloemberg, Siem Heisterkamp en Nico Nagelkerke wil ik bedanken voor hun 
methodologische adviezen. Bennie, elk Pienter-gerelateerd (steekproefjprobleem loste je 
enthousiast en praktisch op. Siem, mede dankzij jouw ingewikkelde berekeningen op grond van 
de non-respondenten uit de pilot, kunnen we betrouwbare seroprevalentie schattingen doen in het 
landelijke Pienter-project. Nico, in een mum van tijd en met veel geintjes kwam je met ideeèn voor 
statistische analyses. 
Het Pienter-project team, de betrokken GGD-medewerkers, de medewerkers van het 
Laboratorium voor veldonderzoek vaccins, Laboratorium voor infectieziekten diagnostiek en 
screening en het Laboratorium voor contrôle biologisch producten die betrokken waren bij de 
laboratoriumbepalingen, wil ik bedanken voor al hun inspanningen bij het verzamelen van de 
enorme hoeveelheid gegevens. Ook realiseer ik me dat de resultaten van het onderzoek te danken 
zijn aan de bereidwilligheid van vele, anonieme Nederlanders om aan het onderzoek deel te 
nemen. De mede-auteurs wil ik bedanken voor hun commentaar. Daarvan zijn de artikelen zeker 
beter geworden. 
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Ook dankzij mijn vriendinnen is dit proefschrift geworden tot wat het is. Samen met mijn 
middelbare schoolvriendinnen - Gaby Weiss, Nicole Dijkstra en Judith van Basten - heb ik op 
school toch behalve het vele lachen en soms huilen (niet altijd van het lachen) toch genoeg 
opgestoken (ik weet inmiddels wat 'ableto' is) om te kunnen gaan studeren. Lieve Josan 
(Verheyen)-van Gool, nog steeds mis ik af en toe de tijd dat wij samen op de Drie Octoberstraat 
woonden. Bedankt voor al je studie(?)adviezen! Tijdens de GW-practica maakte ik met mijn GW-
vriendinnen kennis met de begrippen antilichaam en statistiek. Maar tijdens onze GW-diners en 
weekenden praten we gelukkig over heel veel andere dingen. De iets grotere mond die ik door de 
vele, gezellige dispuutsactiviteiten kreeg, komt soms best goed van pas. Mijn hockeyvriendinnen 
zorgen er mede voor dat ik het ontzettend naar mijn zin heb in Utrecht. Gelukkig heb ik links-
achter meestal genoeg te doen om eventuele stress kwijt te raken. 
Ik ben heel blij dat Petra Beemsterboer en Edith Schasfoort mij als paranimfen bij staan. 
Peet, vanaf de eerste dag in Leiden zijn we vriendinnen. Wat ik het meest aan jou waardeer is dat 
je dat je jezelf bent. Je grote betrokkenheid bij dingen die ik doe en denk, je vele waardevolle 
adviezen, hebben niet alleen aan dit boekje bijgedragen maar vooral aan -zoals jij dat hebt 
genoemd- alle dingen waarom in het leven echt om draait! Heel erg bedankt! 
Edith, je bent een geweidige en lieve meid! (Sorry, ik kan er echt niet onderuit, hoewel jij dat niet 
wilt hören). Ontzettend bedankt voor je interesse in veel meer dan alleen mijn promotie-
onderzoek. De vele (telefoon)gesprekken waarin je mijn klets- en serieuze praat aanhoort en al 
onze vakanties zijn geweidig. Ik wil jou en je enthousiaste collega, Annemarie, ook bedanken 
voor alle moeite bij het zoeken naar feestlokaties. 
Lieve Remco, Jorrit en Maran, nu kan ik eens zwart op wit te zetten dat jullie erg belangrijk voor 
mij zijn! Lieve pappa en mamma, het is heerlijk dat jullie er altijd en onvoorwaardelijk voor mij 
zijn! Bedankt voor alle inbreng die jullie ieder op jullie eigen leuke manier aan dit boekje hebben 
geleverd. Jullie zijn geweidig!! 
Lieve Marc, niet alleen jouw relativeringsvermogen was onmisbaar. Wat heb ik toch ongelofelijk 
veel geluk met jou!! 
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